

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 757 037 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
05.02.1997 Bulletin 1997/06

(51) Int Cl.⁶: **C07C 311/42**, A61K 31/63,
C07D 209/20, C07D 213/59,
C07D 233/64, C07D 333/24,
C07D 213/82, C07D 307/68

(21) Application number: **96305554.6**

(22) Date of filing: **29.07.1996**

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE**

(30) Priority: **28.07.1995 JP 212556/95**
19.03.1996 JP 90491/96

(71) Applicant: **ONO PHARMACEUTICAL CO., LTD.**
Chuo-ku Osaka 541 (JP)

(72) Inventors:

- Sakaki, Katsuhito, Ono Pharmaceutical Co., Ltd.
Shimamoto-cho, Mishima-gun, Osaka, 618 (JP)
- Kanazawa, Hidekazu,
Ono Pharmaceutical Co., Ltd.
Shimamoto-cho, Mishima-gun, Osaka, 618 (JP)


- Sugiura, Tsuneyuki,
Ono Pharmaceutical Co., Ltd.
Shimamoto-cho, Mishima-gun, Osaka, 618 (JP)
- Miyazaki, Tohru, Ono Pharmaceutical Co., Ltd.
Shimamoto-cho, Mishima-gun, Osaka, 618 (JP)
- Ohno, Hyroyuki, Ono Pharmaceutical Co., Ltd.
Shimamoto-cho, Mishima-gun, Osaka, 618 (JP)

(74) Representative: **Bentham, Stephen**
J.A. KEMP & CO.
14 South Square
Gray's Inn
London WC1R 5LX (GB)


(54) **Sulfonylamino acid derivatives as metalloproteinase inhibitors**

(57) The present invention relates to:

(i) matrix metalloproteinase (MMP) inhibitors containing sulfonylamino acid derivatives of the formula (Ia):



wherein R¹ is hydrogen, C1-4 alkyl; R² is hydrogen, C1-8 alkyl etc.; E is -CONR³-, in which R³ is hydrogen, C1-4 alkyl etc., -NR³CO-, -CO-O-, -O-CO- etc.; A is hydrogen, C1-8 alkyl, C3-7 cycloalkyl, or Ar; J is bond, C2-4 alkylene etc.; G is -(CH₂)_m-, in which m is 2, 3 or 4, or




in which R⁶ and R⁷ is hydrogen, C1-8 alkyl etc.; and non-toxic salts thereof,

(ii) novel sulfonylamino acid derivatives of the formula (Ib):

Atty. Docket No. 3333/1/US
Serial No. 10/031,181
Stallings et al
Reference 17 of 41

EP 0 757 037 A2



wherein all the symbols are as defined for formula (Ia), with the exclusion of certain compounds; and non-toxic salts thereof, and

(iii) processes for the preparation of the compounds of formula (Ib).

The compounds of formulae (Ia) and (Ib) are useful for prevention and/or treatment of diseases induced by over-expression or excess activity of MMP, such as rheumatoid diseases, arthroseitis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis, invasion or growth of tumor cells, autoimmune diseases (Crohn's disease, Sjogren's syndrome etc.), diseases caused by vascular emigration or infiltration of leukocytes, or arterIALIZATION.

Description

This invention relates to sulfonylamino acid derivatives and matrix metalloproteinase inhibitors containing sulfonylamino acid derivatives as active ingredient. More particularly, this invention relates to:

- (i) matrix metalloproteinase inhibitors containing sulfonylamino acid derivatives of the formula (Ia) as hereinafter defined, and non-toxic salts thereof, as active ingredient,
- (ii) novel sulfonylamino acid derivatives of the formula (Ib) as hereinafter defined, and non-toxic salts thereof, and
- (iii) processes for the preparation of the compounds of formula (Ib).

The matrix metalloproteinases (MMPs) are neutral metalloproteinases and zinc (Zn^{2+}) is essential in the active site for their activation. They degrade collagen, laminin, proteoglycans, fibronectin, elastin, gelatin etc. under physiological conditions and, therefore, are effective on growth and tissue remodeling of articulation tissue, bone tissue and connective tissue. At least 10 classes of MMPs which differ in primary structure are identified.

As common characteristics of these enzymes, MMPs


- (1) have Zn^{2+} in the active site and the activity depends on calcium (Ca^{2+}),
- (2) are secreted as an inactive proenzyme and activated outside of cells,
- (3) have high homology on amino acid sequence,
- (4) have an ability to degrade various extracellular matrix components in vivo,
- (5) are regulated by tissue inhibitors of metalloproteinases (TIMP) which are specific to MMPs.

MMP inhibitors are useful for prevention and / or treatment of various diseases induced by overexpression or excess activation of MMP. Such diseases are, for example, rheumatoid diseases, arthrosclerosis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis of, invasion of or growth of tumor cells, autoimmune diseases (e.g. Crohn's disease, Sjogren's syndrome), diseases caused by vascular emigration or infiltration of leukocytes, arterialization.

Some compounds possessing inhibitory activity against MMP are known. A sequence in the vicinity of the cleavage site of collagen (Gly-Ile-Ala-Gly or Gly-Leu-Ala-Gly) has high affinity for collagenase.


Much research and development on substrate analogous MMP inhibitors, which are chemically modified so as to have zinc affinity groups on a cleavage site of the substrate, has energetically been carried out [Inhibitors of matrix metalloproteinases (MMPs), Nigel RA Beeley, Phillip RJ Ansell, Andrew JP Docherty et al., Curr. Opin. Ther. Patents, 4, 7-16 (1994), Current Drugs Ltd ISSN 0962-2594]. However, these substrate-analogous inhibitors might have various problems. Therefore, it is desired to obtain a non-peptide inhibitor and some compounds are reported.

For example, in the specification of EP 606046, aryl-sulfonamide derivatives of the formula (X):



wherein (a) Ar^x is carbocyclic or heterocyclic aryl; R^x is hydrogen, lower alkyl, carbocyclic aryl-lower alkyl etc.; $\text{R}^1 \text{X}$ is hydrogen, lower alkyl, carbocyclic aryl-lower alkyl etc.; $\text{R}^2 \text{X}$ is hydrogen, lower alkyl; or (b) R^x and $\text{R}^1 \text{X}$ together with the chain to which they are attached form 1,2,3,4-tetrahydro-isoquinoline, piperidine etc.; Ar^x and $\text{R}^2 \text{X}$ are as defined in (a); or (c) $\text{R}^1 \text{X}$ and $\text{R}^2 \text{X}$ together with the carbon to which they are attached form C3-7 cycloalkane, oxa-cyclohexane, thia-cyclohexane etc. which is unsubstituted or substituted by lower alkyl; and Ar^x and $\text{R}^2 \text{X}$ are as defined in (a); inter alia, are disclosed to have inhibitory activity against matrix metalloproteinase.

Phenylsulfonylamino acid derivatives of the formula (Y):




10 wherein

- 15
- R^{1Y} is hydrogen, R^{2Y} is hydrogen;
 - R^{1Y} is 4-methoxy, R^{2Y} is hydrogen;
 - R^{1Y} is 4-fluoro, R^{2Y} is hydrogen;
 - R^{1Y} is 4-nitro, R^{2Y} is hydrogen;
 - R^{1Y} is 3-nitro, R^{2Y} is hydrogen;
 - R^{1Y} is 2-nitro, R^{2Y} is hydrogen;
 - R^{1Y} is 4-formyl, R^{2Y} is hydrogen;
 - R^{1Y} is hydrogen, R^{2Y} is (S)-phenyl;
 - 20 R^{1Y} is hydrogen, R^{2Y} is (R)-phenyl;
 - R^{1Y} is 4-methyl, R^{2Y} is (S)-phenyl;
 - R^{1Y} is 4-methyl, R^{2Y} is (R)-phenyl;
 - R^{1Y} is 4-methoxy, R^{2Y} is (S)-phenyl;
 - R^{1Y} is 4-methoxy, R^{2Y} is (R)-phenyl;
 - 25 R^{1Y} is 4-fluoro, R^{2Y} is (S)-phenyl;
 - R^{1Y} is 4-fluoro, R^{2Y} is (R)-phenyl;
 - R^{1Y} is 4-nitro, R^{2Y} is (S)-phenyl; or
 - R^{1Y} is 4-nitro, R^{2Y} is (R)-phenyl;

30 inter alia, are disclosed to have inhibitory activity against aldose reductase [Biochemical Pharmacology, 40, 2219-2226 (1990)].

In the specification of EP347168, p-substituted phenyl esters of pivalic acid derivatives of the formula (Z):



40 wherein Y^Z is sulfonyl (-SO₂-) or carbonyl (-CO-); R^{1Z} and R^{2Z}, same or different, is hydrogen, C1-16 alkyl which may be substituted by carboxy (-COOH); R^{3Z} is hydrogen, hydroxy, C1-6 alkyl, halogen, C1-4 alkoxy or C2-5 acyloxy; m^Z is 1-4; inter alia, are disclosed to have inhibitory activity against elastase.

45 The following compounds, inter alia, are disclosed to possess antimicrobial activity [J. Serb. Chem. Soc. 56(6), 311-318 (1991)].

- 50
- N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]glycine,
 - N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D,L-alanine,
 - N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-β-alanine,
 - N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-valine,
 - N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D,L-valine,
 - N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-leucine,
 - N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D,L-leucine,
 - 55 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D,L-serine,
 - N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-phenylalanine,
 - N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-tyrosine,
 - N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D,L-alanine methyl ester,

N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-valine methyl ester,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D,L-valine methyl ester,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-leucine methyl ester,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D,L-serine methyl ester, and
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-tyrosine methyl ester.

The following compounds, inter alia, are disclosed to possess antifilarial activity [Indian J. Chem. 30B, 182-187 (1991)].

N-[[4-(3-Nitrobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
 N-[[3-(3-Nitrobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
 N-[[4-(3-Aminobenzoylamino)phenyl]sulfonyl]-L-aspartic acid and
 N-[[3-(3-Aminobenzoylamino)phenyl]sulfonyl]-L-aspartic acid.

The following compounds, inter alia, are disclosed to possess antineoplastic activity [Indian J. Chem. 28B, 843-847 (1989)].


N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-glutamic acid,
 N-[[4-(4-chlorobenzoylamino)phenyl]sulfonyl]-L-glutamic acid and
 N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]-L-glutamic acid.

Energetic investigations have been carried out in order to make a matrix metalloproteinase inhibitor. The present inventors have found that a series of sulfonylamino acid derivatives of the formula (Ia) have inhibitory activity against matrix metalloproteinase and have accomplished the present invention.

Sulfonylamino acid derivatives of the formula (Ia) of the present invention are not known as matrix metalloproteinase inhibitors at all. And sulfonylamino acid derivatives of the formula (Ib) of the present invention are novel compounds that are not known at all.

Moreover, the compounds of the present invention possess, especially, a selective inhibitory activity against gelatinases classified in matrix metalloproteinases.

The present invention provides the use of a compound of formula (Ia):



wherein

R¹ is hydrogen, or C1-4 alkyl;

R² is (1) hydrogen, (2) C1-8 alkyl, (3) phenyl, or (4) C1-4 alkyl substituted by phenyl, -OCOR¹⁶, in which R¹⁶ is C1-4 alkyl; or -CONR¹⁷R¹⁸, in which R¹⁷ and R¹⁸ each, independently, is hydrogen or C1-4 alkyl;

E is

(1) -CONR³-, in which R³ is hydrogen, C1-4 alkyl, phenyl, or C1-4 alkyl substituted by phenyl;

(2) -NR³CO-, in which R³ is as hereinbefore defined;

(3) -CO-O-,

(4) -O-CO-,

(5) -NR³-CO-NR³-, in which R³ is as hereinbefore defined;

(6) -CO-CH₂-,

(7) -CO-,

(8) -O-CO-NR³-, in which R³ is as hereinbefore defined;

(9) -NR³-CO-O-, in which R³ is as hereinbefore defined;

(10) -O-CO-O-,

(11) -CS-NR³-, in which R³ is as hereinbefore defined;

(12) -NR³-CS-, in which R³ is as hereinbefore defined;

- (13) $-\text{NR}^3-\text{CS}-\text{NR}^3-$, in which R^3 is as hereinbefore defined;
 (14) $-\text{O}-\text{CS}-\text{NR}^3-$, in which R^3 is as hereinbefore defined;
 (15) $-\text{NR}^3-\text{CS}-\text{O}-$, in which R^3 is as hereinbefore defined;
 (16) $-\text{CS}-\text{O}-$,
 (17) $-\text{O}-\text{CS}-$, or
 (18) $-\text{O}-\text{CS}-\text{O}-$,

A is (1) hydrogen, (2) C1-8 alkyl, (3) C3-7 cycloalkyl, or (4) Ar, in which Ar is carbocyclic aryl or heterocyclic aryl, and is unsubstituted or substituted by 1-3 of C1-15 alkyl, C1-15 alkoxy, halogen, nitro, cyano, guanidino, amidino, hydroxy, benzyloxy, $-\text{NR}^9\text{R}^{10}$, in which R^9 and R^{10} each, independently, is hydrogen or C1-4 alkyl; $-\text{COOR}^{11}$, in which R^{11} is hydrogen or C1-4 alkyl; trifluoromethyl, phenyl or heterocyclic ring;
 J is (1) a bond, (2) C2-4 alkylene, (3) C2-4 alkenylene, or (4)




in which R^4 and R^5 each, independently, is (i) hydrogen, (ii) C1-4 alkyl, or (iii) C1-4 alkoxy, or R^4 and R^5 , taken together with the carbon to which they are attached, form a C3-7 cycloalkyl group,
 G is (1) $-(\text{CH}_2)_m-$, in which m is 2, 3 or 4, or (2)



in which R^6 and R^7 each, independently, is (i) hydrogen, (ii) C1-8 alkyl, (iii) $-\text{COOR}^8$, in which R^8 is hydrogen, C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl; (iv) Ar, in which Ar is as hereinbefore defined; (v) heterocyclic ring, (vi) C1-8 alkyl substituted by: $-\text{COOR}^8$, in which R^8 is as hereinbefore defined; C1-4 alkoxy; hydroxy; benzyloxy; $-\text{NR}^{12}\text{R}^{13}$, in which R^{12} and R^{13} each, independently, is hydrogen or C1-4 alkyl; $-\text{NR}^{14}\text{COOR}^{15}$, in which R^{14} is hydrogen or C1-4 alkyl, and R^{15} is hydrogen, C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl; Ar; or heterocyclic ring; with the proviso that one of the carbon atoms in C1-8 alkyl may be replaced by a sulfur atom; or R^6 and R^7 , taken together with the carbon to which they are attached, form a C3-7 cycloalkyl group;
 with the proviso that, when E is $-\text{O}-\text{CO}-\text{NR}^3-$, $-\text{O}-\text{CO}-\text{O}-$, $-\text{O}-\text{CS}-\text{NR}^3-$ or $-\text{O}-\text{CS}-\text{O}-$, and J is a bond, A is not hydrogen;
 or a non-toxic salt thereof, in the manufacture of a medicament for the prevention and/or treatment of a disease induced by overexpression or excess activity of a metalloproteinase.

The present invention also provides a compound of formula (Ib):




wherein


- R^1 is hydrogen, or C1-4 alkyl;
 R^2 is (1) hydrogen, (2) C1-8 alkyl, (3) phenyl, or (4) C1-4 alkyl substituted by phenyl, $-\text{OCOR}^{16}$, in which R^{16} is C1-4 alkyl; or $-\text{CONR}^{17}\text{R}^{18}$, in which R^{17} and R^{18} each, independently, is hydrogen or C1-4 alkyl;
 E is
 (1) $-\text{CONR}^3-$, in which R^3 is hydrogen, C1-4 alkyl, phenyl, or C1-4 alkyl substituted by phenyl;
 (2) $-\text{NR}^3\text{CO}-$, in which R^3 is as hereinbefore defined;
 (3) $-\text{CO}-\text{O}-$,

- (4) -O-CO-,
 (5) -NR³-CO-NR³-, in which R³ is as hereinbefore defined;
 (6) -CO-CH₂-,
 (7) -CO-,
 (8) -O-CO-NR³-, in which R³ is as hereinbefore defined;
 (9) -NR³-CO-O-, in which R³ is as hereinbefore defined;
 (10) -O-CO-O-,
 (11) -CS-NR³-, in which R³ is as hereinbefore defined;
 (12) -NR³-CS-, in which R³ is as hereinbefore defined;
 (13) -NR³-CS-NR³-, in which R³ is as hereinbefore defined;
 (14) -O-CS-NR³-, in which R³ is as hereinbefore defined;
 (15) -NR³-CS-O-, in which R³ is as hereinbefore defined;
 (16) -CS-O-,
 (17) -O-CS-, or
 (18) -O-CS-O-,

A is (1) hydrogen, (2) C1-8 alkyl, (3) C3-7 cycloalkyl, or (4) Ar, in which Ar is carbocyclic aryl or heterocyclic aryl, and is unsubstituted or substituted by 1-3 of C1-15 alkyl, C1-15 alkoxy, halogen, nitro, cyano, guanidino, amidino, hydroxy, benzyloxy, -NR⁹R¹⁰, in which R⁹ and R¹⁰ each, independently, is hydrogen or C1-4 alkyl; -COOR¹¹, in which R¹¹ is hydrogen or C1-4 alkyl; trifluoromethyl, phenyl or heterocyclic ring;
 J is (1) a bond, (2) C2-4 alkylene, (3) C2-4 alkenylene, or (4)



in which R⁴ and R⁵ each, independently, is (i) hydrogen, (ii) C1-4 alkyl, or (iii) C1-4 alkoxy, or R⁴ and R⁵, taken together with the carbon to which they are attached, form a C3-7 cycloalkyl group,
 G is (1) -(CH₂)_m-, in which m is 2, 3 or 4, or (2)



in which R⁶ and R⁷ each, independently, is (i) hydrogen, (ii) C1-8 alkyl, (iii) -COOR⁸, in which R⁸ is hydrogen, C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl; (iv) Ar, in which Ar is as hereinbefore defined; (v) heterocyclic ring, (vi) C1-8 alkyl substituted by: -COOR⁸, in which R⁸ is as hereinbefore defined; C1-4 alkoxy; hydroxy; benzyloxy; -NR¹²R¹³, in which R¹² and R¹³ each, independently, is hydrogen or C1-4 alkyl; -NR¹⁴COOR¹⁵, in which R¹⁴ is hydrogen or C1-4 alkyl, and R¹⁵ is hydrogen, C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl; Ar; or heterocyclic ring; with the proviso that one of the carbon atoms in C1-8 alkyl may be replaced by a sulfur atom; or R⁶ and R⁷, taken together with the carbon to which they are attached, form a C3-7 cycloalkyl group; with the proviso that, when E is -O-CO-NR³-, -O-CO-O-, -O-CS-NR³- or -O-CS-O-, and J is a bond, A is not hydrogen;
 or a non-toxic salt thereof;
 with the exclusion of the following compounds:

- (54) N-[[[4-[2-(4-(1-Pyrrolidinyl)phenyl)butyryloxy]phenyl]sulfonyl]-D,L-3-morpholinoalanine ethyl ester,
 (55) N-[[[4-[2-(4-(1-Nitrophenyl)butyryloxy]phenyl]sulfonyl]-D,L-3-morpholinoalanine ethyl ester,
 (56) N-[[[4-(2-Methoxy-2-phenylacetyloxy)phenyl]sulfonyl]-D,L-3-morpholinoalanine ethyl ester,
 (57) N-[[[4-[[[1-(4-Nitrophenyl)cyclobutyl]carbonyl]-oxy]phenyl]sulfonyl]-D,L-3-morpholinoalanine ethyl ester,
 (58) N-[[[3-Methyl-4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-t-butoxycarbonyl-L-lysine,
 (59) N-[[[4-(2-Phenylbutyryloxy)phenyl]sulfonyl]glycine,
 (60) N-[[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-phenylalanine,
 (61) N-[[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-aspartic acid,
 (62) N-[[[4-[[[1-(4-Nitrophenyl)cyclobutyl]carbonyl]oxy]phenyl]sulfonyl]-D,L-aspartic acid,
 (63) 1-[[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonylamide]-1-cyclopropanecarboxylic acid,
 (64) N-[[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-2-(2-furanyl)glycine,
 (65) N-[[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-2-(2-thienyl)glycine,

- (66) N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-L-valine,
 (67) N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-S-carboxymethyl-L-cysteine,
 (68) N-[[4-[2-Ethyl-2-(4-methoxyphenyl)butyryloxy]phenyl]sulfonyl]-glycine,
 (69) N-[[3-Methyl-4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-L-lysine, and
 (70) 5-[[3-Methyl-4-[2-[4-(1-pyrrolidinyl)phenyl] butyryloxy]phenyl]sulfonyl]amino]pentanoic acid;

and with the exclusion of compounds specifically named and characterised in the prior art.

The following compounds are believed to be known:

- (1) N-[[4-(Benzoylamino)phenyl]sulfonyl]glycine,
 (2) N-[[3-(Benzoylamino)phenyl]sulfonyl]glycine,
 (3) N-[[2-(Benzoylamino)phenyl]sulfonyl]glycine,
 (4) N-[[4-(Acetylamino)phenyl]sulfonyl]glycine,
 (5) N-[[4-(Phenylacetylamino)phenyl]sulfonyl]glycine,
 (6) N-[[4-[(Phenylethylcarbonyl)amino]phenyl]sulfonyl]glycine,
 (7) N-[[4-(Cinnamoylamino)phenyl]sulfonyl]glycine,
 (8) N-[[4-(N-Phenylureido)phenyl]sulfonyl]glycine,
 (9) N-[[4-(N-Phenylthioureido)amino]phenyl]sulfonyl]glycine,
 (10) N-[[4-[(Benzyloxycarbonyl)amino]phenyl]sulfonyl]glycine,
 (11) N-[[4-[(Phenylloxymethylcarbonyl)amino]phenyl]sulfonyl]glycine,
 (12) N-[[4-[(Benzyloxymethylcarbonyl)amino]phenyl]sulfonyl]glycine,
 (13) N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]glycine,
 (14) N-[[4-(4-Fluorobenzoylamino)phenyl]sulfonyl]glycine,
 (15) N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]glycine,
 (16) N-[[4-(3-Nitrobenzoylamino)phenyl]sulfonyl]glycine,
 (17) N-[[4-(2-Nitrobenzoylamino)phenyl]sulfonyl]glycine,
 (18) N-[[4-(4-Formylbenzoylamino)phenyl]sulfonyl]glycine,
 (19) N-[[4-(Benzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
 (20) N-[[4-(Benzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
 (21) N-[[4-(4-Methylbenzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
 (22) N-[[4-(4-Methylbenzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
 (23) N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]-D- α -phenyl-glycine,
 (24) N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]-L- α -phenyl-glycine,
 (25) N-[[4-(4-Fluorobenzoylamino)phenyl]sulfonyl]-D- α -phenyl-glycine,
 (26) N-[[4-(4-Fluorobenzoylamino)phenyl]sulfonyl]-L- α -phenyl-glycine,
 (27) N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]-D- α -phenyl-glycine,
 (28) N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]-L- α -phenyl-glycine,
 (29) N-[[4-(4-Pivaloyloxyphenyl)sulfonyl]-D,L- α -phenyl-glycine,
 (30) N-[[4-(4-Pivaloyloxyphenyl)sulfonyl]-D,L-phenylalanine,
 (31) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-glycine,
 (32) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-alanine,
 (33) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]- β -alanine,
 (34) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-valine,
 (35) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-valine,
 (36) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-leucine,
 (37) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-leucine,
 (38) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-serine,
 (39) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-phenylalanine,
 (40) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-tyrosine,
 (41) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-alanine methyl ester,
 (42) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-valine methyl ester,
 (43) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-valine methyl ester,
 (44) N-[[4-[(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-leucine methyl ester,
 (45) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-serine methyl ester,
 (46) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-tyrosine methyl ester,
 (47) N-[[4-(3-Nitrobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
 (48) N-[[3-(3-Nitrobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
 (49) N-[[4-(3-Aminobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,

- (50) N-[[3-(3-Aminobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
 (51) N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-glutamic acid,
 (52) N-[[4-(4-chlorobenzoylamino)phenyl]sulfonyl]-L-glutamic acid,
 (53) N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]-L-glutamic acid, and
 (71) N-[[[3-Methyl-4-pivaloyloxy)phenyl]sulfonyl]-β-alanine.

The present invention also provides a process for the preparation of a compound of formula (Ib) or a non-toxic salt thereof.

Unless otherwise specified, all isomers are included in the present invention. For example, alkyl, alkoxy and alkylene include straight and branched isomers. Isomers resulting from the presence of asymmetric carbon(s) e.g. branched alkyl are also included within the present invention.

In the formulae (Ia) and (Ib), C1-4 alkyl represented by R¹, R³, R⁴, R⁵, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁶, R¹⁷, or R¹⁸ means methyl, ethyl, propyl, butyl and isomeric groups thereof.

In the formulae (Ia) and (Ib), C1-8 alkyl represented by R², R⁶, R⁷, R⁸, R¹⁵, or A means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and isomeric groups thereof.

In the formulae (Ia) and (Ib), C1-4 alkyl substituted by phenyl represented by R², R³, R⁸, or R¹⁵ means methyl, ethyl, propyl, butyl and isomeric groups thereof substituted by 1 of phenyl.

In the formulae (Ia) and (Ib), C1-4 alkoxy represented by R⁴, R⁵, R⁶, or R⁷ means methoxy, ethoxy, propoxy, butoxy and isomeric groups thereof.

In the formulae (Ia) and (Ib), C1-15 alkyl as a substituent of Ar means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl and isomeric groups thereof.

In the formulae (Ia) and (Ib), C1-15 alkoxy as a substituent of Ar means methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, nonyloxy, decyloxy, undecyloxy, dodecyloxy, tridecyloxy, tetradecyloxy, pentadecyloxy and isomeric groups thereof.

In the formulae (Ia) and (Ib), halogen as a substituent of Ar is fluorine, chlorine, bromine or iodine.

In the formulae (Ia) and (Ib), C2-4 alkylene represented by J means ethylene, trimethylene, tetramethylene and isomeric groups thereof.

In the formulae (Ia) and (Ib), C2-4 alkenylene represented by J means vinylene, propenylene, butenylene, butadienylene and isomeric groups thereof.

In the formulae (Ia) and (Ib), C3-7 cycloalkyl represented by R⁴ and R⁵, taken together with carbon to which they are attached, or by R⁶ and R⁷, taken together with carbon to which they are attached or by A means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

In the formulae (Ia) and (Ib), carbocyclic aryl represented by A, or by Ar in R⁶ or R⁷ preferably means C5-10 carbocyclic aryl, for example, benzene, pentalene, indene, naphthalene, azulene.

In the formulae (Ia) and (Ib), heterocyclic aryl represented by A, or by Ar in R⁶ and R⁷ preferably means C5-15 membered mono- or bi-heterocyclic aryl containing 1-2 of nitrogen, 1 of oxygen and/or 1 of sulfur, for example, a radical derived from pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepin, oxazepine, thiophene, thian (thiopyran), thiopin, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, indole, isoindole, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, indazole, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, benzoxazole, benzothiazole or benzoimidazole.

In the formulae (Ia) and (Ib), heterocyclic ring represented by R⁶ or R⁷, or present as a substituent of Ar, preferably means C5-15 membered mono- or bi-heterocyclic ring containing 1-2 of nitrogen and/or 1 of oxygen and/or 1 of sulfur. The heterocyclic ring includes partially or fully saturated analogues of the above C5-15 membered mono- or bi-heterocyclic aryl containing 1-2 of nitrogen and/or 1 of oxygen and/or 1 of sulfur, for example, a radical derived from pyrroline, pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, piperazine, tetrahydropyrimidine, tetrahydropyridazine, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrothiophene, tetrahydrothiophene, dihydrothiain (dihydrothiopyran), tetrahydrothiain (tetrahydrothiopyran), dihydrooxazole, tetrahydrooxazole, dihydroisoxazole, tetrahydroisoxazole, dihydrothiazole, tetrahydrothiazole, dihydroisothiazole, tetrahydroisothiazole, morpholine, thiomorpholine, indoline, isoindoline, dihydrobenzofuran, perhydrobenzofuran, dihydroisobenzofuran, perhydrobenzofuran, dihydrobenzothiophene, perhydrobenzothiophene, dihydroisobenzothiophene, perhydroisobenzothiophene, dihydroindazole, perhydroindazole, dihydroquinoline, tetrahydroquinoline, perhydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, perhydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, perhydrophthalazine, dihydronaphthyridine, tetrahydronaphthyridine, perhydronaphthyridine, dihydroquinoxaline, tetrahydroquinoxaline, perhydroquinoxaline, dihydroquinazoline, dihydrocinnoline, tetrahydrocinnoline, perhydrocinnoline, dihydrobenzoxazole, perhydrobenzoxazole, dihydrobenzothiazole, perhydrobenzothiazole, dihydrobenzimidazole or perhydrobenzimidazole.

In the present specification, including the claims, it is to be understood that the group E, as written, bonds to

benzene ring at the right side and to J at the left side. For example, when E is written as $-\text{CO}-\text{NR}^3-$, the group AJE-bonded to the benzene ring is $\text{AJ}-\text{CO}-\text{NR}^3-$.

Non-toxic salts of the present invention include all pharmaceutically acceptable salts, for example, general salts, acid addition salts, hydrate salts.

The compounds of formulae (Ia) and (Ib) of the present invention may be converted into the corresponding salts. Water-soluble salts are preferred. Suitable salts, for example, include:


salts of alkali metals (e.g. sodium, potassium), salts of alkaline earth metals (e.g. calcium, magnesium), ammonium salts, salts of pharmaceutically acceptable organic amines (e.g. tetramethylammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris (hydroxymethyl)amine, lysine, arginine, N-methyl-D-glucamine).

The compounds of formulae (Ia) and (Ib) may be converted into the corresponding acid addition salts. Water-soluble salts are preferred. Suitable salts, for example, include salts of inorganic acids e.g. hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, nitrate; salts of organic acids e.g. acetate, trifluoroacetate, lactate, tartarate, oxalate, fumarate, maleate, citrate, benzoate, methanesulphonate, ethanesulphonate, benzenesulphonate, toluenesulphonate, isethionate, glucuronate, gluconate.

The compounds of formulae (Ia) and (Ib) and salts thereof may be converted into the corresponding hydrates by conventional means.


In the compounds of the present invention of formulae (Ia) and (Ib), sulfonylamino acid derivatives of the following formulae, ester derivatives thereof and non-toxic salts thereof are preferred:

the formula I (1):




wherein A and G are as hereinbefore defined,

the formula I (2):




wherein A and G are as hereinbefore defined,

the formula I(3):




wherein A and G are as hereinbefore defined,

the formula I(4):




wherein A and G are as hereinbefore defined,

the formula I(5):




wherein A and G are as hereinbefore defined,

the formula I(6):




wherein A and G are as hereinbefore defined,

the formula I(7):




wherein A and G are as hereinbefore defined,

the formula I(8):




wherein A and G are as hereinbefore defined,

the formula I(9):




wherein A and G are hereinbefore defined,

the formula I(10):




wherein A and G are as hereinbefore defined,

the formula I(11):




wherein A and G are as hereinbefore defined,

the formula I(12):




wherein A and G are as hereinbefore defined,

the formula I(13):




wherein A and G are as hereinbefore defined,

the formula I(14):




wherein A and G are as hereinbefore defined,

the formula I(15):




wherein A and G are as hereinbefore defined,

the formula I(16):




wherein A and G are as hereinbefore defined,

the formula I(17):




wherein A and G are as hereinbefore defined,

the formula I(18):




wherein A and G are as hereinbefore defined,

the formula I(19):




wherein R¹ and E are as hereinbefore defined,

the formula I(20):




wherein R¹ and E are as hereinbefore defined,

the formula I(21):




wherein R¹ and E are as hereinbefore defined,

the formula I(22):




10 wherein R¹ and E are as hereinbefore defined,

the formula I(23):



20 wherein R¹ and E are as hereinbefore defined, and


the formula I(24):



30 wherein A, R⁴ and R⁵ are as hereinbefore defined.

35 The preferred specific compounds of formulae (Ia) and (Ib) are the compounds in Tables 1-23, the compounds numbered (1)-(71) following Table 23, the compounds described in the Examples, ester derivatives thereof and non-toxic salts thereof.


Table 1



(IA)

No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		


Table 2



(IB)

No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 3



(IC)
























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		


Table 4



(ID)

No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 5



(IE)
























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		


Table 6



(IF)

No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 7



(IG)
























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		


Table 8



(IH)

No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		


Table 9



(IJ)

No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		


Table 10



(IK)

No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 11



(IL)
























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		


Table 12



(IM)

No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		


Table 13



(IN)

No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		


Table 14



(IP)

No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 15



(IQ)
























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 16



(IR)
























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 17



(IS)
























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 18



(IT)

























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 19



NO.	E	R ¹
1	-CO-NH-	CH ₃
2	-CO-NH-	CH(CH ₃) ₂
3	-NH-CO-	CH ₃
4	-NH-CO-	CH(CH ₃) ₂
5	-CO-O-	CH ₃
6	-CO-O-	CH(CH ₃) ₂
7	-O-CO-	CH ₃
8	-O-CO-	CH(CH ₃) ₂
9	-NH-CO-NH-	CH ₃
10	-NH-CO-NH-	CH(CH ₃) ₂
11	-O-CO-O-	CH ₃
12	-O-CO-O-	CH(CH ₃) ₂
13	-O-CO-NH-	CH ₃
14	-O-CO-NH-	CH(CH ₃) ₂
15	-NH-CO-O-	CH ₃
16	-NH-CO-O-	CH(CH ₃) ₂
17	-CO-CH ₂ -	CH ₃
18	-CO-CH ₂ -	CH(CH ₃) ₂
19	-CO-	CH ₃
20	-CO-	CH(CH ₃) ₂
21	-CS-NH-	CH ₃
22	-CS-NH-	CH(CH ₃) ₂
23	-NH-CS-	CH ₃
24	-NH-CS-	CH(CH ₃) ₂
25	-CS-O-	CH ₃
26	-CS-O-	CH(CH ₃) ₂
27	-O-CS-	CH ₃
28	-O-CS-	CH(CH ₃) ₂
29	-NH-CS-NH-	CH ₃
30	-NH-CS-NH-	CH(CH ₃) ₂
31	-O-CS-O-	CH ₃
32	-O-CS-O-	CH(CH ₃) ₂
33	-O-CS-NH-	CH ₃
34	-O-CS-NH-	CH(CH ₃) ₂
35	-NH-CS-O-	CH ₃
36	-NH-CS-O-	CH(CH ₃) ₂


Table 20



(IW)

NO.	E	R ¹
1	-CO-NH-	CH ₃
2	-CO-NH-	CH(CH ₃) ₂
3	-NH-CO-	CH ₃
4	-NH-CO-	CH(CH ₃) ₂
5	-CO-O-	CH ₃
6	-CO-O-	CH(CH ₃) ₂
7	-O-CO-	CH ₃
8	-O-CO-	CH(CH ₃) ₂
9	-NH-CO-NH-	CH ₃
10	-NH-CO-NH-	CH(CH ₃) ₂
11	-O-CO-C-	CH ₃
12	-O-CO-O-	CH(CH ₃) ₂
13	-O-CO-NH-	CH ₃
14	-O-CO-NH-	CH(CH ₃) ₂
15	-NH-CO-O-	CH ₃
16	-NH-CO-O-	CH(CH ₃) ₂
17	-CO-CH ₂ -	CH ₃
18	-CO-CH ₂ -	CH(CH ₃) ₂
19	-CO-	CH ₃
20	-CO-	CH(CH ₃) ₂
21	-CS-NH-	CH ₃
22	-CS-NH-	CH(CH ₃) ₂
23	-NH-CS-	CH ₃
24	-NH-CS-	CH(CH ₃) ₂
25	-CS-O-	CH ₃
26	-CS-O-	CH(CH ₃) ₂
27	-O-CS-	CH ₃
28	-O-CS-	CH(CH ₃) ₂
29	-NH-CS-NH-	CH ₃
30	-NH-CS-NH-	CH(CH ₃) ₂
31	-O-CS-O-	CH ₃
32	-O-CS-O-	CH(CH ₃) ₂
33	-O-CS-NH-	CH ₃
34	-O-CS-NH-	CH(CH ₃) ₂
35	-NH-CS-O-	CH ₃
36	-NH-CS-O-	CH(CH ₃) ₂


Table 21



(IY)

NO.	E	R ¹
1	-CO-NH-	CH ₃
2	-CO-NH-	CH(CH ₃) ₂
3	-NH-CO-	CH ₃
4	-NH-CO-	CH(CH ₃) ₂
5	-CO-O-	CH ₃
6	-CO-O-	CH(CH ₃) ₂
7	-O-CO-	CH ₃
8	-O-CO-	CH(CH ₃) ₂
9	-NH-CO-NH-	CH ₃
10	-NH-CO-NH-	CH(CH ₃) ₂
11	-O-CO-O-	CH ₃
12	-O-CO-O-	CH(CH ₃) ₂
13	-O-CO-NH-	CH ₃
14	-O-CO-NH-	CH(CH ₃) ₂
15	-NH-CO-O-	CH ₃
16	-NH-CO-O-	CH(CH ₃) ₂
17	-CO-CH ₂ -	CH ₃
18	-CO-CH ₂ -	CH(CH ₃) ₂
19	-CO-	CH ₃
20	-CO-	CH(CH ₃) ₂
21	-CS-NH-	CH ₃
22	-CS-NH-	CH(CH ₃) ₂
23	-NH-CS-	CH ₃
24	-NH-CS-	CH(CH ₃) ₂
25	-CS-O-	CH ₃
26	-CS-O-	CH(CH ₃) ₂
27	-O-CS-	CH ₃
28	-O-CS-	CH(CH ₃) ₂
29	-NH-CS-NH-	CH ₃
30	-NH-CS-NH-	CH(CH ₃) ₂
31	-O-CS-O-	CH ₃
32	-O-CS-O-	CH(CH ₃) ₂
33	-O-CS-NH-	CH ₃
34	-O-CS-NH-	CH(CH ₃) ₂
35	-NH-CS-O-	CH ₃
36	-NH-CS-O-	CH(CH ₃) ₂


Table 22



(IZ)

NO.	E	R ¹
1	-CO-NH-	CH ₃
2	-CO-NH-	CH(CH ₃) ₂
3	-NH-CO-	CH ₃
4	-NH-CO-	CH(CH ₃) ₂
5	-CO-O-	CH ₃
6	-CO-O-	CH(CH ₃) ₂
7	-O-CO-	CH ₃
8	-O-CO-	CH(CH ₃) ₂
9	-NH-CO-NH-	CH ₃
10	-NH-CO-NH-	CH(CH ₃) ₂
11	-O-CO-O-	CH ₃
12	-O-CO-O-	CH(CH ₃) ₂
13	-O-CO-NH-	CH ₃
14	-O-CO-NH-	CH(CH ₃) ₂
15	-NH-CO-O-	CH ₃
16	-NH-CO-O-	CH(CH ₃) ₂
17	-CO-CH ₂ -	CH ₃
18	-CO-CH ₂ -	CH(CH ₃) ₂
19	-CO-	CH ₃
20	-CO-	CH(CH ₃) ₂
21	-CS-NH-	CH ₃
22	-CS-NH-	CH(CH ₃) ₂
23	-NH-CS-	CH ₃
24	-NH-CS-	CH(CH ₃) ₂
25	-CS-O-	CH ₃
26	-CS-O-	CH(CH ₃) ₂
27	-O-CS-	CH ₃
28	-O-CS-	CH(CH ₃) ₂
29	-NH-CS-NH-	CH ₃
30	-NH-CS-NH-	CH(CH ₃) ₂
31	-O-CS-O-	CH ₃
32	-O-CS-O-	CH(CH ₃) ₂
33	-O-CS-NH-	CH ₃
34	-O-CS-NH-	CH(CH ₃) ₂
35	-NH-CS-O-	CH ₃
36	-NH-CS-O-	CH(CH ₃) ₂

Table 23




NO.	E	R ¹
1	-CO-NH-	CH ₃
2	-CO-NH-	CH(CH ₃) ₂
3	-NH-CO-	CH ₃
4	-NH-CO-	CH(CH ₃) ₂
5	-CO-O-	CH ₃
6	-CO-O-	CH(CH ₃) ₂
7	-O-CO-	CH ₃
8	-O-CO-	CH(CH ₃) ₂
9	-NH-CO-NH-	CH ₃
10	-NH-CO-NH-	CH(CH ₃) ₂
11	-O-CO-O-	CH ₃
12	-O-CO-O-	CH(CH ₃) ₂
13	-O-CO-NH-	CH ₃
14	-O-CO-NH-	CH(CH ₃) ₂
15	-NH-CO-O-	CH ₃
16	-NH-CO-O-	CH(CH ₃) ₂
17	-CO-CH ₂ -	CH ₃
18	-CO-CH ₂ -	CH(CH ₃) ₂
19	-CO-	CH ₃
20	-CO-	CH(CH ₃) ₂
21	-CS-NH-	CH ₃
22	-CS-NH-	CH(CH ₃) ₂
23	-NH-CS-	CH ₃
24	-NH-CS-	CH(CH ₃) ₂
25	-CS-O-	CH ₃
26	-CS-O-	CH(CH ₃) ₂
27	-O-CS-	CH ₃
28	-O-CS-	CH(CH ₃) ₂
29	-NH-CS-NH-	CH ₃
30	-NH-CS-NH-	CH(CH ₃) ₂
31	-O-CS-O-	CH ₃
32	-O-CS-O-	CH(CH ₃) ₂
33	-O-CS-NH-	CH ₃
34	-O-CS-NH-	CH(CH ₃) ₂
35	-NH-CS-O-	CH ₃
36	-NH-CS-O-	CH(CH ₃) ₂

- (1) N-[[4-(Benzoylamino)phenyl]sulfonyl]glycine,
- (2) N-[[3-(Benzoylamino)phenyl]sulfonyl]glycine,
- (3) N-[[2-(Benzoylamino)phenyl]sulfonyl]glycine,
- (4) N-[[4-(Acetylamino)phenyl]sulfonyl]glycine,
- 5 (5) N-[[4-(Phenylacetylamino)phenyl]sulfonyl]glycine,
- (6) N-[[4-[(Phenylethylcarbonyl)amino]phenyl]sulfonyl]glycine,
- (7) N-[[4-(Cinnamoylamino)phenyl]sulfonyl]glycine,
- (8) N-[[4-(N-Phenylureido)phenyl]sulfonyl]glycine,
- (9) N-[[4-(N-Phenylthioureido)amino]phenyl]sulfonyl]glycine,
- 10 (10) N-[[4-[(Benzyloxycarbonyl)amino]phenyl]sulfonyl]glycine,
- (11) N-[[4-[(Phenylloxymethylcarbonyl)amino]phenyl]sulfonyl]glycine,
- (12) N-[[4-[(Benzyloxymethylcarbonyl)amino]phenyl]sulfonyl]glycine,
- (13) N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]glycine,
- (14) N-[[4-(4-Fluorobenzoylamino)phenyl]sulfonyl]glycine,
- 15 (15) N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]glycine,
- (16) N-[[4-(3-Nitrobenzoylamino)phenyl]sulfonyl]glycine,
- (17) N-[[4-(2-Nitrobenzoylamino)phenyl]sulfonyl]glycine,
- (18) N-[[4-(4-Formylbenzoylamino)phenyl]sulfonyl]glycine,
- (19) N-[[4-(Benzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
- 20 (20) N-[[4-(Benzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
- (21) N-[[4-(4-Methylbenzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
- (22) N-[[4-(4-Methylbenzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
- (23) N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
- (24) N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
- 25 (25) N-[[4-(4-Fluorobenzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
- (26) N-[[4-(4-Fluorobenzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
- (27) N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
- (28) N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
- (29) N-[[4-(4-Pivaloyloxyphenyl)sulfonyl]-D, L- α -phenylglycine,
- 30 (30) N-[[4-(4-Pivaloyloxyphenyl)sulfonyl]-D, L-phenylalanine,
- (31) N-[[4-(2, 4-Dichlorobenzoylamino)phenyl]sulfonyl]glycine,
- (32) N-[[4-(2, 4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-alanine,
- (33) N-[[4-(2, 4-Dichlorobenzoylamino)phenyl]sulfonyl]- β -alanine,
- (34) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-valine,
- 35 (35) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-valine,
- (36) N-[[4-(2, 4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-leucine,
- (37) N-[[4-(2, 4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-leucine,
- (38) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-serine,
- (39) N-[[4-(2, 4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-phenylalanine,
- 40 (40) N-[[4-(2, 4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-tyrosine,
- (41) N-[[4-(2, 4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-alanine methyl ester,
- (42) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-valine methyl ester,
- (43) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-valine methyl ester,
- (44) N-[[4-[[2, 4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-leucine methyl ester,
- 45 (45) N-[[4-(2, 4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-serine methyl ester,
- (46) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-tyrosine methyl ester,
- (47) N-[[4-(3-Nitrobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
- (48) N-[[3-(3-Nitrobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
- (49) N-[[4-(3-Aminobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
- 50 (50) N-[[3-(3-Aminobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
- (51) N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-glutamic acid,
- (52) N-[[4-(4-Chlorobenzoylamino)phenyl]sulfonyl]-L-glutamic acid,
- (53) N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]-L-glutamic acid,
- (54) N-[[4-[2-(4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-3-morpholinoalanine ethyl ester,
- 55 (55) N-[[4-[2-(4-(1-Nitrophenyl)butyryloxy]phenyl]sulfonyl]-D,L-3-morpholino alanine ethyl ester,
- (56) N-[[4-(2-Methoxy-2-phenylacetyloxy)phenyl]sulfonyl]-D,L-3-morpholino alanine ethyl ester,
- (57) N-[[4-[[1-(4-Nitrophenyl)cyclobutyl]carbonyloxy]phenyl]sulfonyl]-D,L-3-morpholinoalanine ethyl ester,
- (58) N-[[3-Methyl-4-[2-(4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-t-butoxycarbonyl-L-lysine,


- (59) N-[[4-(2-Phenylbutyryloxy)phenyl]sulfonyl]glycine,
 (60) N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-phenyl alanine,
 (61) N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-aspartic acid,
 (62) N-[[4-[[[1-(4-Nitrophenyl)cyclobutyl]carbonyl]oxy]phenyl]sulfonyl]-D, L-aspartic acid,
 (63) 1-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonylamide]-1-cyclopropanecarboxylic acid,
 (64) N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-2-(2-furanyl)glycine,
 (65) N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-2-(2-thienyl)glycine,
 (66) N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-L-valine,
 (67) N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-S-carboxymethyl-L-cysteine,
 (68) N-[[4-[2-Ethyl-2-(4-methoxyphenyl)butyryloxy]phenyl]sulfonyl]-glycine,
 (69) N-[[3-Methyl-4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-L-lysine,
 (70) 5-[N-[[3-Methyl-4-[2-[4-(1-pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]amino]pentanoic acid, and
 (71) N-[[3-Methyl-4-pivaloyloxy]phenyl]sulfonyl]- β -alanine.

In the compounds of the present invention of the formula (Ib), the compound in which A-J-E-, substituents of Ar in A, H⁶ and R⁷ in G, and -COOR² are not -COOH or a group containing -COOH, and in which substituents of Ar in A, and H⁶ and R⁷ in G are not amino, hydroxy or a group containing amino or hydroxy, that is the compound of the formula (Ib-1),




wherein R²⁻¹ is C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl, -OCOR¹⁶, in which R¹⁶ is as hereinbefore defined or -CONR¹⁷R¹⁸, in which R¹⁷ and R¹⁸ are as hereinbefore defined; G¹, E¹, J¹ and A¹ are as hereinbefore defined for G, E, J and A, with the proviso that when E¹ is -OCO- or -OCS- and J¹ is a bond, A¹ is not hydrogen; and with the proviso that substituents of Ar in A¹, and R⁶ and R⁷ in G¹ are not -COOH, amino, hydroxy or a group containing COOH, amino or hydroxy; and R¹ is as hereinbefore defined; may be prepared by following methods (a) - (k).


(a) In the compounds of the formula (Ib-1), the compounds in which E¹ is -CONR³-, that is the compounds of the formula



wherein E¹ is -CO-NR³- and the other symbols are as hereinbefore defined; may be prepared by amidation of the compound of the formula (Ib-a):



wherein all the symbols are as hereinbefore defined;
 with the compound of the formula (IIb-a):



(IIIb-a)

wherein all the symbols are as hereinbefore defined; if necessary, followed by deprotection. (Ib-a):

The method of amidation is known. It includes the method

- (1) via an acyl halide,
- (2) via a mixed acid anhydride,
- (3) using a condensing agent.

These methods are explained as follows.

(1) The method via an acyl halide, for example, may be carried out in an organic solvent (e.g. chloroform, methylene chloride, diethyl ether or tetrahydrofuran) or without a solvent, using an acid halide (e.g. oxalyl chloride or thionyl chloride) at -20°C to reflux temperature, and the obtained acyl halide derivative may be reacted with an amine in an organic solvent (e.g. chloroform, methylene chloride, diethyl ether or tetrahydrofuran) in the presence of a tertiary amine (e.g. pyridine, triethyl amine, dimethyl aniline or dimethylaminopyridine) at 0-40°C.

(2) The method via a mixed acid anhydride may be carried out, for example, by reacting a carboxylic acid with an acid halide (e.g. pivaloyl chloride, tosyl chloride, mesyl chloride, ethyl chloroformate or isobutyl chloroformate) in an organic solvent (e.g. chloroform, methylene chloride, diethyl ether or tetrahydrofuran) or without a solvent, in the presence of a tertiary amine (e.g. pyridine, triethylamine, dimethylaniline or dimethylaminopyridine) at -20°C-40°C, and the obtained mixed acid anhydride derivative may be reacted with a corresponding amine in an organic solvent (e.g. chloroform, methylene chloride, diethyl ether or tetrahydrofuran) at 0-40°C.

(3) The method using a condensing agent (e.g. 1,3-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-[3-(dimethylamino) propyl]carbodiimide (EDC) or 2-chloro-1-methylpyridinium iodide) may be carried out, for example, by reacting a carboxylic acid with an amine in an organic solvent (e.g. chloroform, methylene chloride, dimethylformamide or diethyl ether) or without a solvent, optionally in the presence of a tertiary amine (e.g. pyridine, triethylamine, dimethylaniline or dimethylaminopyridine) using a condensing agent at 0-40°C.

The reactions described in (1), (2) and (3) may be carried out under an inert gas (e.g. argon or nitrogen) to avoid water in order to obtain a preferable result.

The method of deprotection is known. It includes

- (1) deprotection under alkaline conditions,
- (2) deprotection under acidic conditions,
- (3) hydrogenolysis,

and a suitable method is selected from (1), (2) and (3) depending on the character of the protecting group.


These methods are explained as follows.

(1) Deprotection under alkaline conditions, for example, may be carried out in an organic solvent (e.g. methanol, tetrahydrofuran(THF) or dioxane), using an alkali metal hydroxide (e.g. potassium hydroxide or sodium hydroxide), an alkaline earth metal hydroxide (e.g. calcium hydroxide) or a carbonate (e.g. sodium carbonate or potassium carbonate), an aqueous solution thereof or a mixture thereof at 0-40°C.


(2) Deprotection under acidic conditions, for example, may be carried out in an organic solvent (e.g. methylene chloride, chloroform, dioxane, ethyl acetate, acetic acid, water or a mixture of two or more thereof), using an organic acid (e.g. trifluoroacetic acid), or an inorganic acid (e.g. hydrogen chloride or hydrogen bromide) or a mixture thereof at 0-120°C.

(3) Hydrogenolysis, for example, may be carried out in a solvent [e.g. an ether (such as tetrahydrofuran, dioxane, dimethoxyethane or diethyl ether), an alcohol (such as methanol or ethanol), a benzene-type solvent (such as benzene or toluene), an amide (such as dimethylformamide), water, ethyl acetate, acetic acid or a mixture of two or more thereof], in the presence of a catalyst (e.g. palladium on carbon, palladium black, palladium hydroxide, platinum dioxide, or Raney-nickel), optionally in the presence of an inorganic acid (e.g. hydrochloric acid, sulfuric acid, hypochlorous acid, boric acid or tetrafluoroboric acid) or an organic acid (e.g. acetic acid, p-toluenesulfonic acid, oxalic acid, trifluoroacetic acid or formic acid), at ordinary or elevated pressure of hydrogen gas or ammonium formate at 0-200°C.

(b) In the compounds of the formula (Ib-1), the compounds in which E¹ is -O-CO-NR³-, that is the compounds of the formula (Ib-b):



wherein E^b is -O-CO-NR³-, and the other symbols are as hereinbefore defined;
may be prepared by reacting the above compound of the formula (IIb-a) with the compound of the formula (IIIb-b):




wherein X is halogen and the other symbols are as hereinbefore defined;
if necessary, followed by deprotection.

This type of reaction is known and, for example, may be carried out in an organic solvent (e.g. acetonitrile or tetrahydrofuran) and optionally in the presence of water, using an organic base (e.g. 4-dimethylaminopyridine) or an inorganic base [e.g. an alkali metal hydroxide (such as sodium hydroxide or potassium hydroxide), an alkaline earth metal hydroxide (such as potassium hydroxide), or a carbonate (such as sodium carbonate or calcium carbonate)] at 0-40°C.

The reaction of deprotection may be carried out by the same method as hereinbefore described.


(c) In the compounds of the formula (Ib-1), the compounds in which E¹ is -NR³-CO-NR³- or -NR³-CS-NR³-, that is the compounds of the formula (Ib-c):



wherein E^c is -NR³-CO-NR³- or -NR³-CS-NR³-, and the other symbols are as hereinbefore defined;
may be prepared by reacting the above compound of the formula (IIb-a) with the compound of the formula (IIIb-c):



wherein all the symbols are as hereinbefore defined; and with the compound of the formula (IVb-c):



wherein T is oxygen or sulfur;
if necessary, followed by deprotection.


This type of reaction is known and, for example, may be carried out in an organic solvent (e.g. dimethylformamide, methylene chloride or tetrahydrofuran), optionally in the presence of an amine (e.g. triethylamine, pyridine or dimethylaminopyridine) at 0-80°C.

The reaction of deprotection may be carried out by the same method as hereinbefore described.

Besides, it may be also prepared by reacting the above compound of the formula (IIb-a) with the compound of the formula (IIIb-c1):



wherein all the symbols are as hereinbefore defined; or with the compound of the formula (IIIb-c2):




wherein all the symbols are as hereinbefore defined; if necessary, followed by deprotection.


This reaction is known and, for example, may be carried out in an organic solvent (e.g. acetone, chloroform, methyl chloride, benzene or tetrahydrofuran), optionally in the presence of an amine (e.g. triethylamine, pyridine or dimethylaminopyridine) at 0-80°C, or by the amidation method (1) via an acyl halide as hereinbefore described.

The reaction of deprotection may be carried out by the same method as hereinbefore described.

(d) In the compounds of the formula (Ib-1), the compounds in which E¹ is -CO-O-, that is the compounds of the formula (Ib-d):



wherein E^d is -CO-O- and the other symbols are as hereinbefore defined; may be prepared by esterification of the compound of the formula (IIb-d):



wherein all the symbols are as hereinbefore defined; with the above compound of the formula (IIIb-a); if necessary, followed by deprotection.

The method of esterification is known. It includes the method

- (1) via an acyl halide,
- (2) using a mixed acid anhydride,
- (3) using a condensing agent.

These methods are explained as follows.

(1) Acyl halide may be prepared in an organic solvent (e.g. chloroform, methylene chloride, diethyl ether or tetrahydrofuran) or without a solvent, using an acid halide (e.g. oxalyl chloride or thionyl chloride) at -20°C to reflux temperature, and the obtained acyl halide derivative may be reacted with an alcohol derivative in an organic solvent (e.g. chloroform, methylene chloride, diethyl ether or tetrahydrofuran), in the presence of a tertiary amine (e.g. pyridine, triethylamine, dimethylaniline or dimethylamino pyridine) at 0-40°C.


(2) Method using mixed acid anhydride may be carried out, for example, by reacting a carboxylic acid derivative with an acyl halide or acid derivative (e.g. ethyl chloroformate or isobutyl chloroformate), in an organic solvent (e.g. chloroform, methylene chloride, diethyl ether or tetrahydrofuran) or without a solvent, in the presence of a tertiary amine (e.g. pyridine, triethylamine, dimethylaniline or dimethylaminopyridine), and the obtained mixed acid anhydride derivative may be reacted with an alcohol derivative in an organic solvent (e.g. chloroform, methylene chloride, diethyl ether or tetrahydrofuran) at 0-40°C.

(3) Method using a condensing agent (e.g. DCC, EDC or 2-chloro-1-methylpyridinium iodide) may be carried out, for example, by reacting a carboxylic acid derivative with an alcohol derivative in an organic solvent (e.g. chloroform, methylene chloride, dimethylformamide or diethyl ether) or without a solvent, in the optional presence of a tertiary amine (e.g. pyridine, triethylamine, dimethylaniline or dimethylaminopyridine), using a condensing agent at 0-40°C.

The reactions described in (1), (2) and (3) may be carried out under an inert gas (e.g. argon or nitrogen) to avoid water in order to obtain a preferable result.

The reaction of deprotection may be carried out by the same method as hereinbefore described.

(e) In the compounds of the formula (Ib-1), the compounds in which E¹ is -O-CO-O-, that is the compounds of the formula (Ib-e):




wherein E^e is -O-CO-O- and the other symbols are as hereinbefore defined;

may be prepared by reacting the above compound of the formula (IIb-d) with the above compound of the formula (IIIb-b); if necessary, followed by deprotection.

This reaction may be carried out by the same method as (b).


The reaction of deprotection may be carried out by the same method as hereinbefore described.

(f) In the compounds of the formula (Ib-1), the compounds in which E¹ is -NR³-CO-, that is the compounds of the formula (Ib-f):



wherein E^f is -NR³-CO- and the other symbols are as hereinbefore defined;

may be prepared by amidation of the compound of the formula (IIb-f):




wherein all the symbols are as hereinbefore defined; with the above compound of the formula (IIIb-c); if necessary,

followed by deprotection.

This reaction of amidation may be carried out by the same method as (a).

The reaction of deprotection may be carried out by the same method as hereinbefore described.

(g) In the compounds of the formula (Ib-1), the compounds in which E¹ is -O-CO-, that is the compounds of the formula (Ib-g):



wherein E^g is -O-CO- and the other symbols are as hereinbefore defined;

may be prepared by esterification of the above compound of the formula (Ib-f) with the compound of the formula (IIIb-g):




wherein all the symbols are as hereinbefore defined; if necessary, followed by deprotection.

This reaction of esterification may be carried out by the same method as (d).


The reaction of deprotection may be carried out by the same method as hereinbefore described.

(h) In the compounds of the formula (Ib-1), the compounds in which E¹ is -NR³-CO-O-, that is the compounds of the formula (Ib-h):



wherein E^h is -NR³-CO-O- and the other symbols are as hereinbefore defined;

may be prepared by reacting the compound of the formula (IIb-h):




wherein all the symbols are as hereinbefore defined; with the above compound of the formula (IIIb-c); if necessary, followed by deprotection.


This reaction may be carried out by the same method as (b).

The reaction of deprotection may be carried out by the same method as hereinbefore described.


(j) In the compounds of the formula (Ib-1), the compounds in which E¹ is -CO- or -CO-CH₂- that is the compounds of the formula (Ib-j):



wherein E^1 is $-\text{CO}-$ or $-\text{CO}-\text{CH}_2-$ and the other symbols are as hereinbefore defined; may be prepared by reacting the compound of the formula (IIb-j-1):



wherein all the symbols are as hereinbefore defined; or the compound of the formula (IIb-j-2):



wherein all the symbols are as hereinbefore defined; with the compound of the formula (IIIb-j):




wherein all the symbols are as hereinbefore defined; if necessary, followed by deprotection.

This reaction using an organocopper agent is known; for example, an organocopper agent, which is prepared in organic solvent (e.g. tetrahydrofuran or ether), using an organic lithium agent and an inorganic copper compound (e.g. copper iodide or copper cyanide) at -78°C – 0°C , may be reacted with an acyl halide at -78°C – 0°C . The reactions may be carried out under an inert gas (e.g. argon or nitrogen) to avoid water in order to obtain a preferable result.


The reaction of deprotection may be carried out by the same method as hereinbefore described.

(j-1) In the compounds of the formula (Ib-1), the compounds in which E^1 is $-\text{CO}-\text{NR}^3$ -, $-\text{O}-\text{CO}-\text{NR}^3$ -, $-\text{NR}^3-\text{CO}-\text{O}-$, $-\text{CO}-\text{O}-$, $-\text{CO}-\text{CH}_2-$ or $-\text{O}-\text{CO}-\text{O}-$, that is the compounds of the formula (Ib-1-AA):



wherein $\text{E}^{1\text{A}}$ is $-\text{CO}-\text{NR}^3$ -, $-\text{O}-\text{CO}-\text{NR}^3$ -, $-\text{NR}^3-\text{CO}-\text{O}-$, $-\text{CO}-\text{O}-$, $-\text{CO}-\text{CH}_2-$ or $-\text{O}-\text{CO}-\text{O}-$ and the other symbols are as hereinbefore defined;

may be prepared by amidation of the compound of the formula (XII):



wherein all the symbols are as hereinbefore defined;
with the compound of the formula (XIII):




wherein all the symbols are as hereinbefore defined;
if necessary, followed by deprotection.


This amidation may be carried out by the amidation method (1) via an acyl halide as hereinbefore described.

The reaction of deprotection may be carried out by the same method as hereinbefore described.

(j-2) In the compounds of the formula (Ib-1), the compounds in which E^1 is $-\text{CO}-\text{NR}^3-$, $-\text{NR}^3-\text{CO}-$, $-\text{NR}^3-\text{CO}-\text{NR}^3-$, $-\text{O}-\text{CO}-\text{NR}^3-$ or $-\text{NR}^3-\text{CO}-\text{O}-$, that is the compounds of the formula (Ib-1-AB):



wherein E^{1B} is $-\text{CO}-\text{NR}^3-$, $-\text{NR}^3-\text{CO}-$, $-\text{NR}^3-\text{CO}-\text{NR}^3-$, $-\text{O}-\text{CO}-\text{NR}^3-$ or $-\text{NR}^3-\text{CO}-\text{O}-$ and the other symbols are as hereinbefore defined; may be also prepared by conversion of $-\text{NH}-$ into $-\text{N}(\text{R}^{3-1})-$, wherein R^{3-1} is C1-4 alkyl, phenyl or C1-4 alkyl substituted by phenyl; in the compound of the formula (Ib-1-AB1):




wherein E^{1BB} is $-\text{CO}-\text{NH}-$, $-\text{NH}-\text{CO}-$, $-\text{NH}-\text{CO}-\text{NH}-$, $-\text{O}-\text{CO}-\text{NH}-$ or $-\text{NH}-\text{CO}-\text{O}-$, R^B is an amino-protecting group (e.g. t-butoxycarbonyl, benzyloxycarbonyl) and the other symbols are as hereinbefore defined; and followed by deprotection of the amino group protected by R^B .


This reaction of conversion of $-\text{NH}-$ into $-\text{N}(\text{R}^{3-1})-$ may be performed in an organic solvent (e.g. dimethylformamide), in the presence of a base (e.g. sodium hydride), using a corresponding R^{3-1} -halide at 0-40°C.

The reaction of deprotection may be carried out by the same method as hereinbefore described.


(k) In the compounds of the formula (Ib-1), the compounds in which E^1 is $-\text{CS}-\text{NR}^3-$, $-\text{NR}^3-\text{CS}-$, $-\text{NR}^3-\text{CS}-\text{NR}^3-$, $-\text{O}-\text{CS}-\text{NR}^3-$, $-\text{NR}^3-\text{CS}-\text{O}-$, $-\text{CS}-\text{O}-$, $-\text{O}-\text{CS}-$ or $-\text{O}-\text{CS}-\text{O}-$ that is the compounds of the formula (Ib-k):



wherein E^k is $-\text{CS}-\text{NR}^3$ -, $-\text{NR}^3-\text{CS}-$ -, $-\text{NR}^3-\text{CS}-\text{NR}^3$ -, $-\text{O}-\text{CS}-\text{NR}^3$ -, $-\text{NR}^3-\text{CS}-\text{O}-$ -, $-\text{CS}-\text{O}-$ -, $-\text{O}-\text{CS}-$ or $-\text{O}-\text{CS}-\text{O}-$ and the other symbols are as hereinbefore defined;
 may be prepared by reacting the compound which is prepared by the above method, of the formula (Ib-a), (Ib-b), (Ib-c), (Ib-d), (Ib-e), (Ib-f), (Ib-g) or (Ib-h), that is the compound of the formula (Ib-m):



wherein E^m is $-\text{CO}-\text{NR}^3$ -, $-\text{NR}^3-\text{CO}-$ -, $-\text{NR}^3-\text{CO}-\text{NR}^3$ -, $-\text{O}-\text{CO}-\text{NR}^3$ -, $-\text{NR}^3-\text{CO}-\text{O}-$ -, $-\text{CO}-\text{O}-$ -, $-\text{O}-\text{CO}-$ or $-\text{O}-\text{CO}-\text{O}-$ and the other symbols are as hereinbefore defined;
 with Lawesson's reagent of the formula (IIIb-k):




if necessary, followed by deprotection.

This reaction using Lawesson's reagent is known and, for example, may be carried out in an organic solvent (e.g. dioxane, benzene, toluene or xylene) at 20-150°C. The reactions may be carried out under an inert gas (e.g. argon or nitrogen) to avoid water in order to obtain a preferable result.

The reaction of deprotection may be carried out by the same method as hereinbefore described.

In the compounds of the present invention of the formula (Ib), the compound in which at least one of $\text{A}-\text{J}-\text{E}$ -, substituents of Ar in A, R^6 or R^7 in G, and $-\text{COOR}^2$ is $-\text{COOH}$ or a group containing $-\text{COOH}$, or in which at least one of substituents of Ar in A, and R^6 or R^7 in G is amino, hydroxy or a group containing amino or hydroxy, that is the compound of the formula (Ib-2):




wherein G^2 , E^2 , J^2 , and A^2 are as hereinbefore defined for G, E, J and A, with the proviso that at least one of $\text{A}^2-\text{J}^2-\text{E}^2$ -, substituents of Ar in A^2 , R^6 or R^7 in G^2 , and $-\text{COOR}^2$ is $-\text{COOH}$ or a group containing $-\text{COOH}$, or at least one of substituents of Ar in A^2 , and R^6 or R^7 in G^2 is amino, hydroxy or a group containing amino or hydroxy, or $\text{A}^2-\text{J}^2-\text{E}^2$ - is $-\text{CSOH}$, and the other symbols are as hereinbefore defined;
 may be prepared by subjecting the compound of the formula (Ib-1) to deprotection.


The reaction of deprotection may be carried out by the same method as hereinbefore described.

Besides, in the compounds of the present invention of the formula (Ib), the compound in which A represents Ar

substituted by at least one amino group, that is the compound of the formula (Ib-3):




wherein A^3 is as hereinbefore defined for Ar, with the proviso that A^3 is substituted by at least one amino group, and the other symbols are as hereinbefore defined; may be prepared by subjecting the compound prepared by the above methods of the formula (Ib-4):




wherein A^4 is as hereinbefore defined for Ar, with the proviso that A^4 is substituted by at least one nitro group, and the other symbols are as hereinbefore defined; to hydrogenolysis.

Hydrogenolysis may be carried out by the same method as hereinbefore described.


The compounds of formulae (IIb-a), (IIb-d), (IIb-f), (IIb-h), (IIb-j-1) and (IIb-j-2) may be prepared by known methods, methods described in the following schemes 1-3 or methods described in the Examples.

Scheme 1

Scheme 2



Scheme 3



50 In the above schemes, Y is a hydroxyl-protecting group (e.g. benzyl, benzyloxycarbonyl), W is a protecting group (e.g. benzyl, methyl) and the other symbols are as hereinbefore defined.

In the above schemes, the compounds of formulae (VI) and (VII) include compounds of the formula (IIb-a). The compound of the formula (IX) includes compounds of the formula (IIb-d). The compound of the formula (XI) includes compounds of the formula (IIb-f).

55 Each reaction in the above schemes may be carried out by a known method. In the above schemes, the compounds of formulae (V), (VIII) and (X) are known per se or may be prepared by known methods.

In each reaction in the present specification, products may be purified by conventional techniques. For example, purification may be carried out by distillation at atmospheric or reduced pressure, by high performance liquid chroma-

tography, by thin layer chromatography or by column chromatography using silica gel or magnesium silicate, by washing or by recrystallization. Purification may be carried out after each reaction, or after a series of reactions.

The other starting materials and reagents in the present invention are known per se or may be prepared by known methods.

The potency of inhibitory activity of the compounds of formulae (Ia) and (Ib) against matrix metalloproteinases is confirmed as below. The IC_{50} value for inhibition of gelatinase A activity is determined as follows.

(1) Inhibitory activity against gelatinase A.

The progelatinase A (7 μ l; in assay buffer (90 μ l)) was purified from human normal skin dermal fibroblasts (HNDF). It was activated by the addition of 10mM p-aminophenylmercuric acetate (APMA) (10 μ l) for 1 hour at 37°C.

The solution of activated gelatinase A (7 μ l/tube, 98 μ l) was mixed with various concentrations of the test compound or dimethylsulfoxide (2 μ l) and gelatin (100 μ l) labeled with 0.05% fluorescein isothiocyanate (FITC) and incubated for 2 hours at 37°C. The reaction was terminated by the addition of 0.1M Tris-HCl (pH9.5) containing 94.7% ethanol (750 μ l). The mixture was stirred and then allowed to stand for 30 minutes at 0°C. The mixture was centrifuged for 30 minutes at 900 x g. The IC_{50} was determined by measuring the fluorescent intensity in supernatant ($Ex=495nm$, and $Em=520nm$). The results are shown in Table 24.

Table 24

Example No.	IC_{50} (μ M)
2	0.11
2(10)	0.66
2(11)	0.80
2(35)	0.013
2(63)	0.0023
3(13)	0.0027
6	0.42
10(1)	0.70

The toxicity of the compounds of the present invention is very low and therefore the compounds may be considered safe for pharmaceutical use.

Inhibition of matrix metalloproteinase is useful for prevention and/or treatment of diseases induced by overexpression or excess activity of matrix metalloproteinases, for example, rheumatoid diseases, arthrostelitis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis, invasion or growth of tumor cells, autoimmune disease (e.g. Crohn's disease, Sjogren's syndrome), disease caused by vascular emigration or infiltration of leukocytes, arterialization in animals including human beings, especially human beings.

For the purpose above described, the compounds of formulae (Ia) or (Ib) of the present invention and non-toxic salts thereof (e.g. acid addition salts or hydrates) may normally be administered systemically or locally, usually by oral or parenteral administration.

The doses to be administered are determined depending upon, for example, age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment. In the human adult, the doses per person are generally from 1 mg to 1000 mg, by oral administration, up to several times per day, and from 1 mg to 100 mg, by parenteral administration (preferably intravenous administration), up to several times per day, or continuous administration for from 1 to 24 hours per day from vein.

As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

The compounds of the present invention may be administered in the form of, for example, solid compositions, liquid compositions or other compositions for oral administration, injections, liniments or suppositories for parenteral administration.

Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules.

Capsules include hard capsules and soft capsules.

In such compositions, one or more of the active compound(s) may be admixed with at least one inert diluent (such

as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone or magnesium metasilicate aluminate). The compositions may also comprise, as is normal practice, additional substances other than inert diluents: e.g. lubricating agents (such as magnesium stearate), disintegrating agents (such as cellulose calcium glycolate), stabilizing agents, and agents to assist dissolution (such as glutamic acid or aspartic acid).

The tablets or pills may, if desired, be coated with a film of gastric or enteric material (such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate), or be coated with two or more films. And further, coating may include containment within capsules of absorbable materials such as gelatin.

Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, syrups and elixirs. In such compositions, one or more of the active compound(s) may be contained in an inert diluent(s) commonly used in the art (e.g. purified water or ethanol). Besides inert diluents, such compositions may also comprise adjuvants (such as wetting agents or suspending agents), sweetening agents, flavouring agents, perfuming agents, and preserving agents.

Other compositions for oral administration include spray compositions which may be prepared by known methods and which comprise one or more of the active compound(s). Spray compositions may comprise additional substances other than inert diluents: e.g. stabilizing agents (such as sodium sulfate), isotonic buffers (such as sodium chloride, sodium citrate or citric acid). For preparation of such spray compositions, for example, the method described in the United States Patent No. 2,868,691 or 3,095,355 may be used.

Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Aqueous solutions and suspensions may include distilled water for injection or physiological salt solution. Non-aqueous solutions and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, alcohol such as ethanol or POLYSORBATE80 (registered trade mark).

Injections may comprise additional ingredients other than inert diluents: e.g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agents, assisting agents such as agents to assist dissolution (e.g. glutamic acid or aspartic acid).

They may be sterilized for example, by filtration through a bacteria-retaining filter, by incorporation of sterilizing agents in the compositions or by irradiation. They may also be manufactured in the form of sterile solid compositions which may be dissolved in sterile water or some other sterile diluent(s) for injection immediately before use.

Other compositions for parenteral administration include liquids for external use, and endermic liniments, ointment, suppositories for rectal administration and pessaries for vaginal administration which comprise one or more of the active compound(s) and may be prepared by methods known per se.

Reference example and Example


The following reference examples and examples illustrate the present invention, but do not limit the present invention.

The solvents in the parentheses show the developing or eluting solvents and the ratios of the solvents used are by volume in chromatographic separations or TLC.

The solvents in the parentheses in NMR show the solvents used in measurement.

Reference example 1

N-[(4-Nitrophenyl)sulfonyl]glycine t-butyl ester




4-Nitrobenzenesulfonyl chloride (46.3 g) was added to a solution of glycine t-butyl ester hydrochloride (35 g) in pyridine (200 ml). The mixture was stirred for 1 hour at room temperature. The reaction mixture was concentrated. The precipitated crystals were washed with water and then a mixture of hexane and ethyl acetate (9 : 1) and dried to give the title compound (61.4 g) having the following physical data.

TLC: Rf 0.18 (Hexane : Ethyl acetate = 4 : 1).

Reference example 2


N-[(4-Aminophenyl)sulfonyl]glycine t-butyl ester



To a solution of the compound prepared in reference example 1 (57.1 g) in ethanol (200 ml) and tetrahydrofuran (200 ml), 10% palladium carbon (2.2 g) was added. The mixture was stirred for 3 hours at room temperature under an atmosphere of hydrogen. The reaction mixture was filtered through celite (registered trade mark). The filtrate was concentrated. The precipitated crystals were washed with a mixture of hexane and ethyl acetate (4 : 1) and dried to give the title compound (50 g) having the following physical data.
TLC: Rf 0.36 (Hexane : Ethyl acetate = 1 : 1).

Example 1

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]glycine t-butyl ester




To a solution of the compound prepared in reference example 2 (1.2 g) in pyridine (10 ml), p-toluoyl chloride (0.5 ml) was added at 0°C. The mixture was stirred for 30 minutes at room temperature. To the reaction mixture, 1N hydrochloric acid (100 ml) was added. The mixture was extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium bicarbonate, a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate and concentrated. The residue was washed with ether and dried to give the title compound (1.52 g) having the following physical data.
TLC: Rf 0.56 (Hexane : Ethyl acetate = 1 : 1),
NMR (CDCl₃): δ 8.08-8.00 (1H, br.s), 7.86 (2H, d, J=9.2Hz), 7.82 (2H, d, J=9.2Hz), 7.78 (2H, d, J=8.2Hz), 7.31 (2H, d, J=8.2Hz), 5.04 (1H, t, J=5.4Hz), 3.67 (2H, d, J=5.4Hz), 2.44 (3H, s), 1.37 (9H, s).

Example 1(1)-1(91)

The compounds having the following physical data were obtained by the same procedure as a series of reactions of Example 1, using a corresponding acyl chloride instead of p-toluoyl chloride.

Example 1(1)

N-[[4-(Isobutyrylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.41 (Hexane : Ethyl acetate = 1:1),

NMR (CDCl₃): δ 7.77 (2H, d, J=9.0Hz), 7.68 (2H, d, J=9.0Hz), 5.15 (1H, t, J=5.4Hz), 3.64 (2H, d, J=5.4Hz), 2.56 (1H, m), 1.36 (9H, s), 1.25 (6H, d, J=6.8Hz).

Example 1(2)


N-[[4-(Acetylamino)phenyl]sulfonyl]glycine t-butyl ester



TLC: Rf 0.36 (Hexane : Ethyl acetate = 3 : 7),
NMR (CDCl₃): δ 7.78 (2H, d, J=8.8Hz), 7.76-7.72 (1H), 7.65 (2H, d, J=8.8Hz), 5.11 (1H, t, J=5.4Hz), 3.65 (2H, d, J=5.4Hz), 2.21 (3H, s), 1.36 (9H, s).

Example 1(3)


N-[[4-(o-Toluoylamino)phenyl]sulfonyl]glycine t-butyl ester



TLC: Rf 0.64 (Hexane : Ethyl acetate = 1 : 1),
NMR (CDCl₃): δ 7.83 (2H, d, J=8.8Hz), 7.76 (2H, d, J=8.8Hz), 7.88-7.72 (1H), 7.52-7.22 (4H, m), 5.01 (1H, t, J=5.4Hz), 3.65 (2H, d, J=5.4Hz), 2.49 (3H, s), 1.37 (9H, s).

Example 1(4)


N-[[4-(m-Toluoylamino)phenyl]sulfonyl]glycine t-butyl ester



TLC: Rf 0.59 (Hexane : Ethyl acetate = 1 : 1),
NMR (CDCl₃): δ 8.10-8.04 (1H, br.s), 7.85 (2H, d, J=9.2Hz), 7.80 (2H, d, J=9.2Hz), 7.72-7.60 (2H, m), 7.43-7.36 (2H, m), 5.05 (1H, t, J=5.4Hz), 3.67 (2H, d, J=5.4Hz), 2.44 (3H, s), 1.37 (9H, s).

Example 1(5)

N-[[4-(2-Chlorobenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.52 (Hexane : Ethyl acetate = 1 : 1),

NMR(CDCl₃): δ 8.22-8.12 (1H, br.s), 7.87 (2H, d, J=8.6Hz), 7.84-7.74 (1H, m), 7.79 (2H, d, J=8.6Hz), 7.50-7.36 (3H, m), 5.03 (1H, t, J=5.6Hz), 3.67 (2H, d, J=5.6Hz), 1.36 (9H, s).

Example 1(6)

N-[[4-(3-Chlorobenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.58 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.02-7.94 (1H, br.s), 7.92-7.72 (6H, m), 7.61-7.40 (2H, m), 5.02 (1H, t, J=5.4Hz), 3.68 (2H, d, J=5.4Hz), 1.37 (9H, s).

Example 1(7)

N-[[4-(4-Chlorobenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.64 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.00-7.90 (1H, br.s), 7.87 (2H, d, J=8.6Hz), 7.83 (2H, d, J=8.8Hz), 7.78 (2H, d, J=8.6Hz), 7.49 (2H, d, J=8.8Hz), 5.00 (1H, t, J=5.4Hz), 3.67 (2H, d, J=5.4Hz), 1.37 (9H, s).

Example 1(8)

N-[[4-(2-Methoxybenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.42 (Hexane : Ethyl acetate = 1 : 1),

NMR(CDCl₃): δ 10.08-10.00 (1H, br.s), 8.28 (1H, dd, J=2.0, 8.0Hz), 7.87 (2H, d, J=9.4Hz), 7.82 (2H, d, J=9.4Hz),

7.60-7.48 (1H, m), 7.21-7.11 (1H, m), 7.06 (1H, d, J=8.4Hz), 4.99 (1H, t, J=5.4Hz), 4.09 (3H, s), 3.67 (2H, d, J=5.4Hz), 1.36 (9H, s).

Example 1(9)

N-[[4-(3-Methoxybenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.52 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.02-7.96 (1H, br.s), 7.87 (2H, d, J=9.2Hz), 7.80 (2H, d, J=9.2Hz), 7.47-7.36 (3H, m), 7.15-7.08 (1H, m), 5.01 (1H, t, J=5.4Hz), 3.88 (3H, s), 3.68 (2H, d, J=5.4Hz), 1.37 (9H, s).

Example 1(10)

N-[[4-(Benzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.70 (Ethyl acetate),

NMR (CDCl₃): δ 8.02 (1H, s), 7.9-7.8 (6H, m), 7.6-7.3 (3H, m), 5.02 (1H, t, J=5.4Hz), 3.68 (2H, d, J=5.4Hz), 1.37 (9H, s).

Example 1(11)

N-[[4-(4-Fluorobenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.53 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃+CD₃OD): δ 7.88 (2H, dd, J=5.2, 8.8Hz), 7.82-7.75 (4H, m), 7.11 (2H, t, J=8.8Hz), 3.60 (2H, s), 1.31 (9H, s).

Example 1(12)

N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.40 (Hexane : Ethyl acetate = 1 : 1),

10 NMR (CDCl₃): δ 7.94-7.90 (1H, br.s), 7.86 (2H, d, J=9.2Hz), 7.85 (2H, d, J=8.8Hz), 7.79 (2H, d, J=9.2Hz), 6.99 (2H, d, J=8.8Hz), 5.00 (1H, t, J=5.4Hz), 3.89 (3H, s), 3.67 (2H, d, J=5.4Hz), 1.37 (9H, s).

Example 1(13)

15 N-[[4-(2-Nitrobenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




25 TLC: Rf 0.62 (Ethyl acetate),

NMR (CD₃OD): δ 8.19 (1H, d, J=8.4Hz), 7.9-7.7 (7H, m), 3.65 (2H, s), 1.35 (9H, s).

Example 1(14)

30 N-[[4-(3-Nitrobenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




40 TLC: Rf 0.72 (Ethyl acetate),

NMR (CDCl₃+CD₃OD): δ 8.85 (1H, s), 8.43 (1H, d, J=8.0Hz), 8.35 (1H, d, J=8.0Hz), 7.94 (2H, d, J=8.8Hz), 7.85 (2H, d, J=8.8Hz), 7.73 (1H, t, J=8.0Hz), 3.68 (2H, s), 1.38 (9H, s).

Example 1(15)

45 N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




55

TLC: Rf 0.74 (Ethyl acetate),

NMR (DMSO-d₆): δ 10.88 (1H, s), 8.39 (2H, d, J=8.8Hz), 8.20 (2H, d, J=8.8Hz), 8.01 (1H, t, J=6.0Hz), 7.97 (2H, d, J=8.8Hz), 7.79 (2H, d, J=8.8Hz), 3.58 (2H, d, J=6.0Hz), 1.32 (9H, s).

Example 1(16)

N-[[4-(4-Ethylbenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.56 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.00-7.98 (1H, br.s), 7.87 (2H, d, J=8.4Hz), 7.81 (2H, d, J=8.4Hz), 7.80 (2H, d, J=8.2Hz), 7.34 (2H, d, J=8.2Hz), 5.00 (1H, t, J=5.4Hz), 3.67 (2H, d, J=5.4Hz), 2.74 (2H, q, J=7.4Hz), 1.37 (9H, s), 1.28 (3H, t, J=7.4Hz).

Example 1(17)

N-[[4-(4-Propylbenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.62 (Hexane : Ethyl acetate = 1 : 1),

NMR(CDCl₃): δ 8.02-7.95 (1H, br.s), 7.86 (2H, d, J=8.8Hz), 7.81 (2H, d, J=8.8Hz), 7.80 (2H, d, J=8.4Hz), 7.31 (2H, d, J=8.4Hz), 5.01 (1H, t, J=5.4Hz), 3.67 (2H, d, J=5.4Hz), 2.67 (2H, t, J=7.4Hz), 1.80-1.60 (2H, m), 1.37 (9H, s), 0.96 (3H, t, J=7.4Hz).

Example 1(18)

N-[[4-(2-Fluorobenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.53 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.65 (1H, br.s), 8.18 (1H, dt, J=2.0, 8.0Hz), 7.88 (2H, d, J=8.8Hz), 7.83 (2H, d, J=8.8Hz), 7.64-7.51 (1H, m), 7.35 (1H, dt, J=1.0, 7.4Hz), 7.28-7.15 (1H, m), 5.02 (1H, t, J=5.4Hz), 3.68 (2H, d, J=5.4Hz), 1.36 (9H, s).

Example 1(19)

N-[[4-(3-Fluorobenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC Rf 0.53 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.00-7.93 (1H, br.s), 7.88 (2H, d, J=8.8Hz), 7.80 (2H, d, J=8.8Hz), 7.68-7.44 (3H, m), 7.35-7.27 (1H, m), 5.01 (1H, t, J=5.4Hz), 3.68 (2H, d, J=5.4Hz), 1.37 (9H, s).

Example 1(20)

N-[4-(Cyclohexylcarbonylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC Rf 0.55 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 7.80 (2H, d, J=8.8Hz), 7.68 (2H, d, J=8.8Hz), 7.44-7.32 (1H, br.s), 5.00 (1H, t, J=5.0Hz), 3.65 (2H, d, J=5.0Hz), 2.35-2.18 (1H, m), 2.04-1.20 (10H, m), 1.36 (9H, s).

Example 1(21)

N-[4-(4-Trifluoromethylbenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC Rf 0.65 (Hexane : Ethyl acetate = 1 : 1),

NMR (DMSO-d₆): δ 10.83 (1H, s), 8.18 (2H, d, J=8.0Hz), 8.04-7.95 (1H), 7.98 (2H, d, J=8.8Hz), 7.91 (2H, d, J=8.0Hz), 7.77 (2H, d, J=8.8Hz), 3.55 (2H, d, J=6.2Hz), 1.32 (9H, s).

Example 1(22)

N-[4-(2-Thienylcarbonylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC Rf 0.26 (Hexane : Ethyl acetate = 1 : 1),

NMR(CDCl₃): δ 7.95 (1H, s), 7.84 (2H, d, J=8.8Hz), 7.77 (2H, d, J=8.8Hz), 7.68 (1H, dd, J=1.0, 3.8Hz), 7.61 (1H, dd,

J=1.0, 4.8Hz), 7.16 (1H, dd, J=3.8, 4.8Hz), 5.05 (1H, t, J=5.4Hz), 3.68 (2H, d, J=5.4Hz), 1.37 (9H, s).

Example 1(23)


N-[[4-(2-Furylcarbonylamino)phenyl]sulfonyl]glycine t-butyl ester



TLC: Rf 0.19 (Hexane : Ethyl acetate = 1 : 1),
NMR (CDCl₃): δ 8.25 (1H, s), 7.86-7.82 (4H, m), 7.55 (1H, d, J=1.8Hz), 7.30 (1H, d, J=3.6Hz), 6.60 (1H, dd, J=1.8, 3.6Hz), 5.03 (1H, t, J=5.6Hz), 3.68 (2H, d, J=5.6Hz), 1.36 (9H, s).

Example 1(24)


N-[[4-(2-Pyridylcarbonylamino)phenyl]sulfonyl]glycine t-butyl ester



TLC: Rf 0.45 (Hexane : Ethyl acetate = 1 : 1),
NMR(CDCl₃): δ 10.33-10.20 (1H, br.s), 8.64-8.60 (1H, m), 8.31 (1H, d, J=7.8Hz), 8.00-7.85 (1H, m), 7.95 (2H, d, J=9.0Hz), 7.88 (2H, d, J=9.0Hz), 7.53 (1H, m), 5.02 (1H, t, J=5.4Hz), 3.68 (2H, d, J=5.4Hz), 1.36 (9H, s).

Example 1(25)


N-[[4-(3-Pyridylcarbonylamino)phenyl]sulfonyl]glycine t-butyl ester



TLC: Rf 0.40 (Ethyl acetate),
NMR (CDCl₃): δ 9.11 (1H, br.s), 8.81 (1H, dd, J=1.6, 4.8Hz), 8.27-8.20 (1H, m), 8.20-8.10 (1H, br.s), 7.88 (2H, d, J=9.0Hz), 7.81 (2H, d, J=9.0Hz), 7.53-7.44 (1H, m), 5.10 (1H, t, J=5.4Hz), 3.69 (2H, d, J=5.4Hz), 1.37 (9H, s).

Example 1(26)

N-[[4-(4-Pyridylcarbonylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.36 (Ethyl acetate),

10 NMR (CDCl₃ + CD₃OD(10 drops)): δ 8.76-8.71 (2H, m), 7.93 (2H, d, J=9.0Hz), 7.89-7.82 (2H, m), 7.85 (2H, d, J=9.0Hz), 3.66 (2H, s), 1.37 (9H, s).

Example 1(27)

15 N-[[4-(3-Thienylcarbonylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.27 (Hexane : Ethyl acetate = 1 : 1),

25 NMR (CDCl₃ + CD₃OD): δ 8.16 (1H, m), 7.87 (2H, d, J=9.0Hz), 7.82 (2H, d, J=9.0Hz), 7.61 (1H, m), 7.40 (1H, m), 3.66 (2H, s), 1.36 (9H, s).

Example 1(28)

30 N-[[4-(3-Furylcarbonylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.29 (Hexane : Ethyl acetate = 1 : 1),

40 NMR (CDCl₃ + CD₃OD): δ 8.17 (1H, m), 7.84 (2H, d, J=9.0Hz), 7.82 (2H, d, J=9.0Hz), 7.49 (1H, m), 6.88 (1H, m), 3.66 (2H, s), 1.37 (9H, s).

Example 1(29)

45 N-[[4-(4-Methoxycarbonylbenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




55 TLC: Rf 0.43 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.05-7.98 (1H, br.s), 7.94 (2H, d, J=8.4Hz), 7.89 (2H, d, J=9.0Hz), 7.82 (2H, d, J=9.0Hz), 5.01 (1H, t, J=5.4Hz), 3.97 (3H, s), 3.69 (2H, d, J=5.4Hz), 1.37 (9H, s).

Example 1(30)

N-[[4-(4-Cyanobenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC Rf 0.41 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.15 (1H, s), 8.00 (2H, d, J=8.2Hz), 7.85 (2H, d, J=9.0Hz), 7.80 (2H, d, J=8.2Hz), 7.79 (2H, d, J=9.0Hz), 5.06 (1H, t, J=5.4Hz), 3.68 (2H, d, J=5.4Hz), 1.37 (9H, s).

Example 1(31)

N-[[4-(4-Benzyloxybenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC Rf 0.58 (Hexane : Ethyl acetate = 1 : 1),

NMR (DMSO-d₆): δ 10.41 (1H, s), 8.04-7.88 (1H, s), 7.97 (2H, d, J=8.4Hz), 7.96 (2H, d, J=8.4Hz), 7.74 (2H, d, J=8.4Hz), 7.52-7.28 (5H, m), 7.16 (2H, d, J=8.4Hz), 5.21 (2H, s), 3.56 (2H, s), 1.32 (9H, s).

Example 1(32)


N-[[4-(4-Carboxybenzoylamino)phenyl]sulfonyl]glycine t-butyl ester



The title compound was not measured the physical data and was used for the next step.

Example 1(33)

N-[[4-(4-Cinnamoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.50 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 7.85 (2H, d, J=8.8Hz), 7.79 (1H, d, J=15.6Hz), 7.77 (2H, d, J=8.8Hz), 7.65-7.50 (3H, m), 7.46-7.38 (3H, m), 6.56 (1H, d, J=15.6Hz), 5.03 (1H, t, J=5.4Hz), 3.67 (2H, d, J=5.4Hz), 1.36 (9H, s).

5 Example 1(34)

N-[[4-[(4-Butylbenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.27 (Hexane : Ethyl acetate = 7 : 3),

NMR (CDCl₃): δ 7.97 (1H, s), 7.87 (2H, d, J=9.0Hz), 7.80 (2H, d, J=9.0Hz), 7.79 (2H, d, J=8.0Hz), 7.32 (2H, d, J=8.0Hz), 5.01 (1H, t, J=5.4Hz), 3.68 (2H, d, J=5.4Hz), 2.69 (2H, t, J=7.4Hz), 1.70-1.50 (2H, m), 1.45-1.20 (2H, m), 1.37 (9H, s), 0.94 (3H, t, J=7.2Hz).

Example 1(35)

N-[[4-(4-Pentylbenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.28 (Hexane : Ethyl acetate = 7 : 3),

NMR (CDCl₃): δ 7.99 (1H, s), 7.86 (2H, d, J=9.0Hz), 7.80 (2H, d, J=9.0Hz), 7.79 (2H, d, J=8.2Hz), 7.31 (2H, d, J=8.2Hz), 5.02 (1H, t, J=5.4Hz), 3.67 (2H, d, J=5.4Hz), 2.68 (2H, t, J=7.4Hz), 1.72-1.50 (2H, m), 1.45-1.20 (4H, m), 1.36 (9H, s), 0.89 (3H, t, J=6.6Hz).

Example 1(36)

N-[[4-(4-Phenylbenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.67 (Hexane : Ethyl acetate = 1 : 1),

NMR (DMSO-d₆): δ 10.61 (1H, s), 8.08 (2H, d, J=8.4Hz), 8.04-7.93 (1H, m), 8.00 (2H, d, J=9.0Hz), 7.85 (2H, d, J=8.4Hz), 7.82-7.72 (2H), 7.77 (2H, d, J=9.0Hz), 7.58-7.36 (3H, m), 3.57 (2H, d, J=6.4Hz), 1.32 (9H, s).

Example 1(37)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-valine t-butyl ester




TLC: Rf 0.39 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.02 (1H, s), 7.9-7.75 (6H, m), 7.65-7.45 (3H, m), 5.14 (1H, d, J=9.9Hz), 3.66 (1H, dd, J=4.4, 9.9Hz), 2.05 (1H, m), 1.26 (9H, s), 1.00 (3H, d, J=7.0Hz), 0.85 (3H, d, J=7.0Hz).

Example 1(38)

N-[[4-(1-Naphthoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.57 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.34-8.24 (1H, m), 8.10 (1H, s), 7.98 (1H, d, J=8.0Hz), 7.94-7.85 (1H, m), 7.85-7.76 (4H, m), 7.72 (1H, dd, J=1.2, 7.2Hz), 7.64-7.51 (2H, m), 7.47 (1H, d, J=7.2Hz), 5.03 (1H, t, J=5.4Hz), 3.65 (2H, d, J=5.4Hz), 1.38 (9H, s).

Example 1(39)

N-[[4-(2-Naphthoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.57 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.40 (1H, d, J=0.8Hz), 8.23 (1H, s), 8.02-7.80 (8H, m), 7.68-7.54 (2H, m), 5.03 (1H, t, J=5.2Hz), 3.68 (2H, d, J=5.2Hz), 1.38 (9H, s).

Example 1(40)

N-[[4-(3-Benzyloxybenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.49 Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 7.95 (1H, s), 7.87 (2H, d, J=9.0Hz), 7.78 (2H, d, J=9.0Hz), 7.54-7.32 (8H, m), 7.24-7.15 (1H, m), 5.14 (2H, s), 5.00 (1H, t, J=5.4Hz), 3.67 (2H, d, J=5.4Hz), 1.37 (9H, s).

5 Example 1(41)

N-[[4-(2-Benzyloxybenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.53 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 10.25 (1H, s), 8.32 (1H, d, J=7.8Hz), 7.66 (2H, d, J=8.8Hz), 7.62-7.47 (5H, m), 7.32-7.22 (1H, m), 7.27 (2H, d, J=8.8Hz), 7.17 (2H, m), 5.23 (2H, s), 4.94 (1H, t, J=5.4Hz), 3.62 (2H, d, J=5.4Hz), 1.34 (9H, s).

20 Example 1(42)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-aspartic acid di-t-butyl ester




TLC: Rf 0.46 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.02 (1H, s), 7.90-7.75 (6H, m), 7.65-7.45 (3H, m), 5.63 (1H, d, J=8.2Hz), 4.00 (1H, m), 2.82 (1H, dd, J=4.6, 16.8Hz), 2.72 (1H, dd, J=4.8, 16.8Hz), 1.44 (9H, s), 1.33 (9H, s).

40 Example 1(43)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-glutamic acid di-t-butyl ester




TLC: Rf 0.42 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.08 (1H, s), 7.9-7.8 (6H, m), 7.65-7.25 (3H, m), 5.26 (1H, d, J=9.4Hz), 3.83 (1H, m), 2.40 (2H, m), 2.15-1.65 (2H, m), 1.46 (9H, s), 1.28 (9H, s).

Example 1(44)

N-[[4-(Phenylacetyl)amino]phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.41 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 7.75 (2H, d, J=8.8Hz), 7.57 (2H, d, J=8.8Hz), 7.48-7.29 (6H, m), 5.03 (1H, t, J=5.4Hz), 3.76 (2H, s), 3.63 (2H, d, J=5.4Hz), 1.35 (9H, s).

Example 1(45)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-leucine t-butyl ester




TLC: Rf 0.45 (Hexane : Ethyl acetate = 1 : 1),

NMR (DMSO-d₆): δ 10.29 (1H, s), 8.2-8.05 (1H), 7.96 (2H, dd, J=1.6, 8.2Hz), 7.72 (2H, d, J=8.8Hz), 7.6-7.45 (5H, m), 3.86 (1H, m), 1.8-1.5 (3H, m), 1.46 (9H, s), 0.91 (3H, d, J=6.2Hz), 0.90 (3H, d, J=6.2Hz).

Example 1(46)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-leucine t-butyl ester




TLC: Rf 0.45 (Hexane : Ethyl acetate = 1 : 1),

NMR (DMSO-d₆): δ 10.29 (1H, s), 8.2-8.05 (1H), 7.96 (2H, dd, J=1.6, 8.0Hz), 7.72 (2H, d, J=8.8Hz), 7.6-7.45 (5H, m), 3.86 (1H, m), 1.8-1.5 (3H, m), 1.46 (9H, s), 0.91 (3H, d, J=6.2Hz), 0.90 (3H, d, J=6.2Hz).

Example 1(47)

N-[[4-(Phenoxyacetyl)amino]phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.55 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 7.84 (2H, d, J=8.8Hz), 7.59 (2H, d, J=8.8Hz), 7.48-7.36 (2H, m), 7.33-7.16 (4H, m), 5.01 (1H, t, J=5.4Hz), 3.67 (2H, d, J=5.4Hz), 1.37 (9H, s).

Example 1(48)

N-[[4-(4-Dimethylaminobenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.23 (Hexane : Ethyl acetate = 1 : 1),

NMR (DMSO-d₆): δ 10.18 (1H, s), 8.0-7.85 (5H, m), 7.72 (2H, d, J=8.8Hz), 6.77 (2H, d, J=9.0Hz), 3.56 (2H, d, J=6.0Hz), 3.01 (6H, s), 1.32 (9H, s).

Example 1(49)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-valine t-butyl ester




TLC: Rf 0.43 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 7.99 (1H, s), 7.9-7.75 (6H, m), 7.6-7.45 (3H, m), 5.13 (1H, d, J=9.8Hz), 3.65 (1H, dd, J=4.4, 9.8Hz), 2.05 (1H, m), 1.26 (9H, s), 1.00 (3H, d, J=6.8Hz), 0.85 (3H, d, J=6.8Hz).

Example 1(50)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-Phenylalanine t-butyl ester




TLC: Rf 0.44 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.02 (1H, s), 7.87 (2H, m), 7.76 (4H, s), 7.65-7.45 (3H, m), 7.3-7.1 (5H, m), 5.13 (1H, d, J=9.0Hz), 4.10 (1H, dt, J=9.0, 6.0Hz), 3.03 (2H, d, J=6.0Hz), 1.23 (9H, s).

Example 1(51)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-Phenylalanine t-butyl ester




TLC: Rf 0.44 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 7.98 (1H, s), 7.88 (2H, m), 7.76 (4H, s), 7.65-7.45 (3H, m), 7.3-7.1 (5H, m), 5.11 (1H, d, J=9.2Hz), 4.10 (1H, dt, J=9.2, 6.0Hz), 3.03 (2H, d, J=6.0Hz), 1.23 (9H, s).

Example 1(52)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-alanine di-t-butyl ester




TLC: Rf 0.37 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.15 (1H, br.s), 7.89 (2H, dd, J=1.6, 8.4Hz), 7.81 (4H, s), 7.65-7.45 (3H, m), 5.30 (1H, br.d, J=8.2Hz), 3.86 (1H, m), 1.36 (3H, d, J=7.2Hz), 1.32 (9H, s).

Example 1(53)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-alanine t-butyl ester




TLC: Rf 0.37 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.10 (1H, br.s), 7.88 (2H, dd, J=1.6, 8.4Hz), 7.81 (4H, s), 7.65-7.45 (3H, m), 5.28 (1H, d, J=8.2Hz), 3.86 (1H, m), 1.36 (3H, d, J=7.0Hz), 1.32 (9H, s).

Example 1(54)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-t-buloxycarbonyl-L-lysine t-butyl ester




TLC: Rf 0.28 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.13 (1H, br.s), 7.91 (2H, m), 7.83 (4H, s), 7.65-7.45 (3H, m), 5.23 (1H, d, J=9.0Hz), 4.38 (1H, m), 3.79 (1H, m), 3.03 (2H, m), 1.9-1.3 (6H, m), 1.44 (9H, s), 1.30 (9H, s).

Example 1(55)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-t-butoxycarbonyl-D-lysine t-butyl ester




TLC: Rf 0.28 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.19 (1H, br.s), 7.91 (2H, m), 7.85 (2H, d, J=8.8Hz), 7.80 (2H, d, J=8.8Hz), 7.65-7.45 (3H, m), 5.22 (1H, d, J=8.8Hz), 4.57 (1H, m), 3.79 (1H, m), 3.03 (2H, m), 1.90-1.25 (6H, m), 1.44 (9H, s), 1.30 (9H, s).

Example 1(56)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-glutamic acid di-t-butyl ester




TLC: Rf 0.41 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.11 (1H, s), 7.88 (2H, d, J=8.4Hz), 7.81 (4H, s), 7.65-7.45 (3H, m), 5.26 (1H, d, J=9.0Hz), 3.82 (1H,

m), 2.4 (2H, m), 2.05 (1H, m), 1.79 (1H, m), 1.46 (9H, s), 1.28 (9H, s).

Example 1(57)

N-[[4-(4-Dodecylbenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.33 (Hexane : Ethyl acetate = 7 : 3),

NMR (CDCl₃): δ 7.98 (1H, s), 7.86 (2H, d, J=9.0Hz), 7.80 (2H, d, J=9.0Hz), 7.79 (2H, d, J=8.4Hz), 7.31 (2H, d, J=8.4Hz), 5.01 (1H, t, J=5.4Hz), 3.67 (2H, d, J=5.4Hz), 2.86 (2H, t, J=7.4Hz), 1.74-1.50 (2H, m), 1.37 (9H, s), 1.36-1.10 (18H, m), 0.88 (3H, t, J=6.8Hz).

Example 1(58)

4-[N-[[4-(Benzoylamino)phenyl]sulfonyl]amino]butyric acid t-butyl ester




TLC: Rf 0.31 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.09 (1H, s), 7.9-7.75 (6H, m), 7.65-7.45 (3H, m), 4.80 (1H, t, J=6.4Hz), 3.00 (2H, q, J=6.4Hz), 2.27 (2H, t, J=6.8Hz), 1.76 (2H, m), 1.43 (9H, s).

Example 1(59)

2-[N-[[4-(Benzoylamino)phenyl]sulfonyl]amino]-3-t-butoxy-L-propionic acid t-butyl ester




TLC: Rf 0.44 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.09 (1H, br.s), 7.9-7.75 (6H, m), 7.65-7.45 (3H, m), 5.45 (1H, d, J=9.4Hz), 4.0-3.95 (1H, m), 3.69 (1H, dd, J=3, 8.5Hz), 3.52 (1H, dd, J=3.2, 8.5Hz), 1.32 (9H, s), 1.11 (9H, s).

Example 1(60)

2-[N-[[4-(Benzoylamino)phenyl]sulfonyl]amino]-3-t-butoxy-D-propionic acid t-butyl ester




TLC: Rf 0.44 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.04 (1H, br.s), 7.9-7.75 (6H, m), 7.65-7.45 (3H, m), 5.44 (1H, d, J=9.2Hz), 4.0-3.95 (1H, m), 3.69 (1H, dd, J=3.0, 8.6Hz), 3.52 (1H, dd, J=3.2, 8.6Hz), 1.32 (9H, s), 1.11 (9H, s).

Example 1(61)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-aspartic acid di-t-butyl ester




TLC: Rf 0.40 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.17 (1H, s), 7.9-7.75 (6H, m), 7.6-7.45 (3H, m), 5.64 (1H, d, J=8.0Hz), 3.99 (1H, m), 2.81 (1H, dd, J=4.6, 16.8Hz), 2.72 (1H, dd, J=4.6, 16.8Hz), 1.43 (9H, s), 1.33 (9H, s).

Example 1(62)

N-[[4-(p-Toluyloylamino)phenyl]sulfonyl]-D-phenylalanine t-butyl ester




TLC: Rf 0.43 (Hexane : Ethyl acetate = 1 : 1),

NMR (CD₃OD + CDCl₃ (1:1)): δ 7.9-7.8 (4H, m), 7.71 (2H, d, J=8.8Hz), 7.35-7.1 (7H, m), 4.04 (1H, t, J=6.6Hz), 2.98 (2H, d, J=6.6Hz), 2.44 (3H, s), 1.23 (9H, s).

Example 1(63)

N-[[4-(4-Pentylbenzoylamino)phenyl]sulfonyl]-D-phenylalanine t-butyl ester




TLC: Rf 0.66 (Hexane : Ethyl acetate = 3 : 2),

NMR (CDCl₃): δ 7.95 (1H, s), 7.84-7.68 (6H, m), 7.35-7.08 (7H, m), 5.10 (1H, d, J=10.0Hz), 4.14-4.00 (1H, m), 3.02 (2H, d, J=6.0Hz), 2.67 (2H, t, J=7.8Hz), 1.72-1.56 (2H, m), 1.48-1.25 (4H, m), 1.21 (9H, s), 0.89 (3H, t, J=5.0Hz).

Example 1(64)

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]-L-valine t-butyl ester




TLC: Rf 0.54 (Hexane : Ethyl acetate = 3 : 2),

NMR (CDCl₃): δ 7.93 (1H, s), 7.83 (2H, d, J=9.0Hz), 7.77 (2H, d, J=9.0Hz), 7.76 (2H, d, J=8.0Hz), 7.30 (2H, d, J=8.0Hz), 5.08 (1H, d, J=10.8Hz), 3.62 (1H, dd, J=4.4, 10.8Hz), 2.44 (3H, s), 2.15-1.90 (1H, m), 1.25 (9H, s), 1.00 (3H, d, J=6.6Hz), 0.85 (3H, d, J=6.6Hz).

Example 1(65)

N-[[4-(4-Hexylbenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.26 (Hexane : Ethyl acetate = 7 : 3),

NMR (CDCl₃): δ 8.04 (1H, s), 7.85 (2H, d, J=9.0Hz), 7.79 (4H, m), 7.30 (2H, d, J=8.0Hz), 5.04 (1H, t, J=5.2Hz), 3.67 (2H, d, J=5.2Hz), 2.68 (2H, t, J=8.0Hz), 1.76-1.50 (2H, m), 1.37 (9H, s), 1.35-1.20 (6H, m), 0.88 (3H, t, J=6.8Hz).

Example 1(66)

N-[[4-(4-Heptylbenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.29 (Hexane : Ethyl acetate = 7 : 3),

10 NMR (CDCl_3): δ 8.03 (1H, s), 7.85 (2H, d, $J=9.0\text{Hz}$), 7.79 (4H, m), 7.31 (2H, d, $J=8.2\text{Hz}$), 5.03 (1H, t, $J=5.6\text{Hz}$), 3.67 (2H, d, $J=5.6\text{Hz}$), 2.68 (2H, t, $J=8.2\text{Hz}$), 1.72-1.50 (2H, m), 1.37 (9H, s), 1.35-1.10 (8H, m), 0.88 (3H, t, $J=6.8\text{Hz}$).

Example 1(67)

15 N-[[4-(4-Isopropylbenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




25 TLC: Rf 0.19 (Hexane : Ethyl acetate = 7 : 3),

NMR (CDCl_3): δ 8.01 (1H, s), 7.86 (2H, d, $J=9.0\text{Hz}$), 7.82-7.72 (4H, m), 7.36 (2H, d, $J=8.4\text{Hz}$), 5.01 (1H, t, $J=5.4\text{Hz}$), 3.67 (2H, d, $J=5.4\text{Hz}$), 2.99 (1H, m), 1.37 (9H, s), 1.29 (6H, d, $J=6.8\text{Hz}$).

Example 1(68)

30 N-[[4-(4-Isobutylbenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




40 TLC: Rf 0.23 (Hexane : Ethyl acetate = 7 : 3),

NMR (CDCl_3): δ 8.04 (1H, s), 7.86 (2H, d, $J=9.0\text{Hz}$), 7.82-7.72 (4H, m), 7.27 (2H, d, $J=8.2\text{Hz}$), 5.03 (1H, t, $J=5.4\text{Hz}$), 3.67 (2H, d, $J=5.4\text{Hz}$), 2.56 (2H, d, $J=7.0\text{Hz}$), 1.91 (1H, m), 1.37 (9H, s), 0.92 (6H, d, $J=6.6\text{Hz}$).

45 Example 1(69)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-2,2-dimethylglycine t-butyl ester




TLC: Rf 0.40 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl_3): δ 8.03 (1H, s), 7.9-7.75 (6H, m), 7.65-7.45 (3H, m), 5.42 (1H, s), 1.45 (9H, s), 1.41 (6H, s).

Example 1(70)

2-[N-[[4-(p-Toluoylamino)phenyl]sulfonyl]amino]-3-t-butoxy-D-propionic acid t-butyl ester




TLC Rf 0.69 (Hexane : Ethyl acetate = 1 : 1),

¹H NMR (CDCl₃): δ 7.99 (1H, s), 7.85 (2H, d, J=8.0Hz), 7.78 (4H, d, J=8.0Hz), 7.30 (2H, d, J=8.0Hz), 5.43 (1H, d, J=9.2Hz), 3.97 (1H, td, J=3.0Hz, 9.2Hz), 3.69 (1H, dd, J=3.0Hz, 8.6Hz), 3.51 (1H, dd, J=3.0Hz, 8.6Hz), 2.43 (3H, s), 1.31 (9H, s).

Example 1(71)

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]-L-leucine t-butyl ester




TLC Rf 0.50 (Hexane : Ethyl acetate = 1 : 1),

¹H NMR (CDCl₃): δ 7.90 (1H, s), 7.85-7.70 (6H, m), 7.32 (2H, d, J=8.0Hz), 5.02 (1H, d, J=10Hz), 3.90-3.75 (1H, m), 2.45 (3H, s), 1.9-1.75 (1H, m), 1.46 (2H, m), 1.26 (9H, s), 0.93 (6H, d, J=6.6Hz).

Example 1(72)

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]-D-alanine t-butyl ester




TLC Rf 0.57 (Hexane : Ethyl acetate = 1 : 1),

¹H NMR (DMSO-d₆): δ 10.47 (1H, s), 8.08 (1H, d, J=8.6Hz), 7.96 (2H, d, J=8.8Hz), 7.88 (2H, d, J=8.8Hz), 7.74 (2H, d, J=8.8Hz), 7.35 (2H, d, J=8.2Hz), 3.80-3.64 (1H, m), 2.39 (3H, s), 1.28 (9H, s), 1.15 (3H, d, J=7.0Hz).

Example 1(73)

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]-D-valine t-butyl ester




TLC: Rf 0.65 (Hexane : Ethyl acetate = 1 : 1),

NMR (DMSO-d6): δ 10.45 (1H, s), 8.02-7.92 (3H, m), 7.88 (2H, d, J=8.0Hz), 7.72 (2H, d, J=8.8Hz), 7.35 (2H, d, J=8.0Hz), 3.48-3.38 (1H, m), 2.39 (3H, s), 2.02-1.80 (1H, m), 1.22 (9H, s), 0.83 (6H, t, J=5.6Hz).

Example 1(74)

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]-D-leucine t-butyl ester




TLC: Rf 0.68 (Hexane : Ethyl acetate = 1 : 1),

NMR (DMSO-d6): δ 10.45 (1H, s), 8.07 (1H, d, J=9.0Hz), 7.95 (2H, d, J=8.8Hz), 7.88 (2H, d, J=8.2Hz), 7.71 (2H, d, J=8.8Hz), 7.35 (2H, d, J=8.2Hz), 3.70-3.54 (1H, m), 2.39 (3H, s), 1.72-1.50 (1H, m), 1.44-1.30 (2H, m), 1.23 (9H, s), 0.84 (3H, d, J=6.6Hz), 0.76 (3H, d, J=6.6Hz).

Example 1(75)

N-[[2-Methyl-4-(p-Toluoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.29 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 7.95 (2H, d, J=8.3Hz), 7.77 (2H, d, J=6.4Hz), 7.75-7.57 (2H, m), 7.31 (2H, d, J=8.3Hz), 5.10 (1H, m), 3.63 (2H, d, J=2.2Hz), 2.68 (3H, s), 2.44 (3H, s), 1.37 (9H, s).

Example 1(76)

N-[[3-Methyl-4-(p-Toluoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.48 (Chloroform : Methanol = 97 : 3)

NMR (CDCl₃): δ 8.38 (1H, d, J=8.4Hz), 7.82-7.73 (4H, m), 7.33 (2H, d, J=7.8Hz), 5.00 (1H, t, J=4.7Hz), 3.67 (2H, d, J=4.7Hz), 2.45 (3H, s), 2.40 (3H, s), 1.38 (9H, s).

Example 1(77)

N-[[4-(2-Hydroxy-4-methylbenzoylamino)phenyl]sulfonyl]-D-alanine t-butyl ester




TLC: Rf 0.29 (Chloroform : Methanol = 97 : 3)

NMR (CDCl₃): δ 11.64 (1H, s), 8.09 (1H, br.s), 7.85 (2H, d, J=8.3Hz), 7.74 (2H, d, J=8.3Hz), 7.43 (1H, d, J=7.5Hz), 6.86 (1H, s), 6.75 (1H, d, J=7.5Hz), 5.25 (1H, t, J=7.6Hz), 3.87 (2H, quint, J=7.6Hz), 2.37 (3H, s), 1.37 (3H, d, J=7.6Hz), 1.32 (9H, s).

Example 1(78)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-tryptophan benzyl ester




TLC: Rf 0.43 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 9.19 (1H, s), 7.94 (2H, dd, J=1.4, 7.8Hz), 7.68-7.40 (7H, m), 7.36-7.24 (5H, m), 7.18-6.98 (5H, m), 6.84 (1H, s), 4.91 (2H, s), 4.25 (1H, dd, J=5.2, 6.8Hz), 3.30-3.06 (2H, m).

Example 1(79)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-tyrosine benzyl ester




TLC: Rf 0.34 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃ + CD₃OD(10 drops)): δ 8.58 (1H, s), 7.80-7.78 (2H, m), 7.71 (2H, d, J=8.8Hz), 7.65-7.29 (8H, m), 7.25-7.17 (2H, m), 6.81 (2H, d, J=8.6Hz), 6.62 (2H, d, J=8.6Hz), 4.97 (2H, s), 4.10 (1H, dd, J=5.8, 7.8Hz), 2.99 (1H, dd, J=5.8, 14.0Hz), 2.81 (1H, dd, J=7.8, 14.0Hz).

Example 1(80)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-tryptophan benzyl ester




TLC: Rf 0.34 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃ + CD₃OD): δ 7.98-7.90 (2H, m), 7.63 (2H, d, J=8.8Hz), 7.60-7.39 (6H, m), 7.35-7.25 (5H, m), 7.17-6.97 (3H, m), 6.85 (1H, s), 4.91 (2H, s), 4.25 (1H, t, J=6.4Hz), 3.30-3.06 (2H, m).

Example 1(81)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-tyrosine benzyl ester




TLC: Rf 0.31 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.64-8.57 (1H, m), 8.15 (1H, s), 7.91 (2H, d, J=8.0Hz), 7.80-7.42 (6H, m), 7.40-7.20 (6H, m), 6.76 (2H, d, J=8.4Hz), 6.58 (2H, d, J=8.4Hz), 5.17 (1H, d, J=9.2Hz), 5.04 (2H, s), 4.18-4.04 (1H, m), 3.01 (1H, dd, J=5.0, 14.2Hz), 2.75 (1H, dd, J=7.8, 14.2Hz).

Example 1(82)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-histidine benzyl ester




TLC: Rf 0.31 (Chloroform : Methanol = 9 : 1),

NMR (CDCl₃ + CD₃OD): δ 8.17 (1H, s), 7.96-7.80 (6H, m), 7.68-7.42 (3H, m), 7.40-7.22 (5H, m), 7.04 (1H, s), 5.10 (2H, s), 3.80 (1H, dd, J=4.6Hz, 7.6Hz), 2.98 (1H, dd, J=4.6, 14.6Hz), 2.81 (1H, dd, J=7.6, 14.6Hz).

Example 1(83)

2-[N-[4-(Benzoylamino)phenyl]sulfonylamino]-(3-pyridyl)-D-alanine benzyl ester




TLC: Rf 0.32 (Hexane : Ethyl acetate = 1 : 5),

NMR (CDCl₃): δ 8.41 (1H, dd, J=2.0Hz, 5.0Hz), 8.25 (1H, d, J=2.0Hz), 8.08 (1H, s), 7.81 (2H, m), 7.74 (4H, s), 7.65-7.45 (3H, m), 7.35-7.3 (4H, m), 7.25-7.15 (2H, m), 7.09 (1H, dd, J=5, 8.0Hz), 5.58 (1H, d, J=8.0Hz), 4.97 (1H, s), 4.27 (1H, dt, J=6.0Hz, 8.0Hz), 3.05 (2H, d, J=6.0Hz).

Example 1(84)

N-[[4-(p-Toluylamino)phenyl]sulfonyl]-D-tryptophan benzyl ester




TLC: Rf 0.32 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃ + CD₃OD): δ 7.81 (2H, d, J=8.0Hz), 7.56 (4H, s), 7.43 (1H, d, J=7.0Hz), 7.35-7.25 (6H, m), 7.15-7.00 (4H, m), 6.81 (1H, s), 4.92 (2H, s), 4.25 (1H, m), 3.18 (2H, m), 2.45 (3H, s).

Example 1(85)

N-[[4-(Benzoylamino)phenyl]sulfonyl]glycine ethyl ester




TLC: Rf 0.26 (Hexane : Ethyl acetate = 1 : 1),

NMR (DMSO-d6): δ 10.59 (1H, s), 8.09 (1H, t, J=6.2Hz), 8.0-7.95 (4H, m), 7.77 (2H, d, J=8.8Hz), 7.65-7.5 (3H, m), 4.00 (2H, q, J=7.0Hz), 3.68 (2H, d, J=6.2Hz), 1.12 (3H, t, J=7.0Hz).

Example 1(86)

N-[[4-(p-Toluylamino)phenyl]sulfonyl]-D-alanine pivaloyloxymethyl ester




TLC: Rf 0.38 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.05 (1H, br.s), 7.82 (4H, s), 7.78 (2H, d, J=8.0Hz), 7.31 (2H, d, J=8.0Hz), 5.67 (1H, d, J=14.6Hz), 5.59 (1H, d, J=14.6Hz), 5.15 (1H, br.d, J=8.8Hz), 4.03 (1H, m), 2.44 (3H, s), 1.39 (3H, d, J=7.0Hz), 1.17 (9H, s).

Example 1(87)

N-[[4-(p-Toluylamino)phenyl]sulfonyl]-D-alanine dimethyl aminocarbonyl ester




TLC: Rf 0.42 (Chloroform : Methanol : Acetic acid : Water = 100 : 10 : 1 : 1),

NMR (CDCl₃ + CD₃OD (3 drops)): δ 7.82 (6H, m), 7.31 (2H, d, J=8.2Hz), 4.56 (1H, d, J=14.6Hz), 4.37 (1H, d, J=14.6Hz), 4.10 (1H, q, J=7.4Hz), 2.94 (3H, s), 2.90 (3H, s), 2.44 (3H, s), 1.46 (3H, d, J=7.4Hz).

Example 1(88)


N-[[4-(p-Toluylamino)phenyl]sulfonyl]-D-alanine benzyl ester



TLC: Rf 0.56 (Chloroform : Methanol : Acetic acid : Water = 100 : 10 : 1 : 1),
NMR (DMSO-d6): δ 10.49 (1H, s), 7.96 (3H, m), 7.89 (2H, d, J=8.0Hz), 7.74 (2H, d, J=8.8Hz), 7.4-7.25 (7H, m), 4.96 (2H, s), 3.94 (1H, m), 2.40 (3H, s), 1.19 (3H, d, J=7.2Hz).

Example 1(89)


N-[[4-(2-Thienylcarbonylamino)phenyl]sulfonyl]-D-alanine t-butyl ester



TLC : Rf 0.25 (Hexane : Ethyl acetate = 2 : 1),
NMR (DMSO-d6): δ 10.51 (1H, s), 8.12-8.05 (2H, m), 7.94-7.88 (3H, m), 7.74 (2H, d, J=8.8Hz), 7.24 (1H, t, J=3.8Hz), 3.72 (1H, quint, J=7.4Hz), 1.27 (9H, s), 1.14 (3H, d, J=7.4Hz).

Example 1(90)


N-[[3-(Benzoylamino)phenyl]sulfonyl]glycine t-butyl ester



TLC: Rf 0.65 (Hexane : Ethyl acetate = 1 : 1),
NMR (CDCl₃): δ 8.26-8.16 (2H, m), 8.00 (1H, t, J=1.8Hz), 7.94-7.87 (2H, m), 7.66-7.46 (5H, m), 5.24 (1H, t, J=5.4Hz), 3.70 (2H, d, J=5.4Hz), 1.35 (9H, s).

Example 1(91)

N-[[2-(Benzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.51 (Hexane : Ethyl acetate = 3 : 2),

NMR (CDCl₃): δ 10.27 (1H, s), 8.73 (1H, d, J=8.4 Hz), 8.05-7.94 (2H, m), 7.90 (1H, dd, J=1.8Hz, 8.0Hz), 7.70-7.45 (4H, m), 7.30-7.18 (1H, m), 5.20 (1H, t, J=5.2Hz), 3.61 (2H, d, J=5.2Hz), 1.33 (9H, s).

Example 2

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]glycine



A mixture of the compound prepared in example 1 (1.45 g) in trifluoroacetic acid (10 ml) and water (1 ml) was stirred for 1 hour at room temperature. The reaction mixture was concentrated. The residue was washed with ether and dried to give the title compound (1.16 g) having the following physical data.


TLC: Rf 0.48 (Chloroform : Methanol : acetic acid = 16 : 3 : 1),

NMR (DMSO-d₆): δ 10.46 (1H, s), 8.02-7.84 (1H), 7.97 (2H, d, J=9.0Hz), 7.88 (2H, d, J=8.0Hz), 7.75 (2H, d, J=9.0Hz), 7.34 (2H, d, J=8.0Hz), 3.55 (2H, d, J=6.2Hz), 2.40 (3H, s).

Example 2(1)-2(80)

The compounds having the following physical data were obtained by the same procedure as a series of reactions of Example 2, or converting to a corresponding salt by conventional method, using the compound prepared in Example 1(1)-1(77) and 1(89)-1(91) instead of the compound prepared in Example 1.

N-[[4-(Isobutyrylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.34 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (CD₃OD): δ 7.80 (2H, d, J=9.5Hz), 7.76 (2H, d, J=9.5Hz), 3.67 (2H, s), 2.64 (1H, m), 1.19 (6H, d, J=6.8Hz).

Example 2(2)

N-[[4-(Acetylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.23 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d₆): δ 10.26 (1H, s), 7.84 (1H, t, J=6.0Hz), 7.73 (2H, d, J=9.6Hz), 7.68 (2H, d, J=9.6Hz), 3.52 (2H, d, J=6.0Hz), 2.07 (3H, s).

Example 2(3)

N-[[4-(o-Toluoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.48 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 10.63 (1H, s), 7.91 (2H, d, J=9.0Hz), 7.96-7.84 (1H), 7.74 (2H, d, J=9.0Hz), 7.51-7.24 (4H, m), 3.54 (2H, d, J=5.8Hz), 2.39 (3H, s).

Example 2(4)

N-[[4-(3-Methylbenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.48 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 12.8-12.4 (1H, br.s), 10.49 (1H, s), 7.96 (2H, d, J=8.8Hz), 7.88 (1H, t, J=6.2Hz), 7.75 (2H, d, J=8.8Hz), 7.80-7.70 (2H, m), 7.50-7.36 (2H, m), 3.55 (2H, d, J=6.2Hz), 2.41 (3H, s).

Example 2(5)

N-[[4-(2-Chlorobenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.42 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (CD₃OD): δ 7.88 (2H, d, J=9.4Hz), 7.83 (2H, d, J=9.4Hz), 7.60-7.38 (4H, m), 3.70 (2H, s).

Example 2(6)

N-[[4-(3-Chlorobenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.42 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (CD₃OD): δ 7.99-7.94 (1H, m), 7.93 (2H, d, J=9.0Hz), 7.93-7.80 (1H, m), 7.84 (2H, d, J=9.0Hz), 7.64-7.46 (2H, m), 3.69 (2H, s).

Example 2(7)

N-[[4-(4-Chlorobenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.42 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (CD₃OD): δ 7.94 (2H, d, J=8.6Hz), 7.92 (2H, d, J=9.0Hz), 7.84 (2H, d, J=9.0Hz), 7.53 (2H, d, J=8.6Hz), 3.70 (2H, s).

Example 2(8)

N-[[4-(2-Methoxybenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.58 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d₆): δ 10.45 (1H, s), 7.91 (1H, t, J=6.2Hz), 7.90 (2H, d, J=8.8Hz), 7.75 (2H, d, J=8.8Hz), 7.61 (1H, dd, J=7.4, 1.6Hz), 7.52 (1H, ddd, J=8.4, 7.4, 2.0Hz), 7.18 (1H, d, J=8.0Hz), 7.07 (1H, td, J=7.6, 1.0Hz), 3.89 (3H, s), 3.56 (2H, d, J=6.2Hz).

Example 2(9)

N-[[4-(3-Methoxybenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.44 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d₆): δ 10.52 (1H, s), 7.96 (2H, d, J=8.8Hz), 7.91 (1H, t, J=6.2Hz), 7.76 (2H, d, J=8.8Hz), 7.58-7.41 (3H, m), 7.21-7.14 (1H, m), 3.84 (3H, s), 3.56 (2H, d, J=6.2Hz).

Example 2(10)

N-[[4-(Benzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.19 (Chloroform : Methanol : Acetic acid : Water = 50 : 10 : 1 : 1),

NMR (CD₃OD): δ 8.0-7.8 (6H, m), 7.6-7.5 (3H, m), 3.70 (2H, s).

Example 2(11)

N-[[4-(4-Fluorobenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.36 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d₆): δ 10.56 (1H, s), 8.05 (2H, dd, J=8.8, 5.4Hz), 7.96 (2H, d, J=9.2Hz), 7.91 (1H, t, J=6.2Hz), 7.77 (2H, d, J=9.2Hz), 3.56 (2H, d, J=6.2Hz).

Example 2(12)

N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.43 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d₆): δ 10.39 (1H, s), 7.97 (2H, d, J=8.8Hz), 7.95 (2H, d, J=9.0Hz), 7.89 (1H, t, J=6.2Hz), 7.75 (2H, d, J=9.0Hz), 7.70 (2H, d, J=8.8Hz), 3.84 (3H, s), 3.55 (2H, d, J=6.2Hz).

Example 2(13)

N-[[4-(2-Nitrobenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.44 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d₆): δ 12.65 (1H, br.s), 11.02 (1H, s), 8.18 (1H, d, J=7.8Hz), 8.0-7.7 (8H, m), 3.57 (2H, d, J=6.0Hz).

Example 2(14)

N-[[4-(3-Nitrobenzoylamino)phenyl]sulfonyl]glycine




TLC Rf 0.56 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d₆): δ 12.65 (1H, br.s), 10.89 (1H, s), 8.81 (1H, t, J=2.0Hz), 8.5-8.4 (2H, m), 8.0-7.85 (4H, m), 7.81 (2H, d, J=8.8Hz), 3.57 (2H, d, J=6.0Hz).

Example 2(15)

N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]glycine




TLC Rf 0.55 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d₆): δ 12.65 (1H, br.s), 10.88 (1H, s), 8.39 (2H, d, J=9.0Hz), 8.20 (2H, d, J=9.0Hz), 7.98 (d, J=8.8Hz) and 7.80 (t, J=6.0Hz) (total 3H), 7.80 (2H, d, J=8.8Hz), 3.58 (2H, d, J=6.0Hz).

Example 2(16)

N-[[4-(4-Ethylbenzoylamino)phenyl]sulfonyl]glycine




TLC Rf 0.53 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (CD₃OD): δ 7.93 (2H, d, J=9.0Hz), 7.87 (2H, d, J=8.6Hz), 7.83 (2H, d, J=9.0Hz), 7.36 (2H, d, J=8.6Hz), 3.69 (2H, s), 2.73 (2H, q, J=7.6Hz), 1.27 (3H, t, J=7.6Hz).

Example 2(17)

N-[[4-(4-Propylbenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.54 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (CD₃OD): δ 7.93 (2H, d, J=9.0Hz), 7.86 (2H, d, J=8.2Hz), 7.83 (2H, d, J=9.0Hz), 7.33 (2H, d, J=8.2Hz), 3.69 (2H, s), 2.68 (2H, dd, J=7.4, 8.2Hz), 1.80-1.60 (2H, m), 0.96 (3H, t, J=7.2Hz).

Example 2(18)

N-[[4-(2-Fluorobenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.48 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d₆): δ 13.40-11.60 (1H, br.s), 10.74 (1H, s), 7.96-7.84 (1H, t, J=6.0Hz), 7.89 (2H, d, J=8.8Hz), 7.76 (2H, d, J=8.8Hz), 7.72-7.52 (2H, m), 7.42-7.28 (2H, m), 3.55 (2H, d, J=6.0Hz).

Example 2(19)

N-[[4-(3-Fluorobenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.38 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d₆): δ 13.40-11.60 (1H, br.s), 10.61 (1H, s), 7.96 (2H, d, J=8.8Hz), 7.92 (1H, t, J=6.0Hz), 7.87-7.72 (2H, m), 7.77 (2H, d, J=8.8Hz), 7.67-7.40 (2H, m), 3.56 (2H, d, J=6.0Hz).

Example 2(20)

N-[[4-(Cyclohexylcarbonylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.43 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (CDCl₃ + CD₃OD(10 drops)): δ 7.77 (2H, d, J=8.8Hz), 7.68 (2H, d, J=8.8Hz), 3.71 (2H, s), 2.40-2.20 (1H, m),

2.00-1.20 (10H, m).

Example 2(21)


N-[[4-(4-Trifluoromethylbenzoylamino)phenyl]sulfonyl]glycine



TLC: Rf 0.40 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),
NMR (DMSO-d6): δ 13.40-11.60 (1H, br.s), 10.76 (1H, s), 8.16 (2H, d, J=8.0Hz), 8.03-7.87 (1H, t, J=6.2Hz), 7.97 (2H, d, J=8.8Hz), 7.91 (2H, d, J=8.0Hz), 7.78 (2H, d, J=8.8Hz), 3.57 (2H, d, J=6.2Hz).

Example 2(22)


N-[[4-(2-Thienylcarbonylamino)phenyl]sulfonyl]glycine



TLC: Rf 0.47 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),
NMR (DMSO-d6): δ 12.60 (1H, br.s), 10.52 (1H, s), 8.06 (1H, d, J=3.8Hz), 8.0-7.9 (4H, m), 7.77 (2H, d, J=8.8Hz), 7.25 (1H, dd, J=3.8, 5.0Hz), 3.57 (2H, d, J=5.8Hz).

Example 2(23)


N-[[4-(2-Furylcarbonylamino)phenyl]sulfonyl]glycine



TLC: Rf 0.45 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),
NMR (DMSO-d6): δ 12.65 (1H, br.s), 10.51 (1H, s), 8.0-7.9 (4H, m), 7.75 (2H, d, J=8.8Hz), 7.40 (1H, d, J=3.4Hz), 6.73 (1H, dd, J=1.6, 3.4Hz), 3.57 (2H, d, J=6.0Hz).

Example 2(24)

N-[[4-(2-Pyridylcarbonylamino)phenyl]sulfonyl]glycine hydrochloride




TLC: Rf 0.50 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 10.98 (1H, s), 8.76 (1H, d, J=4.6Hz), 8.24-8.02 (2H, m), 8.12 (2H, d, J=8.8Hz), 8.01-7.82 (1H, br. s), 7.77 (2H, d, J=8.8Hz), 7.74-7.65 (1H, m), 3.57 (2H, d, J=5.4Hz).

Example 2(25)

N-[[4-(3-Pyridylcarbonylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.25 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 13.50-11.50 (1H, br.s), 10.76 (1H, s), 9.12 (1H, d, J=1.8Hz), 8.77 (1H, dd, J=1.8, 5.0Hz), 8.31 (1H, d, J=1.8, 8.2Hz), 7.97 (2H, d, J=9.0Hz), 7.93 (1H, t, J=5.4Hz), 7.79 (2H, d, J=9.0Hz), 7.58 (1H, dd, J=5.0, 8.2Hz), 3.57 (2H, d, J=5.4Hz).

Example 2(26)

N-[[4-(4-Pyridylcarbonylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.20 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 13.20-12.00 (1H, br.s), 10.80 (1H, s), 8.83-8.76 (2H, m), 8.02-7.90 (1H, t, J=6.2Hz), 7.97 (2H, d, J=8.8Hz), 7.89-7.85 (2H, m), 7.79 (2H, d, J=8.8Hz), 3.57 (2H, d, J=6.2Hz).

Example 2(27)

N-[[4-(3-Thienylcarbonylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.45 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d₆): δ 12.5 (1H, br.s), 10.36 (1H, s), 8.4 (1H, m), 7.95-7.9 (3H, m), 7.76 (2H, d, J=8.9Hz), 7.65 (2H, m), 3.57 (2H, d, J=6.0Hz).

Example 2(28)

N-[[4-(3-Furylcarbonylamino)phenyl]sulfonyl]glycine




TLC: R_f 0.67 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d₆): δ 12.6 (1H, br.s), 10.23 (1H, s), 8.43 (1H, m), 7.95-7.85 (3H, m), 7.82 (1H, m), 7.76 (2H, d, J=8.7Hz), 7.01 (1H, m), 3.57 (2H, d, J=6.0Hz).

Example 2(29)

N-[[4-(4-Methoxycarbonylbenzoylamino)phenyl]sulfonyl]glycine




TLC: R_f 0.41 (Chloroform : Methanol Acetic acid = 16 : 3 : 1),

NMR(DMSO-d₆): δ 13.50-11.50 (1H, br.s), 10.75 (1H, s), 8.12 (2H, d, J=9.2Hz), 8.07 (2H, d, J=9.2Hz), 7.98 (2H, d, J=8.8Hz), 7.94 (1 H, t, J=6.0Hz), 7.78 (2H, d, J=8.8Hz), 3.90 (3H, s), 3.58 (2H, d, J=6.0Hz).

Example 2(30)

N-[[4-(4-Cyanobenzoylamino)phenyl]sulfonyl]glycine




TLC: R_f 0.34 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d₆): δ 13.50-11.50 (1H, br.s), 10.79 (1H, s), 8.12 (2H, d, J=8.8Hz), 8.04 (2H, d, J=8.8Hz), 8.01-7.90 (1H), 7.96 (2H, d, J=8.8Hz), 7.79 (2H, d, J=8.8Hz), 3.58 (2H, d, J=6.2Hz).

Example 2(31)

N-[[4-(4-Benzyloxybenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.48 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 13.50-11.50 (1H, br.s), 10.41 (1H, s), 7.97 (2H, d, J=8.8Hz), 7.96 (2H, d, J=8.8Hz), 7.90 (1H, t, J=6.2Hz), 7.75 (2H, d, J=8.8Hz), 7.54-7.28 (5H, m), 7.16 (2H, d, J=8.8Hz), 5.21 (2H, s), 3.57 (2H, d, J=6.2Hz).

Example 2(32)

N-[[4-(4-Carboxybenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.51 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d6): δ 13.3-12.70 (1H, br.s), 10.74 (1H, s), 8.11 (2H, d, J=9.0Hz), 8.06 (2H, d, J=9.0Hz), 7.98 (2H, d, J=8.8Hz), 7.94 (1H, t, J=6.2Hz), 7.79 (2H, d, J=8.8Hz), 3.58 (2H, d, J=6.2Hz).

Example 2(33)

N-[[4-(Cinnamoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.45 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 12.80-12.40 (1H, br.s), 10.57 (1H, s), 7.91 (1H, t, J=6.2Hz), 7.87 (2H, d, J=8.8Hz), 7.75 (2H, d, J=8.8Hz), 7.70-7.52 (3H, m), 7.50-7.38 (3H, m), 6.85 (1H, d, J=15.8Hz), 3.56 (2H, d, J=6.2Hz).

Example 2(34)

N-[[4-[(4-Butylbenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.55 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 13.40-11.60 (1H, br.s), 10.47 (1H, s), 7.80 (1H, br.t, J=6.0Hz), 7.96 (2H, d, J=8.8Hz), 7.88 (2H, d,

J=8.2Hz), 7.75 (2H, d, J=8.8Hz), 7.35 (2H, d, J=8.2Hz), 3.56 (2H, d, J=6.0Hz), 2.64 (2H, t, J=7.6Hz), 1.76-1.42 (2H, m), 1.42-1.10 (2H, m), 0.90 (3H, t, J=7.4Hz).

Example 2(35)

N-[[4-(4-Pentylbenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.55 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 13.40-11.60 (1H, br.s), 10.48 (1H, s), 7.90 (1H, br.t, J=6.0Hz), 7.97 (2H, d, J=8.8Hz), 7.89 (2H, d, J=8.2Hz), 7.76 (2H, d, J=8.8Hz), 7.35 (2H, d, J=8.2Hz), 3.56 (2H, d, J=6.0Hz), 2.66 (2H, t, J=7.0Hz), 1.72-1.48 (2H, m), 1.48-1.18 (4H, m), 0.87 (3H, t, J=6.6Hz).

Example 2(36)

N-[[4-(4-Phenylbenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.50 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 13.40-11.60 (1H, br.s), 10.62 (1H, s), 8.08 (2H, d, J=8.4Hz), 8.01 (2H, d, J=8.8Hz), 7.93 (1H, t, J=6.0Hz), 7.90-7.70 (2H, m), 7.85 (2H, d, J=8.4Hz), 7.77 (2H, d, J=8.8Hz), 7.60-7.36 (3H, m), 3.58 (2H, d, J=6.0Hz).

Example 2(37)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-valine




TLC: Rf 0.75 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d6): δ 12.6 (1H, br.s), 10.57 (1H, s), 8.0-7.9 (5H, m), 7.75 (2H, d, J=8.8Hz), 7.65-7.5 (3H, m), 3.51 (1H, dd, J=6, 9.4Hz), 2.0-1.85 (1H, m), 0.83 (3H, d, J=6.8Hz), 0.81 (3H, d, J=6.8Hz).

Example 2(38)

N-[[4-(1-Naphthoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.49 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 13.50-11.50 (1H, br.s), 10.92 (1H, s), 8.26-7.86 (6H, m), 7.85-7.70 (3H, m), 7.68-7.50 (3H, m), 3.58 (2H, d, J=5.8Hz).

Example 2(39)

N-[[4-(2-Naphthoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.49 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 13.50-11.50 (1H, br.s), 10.75 (1H, s), 8.61 (1H, s), 8.15-7.99 (6H, m), 7.94 (1H, t, J=6.2Hz), 7.81 (2H, d, J=9.2Hz), 7.72-7.58 (2H, m), 3.59 (2H, d, J=6.2Hz).

Example 2(40)

N-[[4-(3-Benzyloxybenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.54 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 13.50-11.50 (1H, br.s), 10.51 (1H, s), 7.96 (2H, d, J=8.8Hz), 7.90 (1 H, t, J=6.2Hz), 7.76 (2H, d, J=8.8Hz), 7.62-7.22 (9H, m), 5.19 (2H, s), 3.56 (2H, d, J=6.2Hz).

Example 2(41)


N-[[4-(2-Benzyloxybenzoylamino)phenyl]sulfonyl]glycine



TLC: Rf 0.73 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),
 NMR (DMSO-d₆): δ 13.50-11.50 (1H, br.s), 10.50 (1H, s), 7.89 (1H, t, J=6.2Hz), 7.78-7.67 (4H, m), 7.68 (1H, dd, J=1.6, 7.6Hz), 7.60-7.48 (3H, m), 7.44-7.25 (4H, m), 7.10 (1H, dt, J=0.8, 7.6Hz), 5.24 (2H, s), 3.54 (2H, d, J=6.2Hz).

5 Example 2(42)


N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-aspartic acid



TLC: Rf 0.35 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),
 NMR (CD₃OD): δ 8.00-7.80 (6H, m), 7.65-7.50 (3H, m), 4.22 (1H, t, J=9.0Hz), 2.73 (2H, d, J=6.0Hz).

Example 2(43)


N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-glutamic acid



TLC: Rf 0.49 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),
 NMR (CD₃OD): δ 8.00-7.80 (6H, m), 7.65-7.50 (3H, m), 3.93 (1H, dd, J=2.8, 9.0Hz), 2.41 (2H, t, J=7.5Hz), 2.15-1.95 (1H, m), 1.90-1.75 (1H, m).

Example 2(44)


N-[[4-(Phenylacetyl)amino]phenyl]sulfonyl]glycine



TLC: Rf 0.44 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),
 NMR (DMSO-d₆): δ 10.51 (1H, s), 7.86 (1H, t, J=6.2Hz), 7.76 (2H, d, J=8.8Hz), 7.69 (2H, d, J=8.8Hz), 7.40-7.18 (5H, m), 3.67 (2H, s), 3.53 (2H, d, J=6.2Hz).

Example 2(45)


N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-leucine



TLC: Rf 0.41 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),
 NMR (DMSO-d6): δ 10.29 (1H, s), 8.16 (1H, br.t, J=9.0Hz), 7.97 (2H, m), 7.72 (2H, d, J=8.6Hz), 7.6-7.45 (5H, m), 3.86 (1H, m), 1.8-1.5 (3H, m), 0.91 (6H, d, J=5.4Hz).

Example 2(46)


N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-leucine



TLC: Rf 0.41 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),
 NMR (DMSO-d6): δ 10.29 (1H, s), 8.16 (1H, br.t, J=9.0Hz), 7.97 (2H, m), 7.72 (2H, d, J=8.8Hz), 7.6-7.45 (5H, m), 3.86 (1H, m), 1.8-1.5 (3H, m), 0.90 (6H, d, J=6.2Hz).

Example 2(47)


N-[[4-(Phenoxycarbonylamino)phenyl]sulfonyl]glycine



TLC: Rf 0.44 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),
 NMR (DMSO-d6): δ 13.20-12.00 (1H, br.s), 10.64 (1H, s), 7.89 (1H, t, J=6.2Hz), 7.75 (2H, d, J=8.8Hz), 7.65 (2H, d, J=8.8Hz), 7.51-7.38 (2H, m), 7.33-7.20 (3H, m), 3.55 (2H, d, J=6.2Hz).

Example 2(48)

N-[[4-(4-Dimethylaminobenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.54 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d6): δ 10.18 (1H, s), 8.00-7.80 (5H, m), 7.73 (2H, d, J=8.8Hz), 6.77 (2H, d, J=9.0Hz), 3.55 (2H), 3.03 (6H, s).

5 Example 2(49)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-valine




TLC: Rf 0.73 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d6): δ 12.6 (1H, br.s), 10.56 (1H, s), 8.0-7.85 (5H, m), 7.75 (2H, d, J=8.8Hz), 7.65-7.5 (3H, m), 3.51 (1H, dd, J=6.1, 9.3Hz), 2.0-1.85 (1H, m), 0.83 (3H, d, J=6.8Hz), 0.81 (3H, d, J=6.8Hz).

Example 2(50)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-Phenylalanine




TLC: Rf 0.68 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d6): δ 12.71 (1H, br.s), 10.54 (1H, s), 8.17 (1H, d, J=9.0Hz), 7.97 (2H, m), 7.86 (2H, m), 7.65-7.5 (5H, m), 7.25-7.1 (5H, m), 3.95-3.8 (1H, m), 2.94 (1H, dd, J=5.8, 13.8Hz), 2.72 (1H, dd, J=8.8, 13.8Hz).

Example 2(51)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-Phenylalanine




TLC: Rf 0.68 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d6): δ 12.71 (1H, br.s), 10.53 (1H, s), 8.17 (1H, d, J=9.0Hz), 7.97 (2H, m), 7.86 (2H, m), 7.65-7.5 (5H, m), 7.3-7.1 (5H, m), 3.95-3.8 (1H, m), 2.94 (1H, dd, J=5.8, 13.8Hz), 2.73 (1H, dd, J=8.4, 13.8Hz).

Example 2(52)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-alanine




TLC: Rf 0.62 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR(DMSO-d6): δ 12.6 (1H, br.s), 10.58 (1H, s), 8.04 (1H, d, J=8.6Hz), 8.0-7.9 (4H, m), 7.76 (2H, d, J=8.8Hz), 7.65-7.5 (3H, m), 3.75 (1H, m), 1.16 (3H, d, J=7.4Hz).

Example 2(53)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-alanine




TLC: Rf 0.62 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR(DMSO-d6): δ 12.6 (1H, br.s), 10.58 (1H, s), 8.04 (1H, d, J=8.6Hz), 8.0-7.9 (4H, m), 7.77 (2H, d, J=8.8Hz), 7.65-7.5 (3H, m), 3.76 (1H, m), 1.16 (3H, d, J=7.4Hz).

Example 2(54)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-lysine




TLC: Rf 0.19 (Chloroform : Methanol : Acetic acid : Water = 2 : 1 : 0.1 : tailing),

NMR (DMSO-d6 + CF₃COOH(1 drop)): δ 10.59 (1H, s), 8.05-7.95 (5H, m), 7.80-7.50 (4H, m), 3.70-3.60 (1H, m), 2.80-2.65 (2H, m), 1.70-1.20 (6H, m).

Example 2(55)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-lysine




TLC: Rf 0.19 (Chloroform : Methanol : Acetic acid : Water = 2 : 1 : 0.1 : tailing),

NMR (DMSO-d6 + CF3COOH(1 drop)): δ 10.59 (1H, s), 8.05-7.95 (5H, m), 7.80-7.50 (4H, m), 3.70-3.60 (1H, m), 2.50-2.65 (2H, m), 1.70-1.20 (6H, m).

Example 2(56)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-glutamic acid




TLC: Rf 0.45 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d6): δ 12.4 (2H, br.s), 10.57 (1H, s), 8.05 (1H, d, J=9.0Hz), 7.97 (4H, m), 7.74 (2H, d, J=8.8Hz), 7.65-7.5 (1H, m), 3.76 (1H, m), 2.23 (2H, t, J=7.4Hz), 1.95-1.55 (2H, m).

Example 2(57)

N-[[4-(4-Dodecylbenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.68 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 13.50-11.50 (1H, br.s), 10.46 (1H, s), 7.97 (2H, d, J=8.8Hz), 7.89 (1H, t, J=6.2Hz), 7.88 (2H, d, J=8.8Hz), 7.76 (2H, d, J=8.8Hz), 7.34 (2H, d, J=8.4Hz), 3.55 (2H, d, J=6.2Hz), 2.65 (2H, t, J=7.8Hz), 1.70-1.48 (2H, m), 1.40-1.10 (18H, m), 0.85 (3H, t, J=6.6Hz).

Example 2(58)

4-[N-[[4-(Benzoylamino)phenyl]sulfonyl]amino]butyric acid




TLC: Rf 0.76 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d6): δ 12.05 (1H, br.s), 10.59 (1H, s), 8.05-7.95 (4H, m), 7.76 (2H, d, J=8.8Hz), 7.65-7.45 (4H, m), 2.75 (2H, q, J=6.8Hz), 2.22 (2H, d, J=7.2Hz), 1.60 (2H, m).

Example 2(59)

N-[[4-(Benzoylamino)phenyl]sulfonyl]amino]-L-serine




TLC: Rf 0.42 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d6): δ 10.57 (1H, s), 8.0-7.95 (4H, m), 7.88 (1H, d, J=8.6Hz), 7.76 (2H, d, J=8.6Hz), 7.65-7.5 (3H, m), 3.74 (1H, m), 3.49 (2H, d, J=5.2Hz).

Example 2(60)

N-[[4-(Benzoylamino)phenyl]sulfonyl]amino]-D-serine




TLC: Rf 0.42 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d6): δ 10.57 (1H, s), 8.0-7.9 (4H, m), 7.88 (1H, d, J=8.6Hz), 7.76 (2H, d, J=8.8Hz), 7.65-7.5 (3H, m), 3.75 (1H, m), 3.49 (2H, d, J=5.4Hz).

Example 2(61)


N-[[4-(Benzoylamino)phenyl]sulfonyl]amino]-D-aspartic acid



TLC: Rf 0.35 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),
 NMR (DMSO-d6): δ 10.57 (1H, s), 8.07 (1H, d, J=8.6Hz), 8.0-7.9 (4H, m), 7.76 (2H, d, J=8.8Hz), 7.65-7.5 (3H, m), 4.05 (1H, m), 2.59 (1H, dd, J=6.6, 16.8Hz), 2.40 (1H, dd, J=6.6, 16.8Hz).

Example 2(62)


N-[[4-(p-Toluoylamino)phenyl]sulfonyl]-D-phenylalanine



TLC: Rf 0.28 (Chloroform : Methanol : Acetic acid : Water = 100 : 10 : 1 : 1),
 NMR (DMSO-d6): δ 12.9-12.4 (1H, br.s), 10.44 (1H, s), 8.17 (1H, d, J=9.2Hz), 7.9-7.8 (4H, m), 7.54 (2H, d, J=8.6Hz), 7.36 (2H, d, J=8.2Hz), 7.3-7.1 (5H, m), 3.9-3.8 (1H, m), 2.93 (1H, dd, J=6.0, 14Hz), 2.72 (1H, dd, J=8.8, 14Hz), 2.40 (3H, s).

Example 2(63)


N-[[4-(4-Pentylbenzoylamino)phenyl]sulfonyl]-D-phenylalanine



TLC: Rf 0.21 (Chloroform : Methanol : Acetic acid = 95 : 4 : 1),
 NMR (DMSO-d6): δ 13.00-12.20 (1H, br.s), 10.40 (1H, s), 8.11 (1H, d, J=9.0Hz), 7.88 (2H, d, J=8.6Hz), 7.84 (2H, d, J=8.4Hz), 7.52 (2H, d, J=8.6Hz), 7.34 (2H, d, J=8.4Hz), 7.28-7.08 (5H, m), 3.92-3.78 (1H, m), 2.93 (1H, dd, J=5.8, 13.4Hz), 2.71 (1H, dd, J=8.8, 13.4Hz), 2.66 (2H, t, J=8.2Hz), 1.70-1.50 (2H, m), 1.44-1.18 (4H, m), 0.87 (3H, t, J=6.8Hz).

Example 2(64)


N-[[4-(p-Toluoylamino)phenyl]sulfonyl]-L-valine



TLC Rf 0.45 (Chloroform : Methanol : Acetic acid = 45 : 4 : 1),
 NMR (DMSO-d6): δ 12.90-12.30 (1H, br.s), 10.45 (1H, s), 7.94 (1H, br.d, J=9.6Hz), 7.95 (2H, d, J=8.8Hz), 7.88 (2H, d, J=8.2Hz), 7.73 (2H, d, J=8.8Hz), 7.34 (2H, d, J=8.2Hz), 3.49 (1H, dd, J=6.2, 9.6Hz), 2.39 (3H, s), 2.00-1.90 (1H, m), 0.83 (3H, d, J=6.8Hz), 0.80 (3H, d, J=6.8Hz).

Example 2(65)


N-[[4-(4-Hexylbenzoylamino)phenyl]sulfonyl]glycine



TLC Rf 0.18 (Chloroform : Methanol : Acetic acid = 90 : 10 : 1),
 NMR (DMSO-d6): δ 13.40-12.00 (1H, br.s), 10.46 (1H, s), 7.97 (3H, m), 7.88 (2H, d, J=8.0Hz), 7.87 (1H), 7.75 (2H, d, J=8.0Hz), 7.34 (2H, d, J=8.0Hz), 3.55 (2H, d, J=5.8Hz), 2.66 (2H, t, J=7.8Hz), 1.70-1.50 (2H, m), 1.40-1.15 (6H, m), 0.86 (3H, t, J=6.6Hz).

Example 2(66)


N-[[4-(4-Heptylbenzoylamino)phenyl]sulfonyl]glycine



TLC Rf 0.18 (Chloroform : Methanol : Acetic acid = 90 : 10 : 1),
 NMR (DMSO-d6): δ 13.00-12.40 (1H, br.s), 10.48 (1H, s), 7.97 (3H, m), 7.89 (2H, d, J=8.2Hz), 7.87 (1H), 7.77 (2H, d, J=8.0Hz), 7.35 (2H, d, J=8.2Hz), 3.57 (2H, d, J=6.2Hz), 2.66 (2H, t, J=7.8Hz), 1.70-1.44 (2H, m), 1.40-1.10 (8H, m), 0.86 (3H, t, J=7.0Hz).

Example 2(67)


N-[[4-(4-Isopropylbenzoylamino)phenyl]sulfonyl]glycine



TLC: Rf 0.51 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),
 NMR (DMSO-d6): δ 13.20-12.00 (1H, br.s), 10.48 (1H, s), 7.96 (3H, m), 7.89 (2H, d, J=8.2Hz), 7.76 (2H, d, J=8.8Hz), 7.41 (2H, d, J=8.2Hz), 3.57 (2H, d, J=6.0Hz), 2.99 (1H, m), 1.24 (6H, d, J=6.8Hz).

Example 2(68)


N-[[4-(4-Isobutylbenzoylamino)phenyl]sulfonyl]glycine



TLC: Rf 0.53 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),
 NMR (DMSO-d6): δ 13.20-12.00 (1H, br.s), 10.49 (1H, s), 7.96 (3H, m), 7.89 (2H, d, J=8.2Hz), 7.76 (2H, d, J=8.8Hz), 7.33 (2H, d, J=8.2Hz), 3.57 (2H, d, J=6.2Hz), 2.54 (2H, d, J=7.2Hz), 1.88 (1H, m), 0.89 (6H, d, J=6.4Hz).

Example 2(69)


N-[[4-(Benzoylamino)phenyl]sulfonyl]-2,2-dimethylglycine



TLC: Rf 0.14 (Chloroform : Methanol : Acetic acid : Water = 100 : 10 : 1 : 1),
 NMR (DMSO-d6): δ 12.55 (1H, br.s), 10.56 (1H, s), 8.0-7.85 (5H, m), 7.77 (2H, d, J=8.8Hz), 7.65-7.5 (3H, m), 1.27 (6H, s).

Example 2(70)

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]amino]-D-serine




TLC: Rf 0.25 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 13.40-11.60 (1H, br.s), 10.47 (1H, s), 7.95 (2H, d, J=8.8Hz), 7.88 (2H, d, J=8.2Hz), 7.86 (1H, d, J=8.4Hz), 7.75 (2H, d, J=8.8Hz), 7.35 (2H, d, J=8.2Hz), 3.80-3.68 (1H, m), 3.53-3.47 (2H), 2.39 (3H, s).

5 Example 2(71)

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]-L-leucine




TLC: Rf 0.22 (Chloroform : Methanol : Acetic acid : Water = 100 : 10 : 1 : 1),

NMR (DMSO-d6): δ 12.55 (1H, br.s), 10.48 (1H, s), 8.04 (1H, d, J=8.8Hz), 7.96 (2H, d, J=8.8Hz), 7.89 (2H, d, J=8.2Hz), 7.73 (2H, d, J=8.8Hz), 7.36 (2H, d, J=8.2Hz), 3.65 (1H, m), 2.40 (3H, s), 1.59 (1H, m), 1.37 (2H, m), 0.82 (3H, d, J=6.6Hz), 0.72 (3H, d, J=6.4Hz).

Example 2(72)

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]-D-alanine




TLC: Rf 0.30 (Chloroform : Methanol : Acetic acid = 90 : 10 : 1),

NMR (DMSO-d6): δ 13.20-12.00 (1H, br.s), 10.48 (1H, s), 8.02 (1H, d, J=8.2Hz), 7.97 (2H, d, J=8.8Hz), 7.88 (2H, d, J=8.4Hz), 7.75 (2H, d, J=8.8Hz), 7.35 (2H, d, J=8.4Hz), 3.82-3.66 (1H, m), 2.39 (3H, s), 1.15 (3H, d, J=7.0Hz).

Example 2(73)

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]-D-valine




TLC: Rf 0.53 (Chloroform : Methanol : Acetic acid = 90 : 10 : 1),

NMR (DMSO-d6): δ 12.80-12.40 (1H, br.s), 10.46 (1H, s), 7.95 (2H, d, J=8.8Hz), 7.94-7.90 (1H), 7.89 (2H, d, J=8.2Hz), 7.74 (2H, d, J=8.8Hz), 7.35 (2H, d, J=8.2Hz), 3.60-3.45 (1H, m), 2.39 (3H, s), 2.02-1.80 (1H, m), 0.81 (6H, d, J=6.8Hz).

Example 2(74)

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]-D-leucine




5

10 TLC: Rf 0.54 (Chloroform : Methanol : Acetic acid = 90 : 10 : 1),
 NMR (DMSO-d6): δ 12.80-12.30 (1H, br.s), 10.46 (1H, s), 8.02 (1H, d, J=9.0Hz), 7.96 (2H, d, J=8.8Hz), 7.89 (2H, d, J=8.2Hz), 7.73 (2H, d, J=8.8Hz), 7.35 (2H, d, J=8.2Hz), 3.75-3.55 (1H, m), 2.39 (3H, s), 1.70-1.48 (1H, m), 1.46-1.30 (2H, m), 0.82 (3H, d, J=6.6Hz), 0.72 (3H, d, J=6.6Hz).

15 Example 2(75)

N-[[2-Methyl-4-(p-Toluoylamino)phenyl]sulfonyl]glycine

20



25


TLC: Rf 0.61 (Chloroform : Methanol = 2 : 1),
 NMR (DMSO-d6): δ 10.38 (1H, s), 8.02 (1H, t, J=3.6Hz), 7.88 (2H, d, J=8.1Hz), 7.80-7.77 (3H, m), 7.34 (2H, d, J=8.1 Hz), 3.58 (2H, d, J=3.6Hz), 2.59 (3H, s), 2.40 (3H, s).

30

Example 2(76)

N-[[3-Methyl-4-(p-Toluoylamino)phenyl]sulfonyl]glycine

35



40


TLC: Rf 0.24 (Chloroform : Methanol = 2 : 1),
 NMR (DMSO-d6): δ 12.64 (1H, br.s), 9.88 (1H, s), 7.94 (1H, t, J=6.2Hz), 7.85 (2H, d, J=8.1 Hz), 7.66 (3H, m), 7.30 (2H, d, J=8.1 Hz), 3.55 (2H, d, J=6.2Hz), 2.36 (3H, s), 2.28 (3H, s).

45

Example 2(77)

N-[[4-(2-Hydroxy-4-methylbenzoylamino)phenyl]sulfonyl]-D-alanine

50




55

TLC: Rf 0.37 (Chloroform : Methanol = 2 : 1),

NMR (DMSO-d6): δ 12.62 (1H, br.s), 11.66 (1H, s), 10.56 (1H, s), 8.06 (1H, d, J=8.6Hz), 7.93-7.70 (5H, m), 6.82 (1H, s), 6.80 (1H, d, J=7.2Hz), 3.76 (1H, m), 2.31 (3H, s), 1.15 (3H, d, J=7.2Hz).

Example 2(78)

N-[[4-(2-Thienylcarbonylamino)phenyl]sulfonyl]-D-alanine




TLC: Rf 0.21 (Chloroform : Methanol : Water = 4 : 1 : 0.1),

NMR (DMSO-d6): δ 12.60 (1H, br.s), 10.49 (1H, s), 8.05-7.98 (2H, m), 7.91-7.85 (3H, m), 7.73 (2H, d, J=8.8Hz), 7.21 (1H, t, J=3.8Hz), 3.77-3.68 (1H, m), 1.13 (3H, d, J=7.2Hz).

Example 2(79)

N-[[3-(Benzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.36 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 10.54 (1H, s), 8.33 (1H, s), 8.14-7.90 (4H, m), 7.68-7.44 (5H, m), 3.60 (2H, d, J=6.0Hz).

Example 2(80)

N-[[2-(Benzoylamino)phenyl]sulfonyl]glycine




TLC : Rf 0.34 (Chloroform : Methanol : Acetic acid = 90 : 10 : 1),

NMR (DMSO-d6): δ 13.00-12.60 (1H, br.s), 10.26 (1H, s), 8.67-8.56 (1H), 8.52-8.44 (1H, m), 8.02-7.92 (2H, m), 7.87 (1H, dd, J=1.4, 7.8Hz), 7.74-7.54 (4H, m), 7.38-7.27 (1H, m), 3.65 (2H, d, J=4.6Hz).

Example 3

N-[[4-(2-Aminobenzoylamino)phenyl]sulfonyl]glycine



To a solution of the compound prepared in example 2(13) (569 mg) in N, N-dimethylformamide (7.5 ml) and methanol (7.5 ml), 10% palladium carbon (100 mg) and ammonium formate (378 mg) was added. The mixture was stirred for 1 hour at room temperature. The reaction mixture was filtered and the filtrate was concentrated. The residue was washed with water and ether and dried to give the title compound having the following physical data.

TLC: Rf 0.47 (Chloroform :Methanol : acetic acid = 2 : 1 : 0.1),


NMR (DMSO-d6): δ 12.60 (1H, br.s), 10.30 (1H, s), 7.95-7.85 (3H, m), 7.74 (2H, d, J=8.8Hz), 7.64 (2H, d, J=8.0Hz), 7.22 (1H, t, J=8.0Hz), 6.76 (1H, d, J=8.0Hz), 6.60 (1H, t, J=8.0Hz), 6.38 (2H, br), 3.56 (2H, d, J=6.2Hz).

Example 3(1)-3(13)

The compounds having the following physical data were obtained by the same procedure as a series of reactions of Example 3, using a compound prepared in Example 2(14), 2(15), 2(31), 2(33), 2(40), 2(41), 1(78), 1(79), 1(80), 1(81), 1(82), 1(83) and 1(84) instead of a compound prepared in example 2(13).

Example 3(1)

N-[[4-(3-Aminobenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.39 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d6): δ 10.41 (1H, s), 7.85-7.0 (3H, m), 7.74 (2H, d, J=8.4Hz), 7.2-7.05 (3H, m), 6.77 (1H, d, J=7.6Hz), 3.56 (2H, d, J=6.0Hz).

Example 3(2)

N-[[4-(4-Aminobenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.35 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d6): δ 12.60 (1H, br.s), 10.08 (1H, s), 7.94 (2H, d, J=8.8Hz), 7.86 (1H, t, J=6.0Hz), 7.73 and 7.72 (total 4H, each d, both J=8.8Hz), 6.61 (2H, d, J=8.8Hz), 5.83 (2H, br), 3.55 (2H, d, J=6.0Hz).

Example 3(3)

N-[[4-(4-Hydroxybenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.58 (Chloroform : Methanol : Acetic acid = 20 : 10 : 1),

10 NMR (DMSO-d6): δ 10.31 (1H, s), 8.01-7.82 (1H, m), 7.95 (2H, d, J=8.8Hz), 7.87 (2H, d, J=8.4Hz), 7.75 (2H, d, J=8.8Hz), 6.88 (2H, d, J=8.4Hz), 3.53 (2H, m).

Example 3(4)

15 N-[[4-[(2-Phenylethyl)carbonylamino]phenyl]sulfonyl]glycine




25 TLC: Rf 0.45 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 10.29 (1H, s), 7.80-7.50 (5H, m), 7.36-7.08 (5H, m), 3.50-3.40 (2H, m), 3.00-2.78 (2H, m), 2.74-2.50 (2H, m).

Example 3(5)

30 N-[[4-[(3-Hydroxybenzoylamino)phenyl]sulfonyl]glycine




40 TLC: Rf 0.24 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 10.48 (1H, s), 7.96 (2H, d, J=8.8Hz), 7.95-7.76 (1H, m), 7.75 (2H, d, J=8.8Hz), 7.44-7.28 (3H, m), 7.40-6.95 (1H, m), 3.60-3.50 (2H, m).

45 Example 3(6)

N-[[4-[(2-Hydroxybenzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.38 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 13.20-10.80 (1H, br.s), 10.65 (1H, s), 8.00-7.84 (2H, m), 7.92 (2H, d, J=8.8Hz), 7.78 (2H, d,

J=8.8Hz), 7.44 (1H, m), 7.06-6.92 (2H, m), 3.60-3.48 (2H, m).

Example 3(7)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-tryptophan




TLC: Rf 0.26 (Chloroform : Methanol : Acetic acid = 90 : 10 : 1),

NMR (DMSO-d₆): δ 13.50-11.60 (1H, br,s), 10.78 (1H, s), 10.49 (1H, s), 8.12-8.00 (1H, m), 7.97 (2H, dd, J=1.6, 7.6Hz), 7.85 (2H, d, J=9.0Hz), 7.64-7.49 (5H, m), 7.37-7.25 (2H, m), 7.10-6.86 (3H, m), 4.00-3.80 (1H, m), 3.06 (1H, dd, J=6.6Hz, 14.4Hz), 2.87 (1H, dd, J=7.2, 14.4Hz).

Example 3(8)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-tyrosine




TLC: Rf 0.56 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d₆): δ 10.53 (1H, s), 9.25-9.05 (1H, br,s), 8.00-7.93 (3H, m), 7.89 (2H, d, J=8.8Hz), 7.61 (2H, d, J=8.8Hz), 7.60-7.48 (3H, m), 6.92 (2H, d, J=8.4Hz), 6.60 (2H, d, J=8.4Hz), 3.80-3.64 (1H, m), 2.80 (1H, dd, J=5.8, 13.6Hz), 2.65 (1H, dd, J=7.6, 13.6Hz).

Example 3(9)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-tryptophan




TLC: Rf 0.26 (Chloroform : Methanol : Acetic acid = 90 : 10 : 1),

NMR (DMSO-d6): δ 12.80-12.30 (1H, br.s), 10.79 (1H, s), 10.50 (1H, s), 8.09 (1H, d, J=8.6Hz), 8.02-7.93 (2H, m), 7.85 (2H, d, J=8.8Hz), 7.68-7.50 (5H, m), 7.38-7.25 (2H, m), 7.11-6.87 (3H, m), 4.00-3.81 (1H, m), 3.05 (1H, dd, J=6.6, 14.8Hz), 2.86 (1H, dd, J=7.8, 14.8Hz).

Example 3(10)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-tyrosine




TLC: Rf 0.56 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 12.80-12.00 (1H, br.s), 10.54 (1H, s), 9.20 (1H, s), 8.06 (1H, d, J=8.8Hz), 8.02-7.93 (2H, m), 7.89 (2H, d, J=8.8Hz), 7.70-7.50 (5H, m), 6.92 (2H, d, J=8.4Hz), 6.61 (2H, d, J=8.4Hz), 3.90-3.70 (1H, m), 2.81 (1H, dd, J=6.4, 13.6Hz), 2.62 (1H, dd, J=8.2, 13.6Hz).

Example 3(11)

N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-histidine




TLC: Rf 0.16 (Chloroform : Methanol : Acetic acid = 14 : 6 : 1),

NMR (DMSO-d6): δ 10.82 (1H, s), 8.29 (1H, s), 8.10 (2H, d, J=9.0Hz), 8.04 (2H, d, J=9.0Hz), 8.00-7.92 (2H, m), 7.68-7.48 (4H, m), 7.45 (1H, s), 3.45-3.35 (1H, m), 3.05 (1H, dd, J=3.6, 15.6Hz), 2.70 (1H, dd, J=9.0, 15.6Hz).

Example 3(12)

2-[N-4-(Benzoylamino)phenyl]sulfonylamino]-(3-pyridyl)-D-alanine




TLC Rf 0.35 (Chloroform : Methanol : Acetic acid = 2 : 1 : 0.1),

NMR (DMSO-d6): δ 12.84 (1H, br.s), 10.54 (1H, s), 8.37 (2H, m), 8.02 (1H, d, $J=9.0$ Hz), 7.96 (2H, m), 7.86 (2H, d, $J=6$ Hz), 7.65-7.5 (6H, m), 7.21 (1H, dd, $J=4.9, 7.5$ Hz), 3.89 (1H, m), 3.05-2.7 (2H, m).

Example 3(13)

N-[[4-(p-Toluylamino)phenyl]sulfonyl]-D-tryptophan




TLC Rf 0.13 (Chloroform : Methanol : Acetic acid : Water = 100 : 10 : 1 : 1),

NMR (DMSO-d6): δ 12.57 (1H, br.s), 10.8 (1H, s), 10.42 (1H, s), 8.13 (1H, d, $J=8.8$ Hz), 7.9-7.8 (4H, m), 7.59 (2H, d, $J=6$ Hz), 7.4-7.25 (4H, m), 7.1-6.9 (3H, m), 3.95-3.85 (1H, m), 3.04 (1H, dd, $J=6.0, 18.0$ Hz), 2.84 (1H, dd, $J=7.4, 17.0$ Hz), 2.39 (3H, s).

Reference example 3


Sodium 4-(Benzyloxycarbonyloxy)benzenesulfonate



To an aqueous solution (40 ml) of sodium hydride (3.8 g), sodium 4-hydroxybenzenesulfonate dihydroxide (20 g) and tetrahydrofuran (28 ml) was added. To the mixture, benzyl chloroformate (12.3 ml) was added at 0°C. The mixture was stirred for 1 hour at 0°C and for 1 hour at room temperature. The reaction mixture was concentrated. The precipitated crystals was washed with water and dried to give the title compound (18.1 g) having the following physical data.
NMR (CD₃OD): δ 7.85 (2H, d, $J=8.0$ Hz), 7.50-7.30 (5H, m), 7.25 (2H, d, $J=8.0$ Hz), 5.25 (2H, s).

Reference example 4

4-(Benzyloxycarbonyloxy)benzenesulfonyl chloride




To a suspension of the compound prepared in reference example 3 (10.2 g) in N, N-dimethylformamide (30 ml), sulfonyl chloride (3.4 ml) was added at 0°C. The mixture was stirred for 1 hour at room temperature. The reaction mixture was poured into ice-water (50 ml). The precipitated crystals were washed with water and dried to give the title compound (9.6 g) having the following physical data.

NMR (CD₃OD) : δ 8.10 (2H, d, J=8.0Hz), 7.50 (2H, d, J=8.0Hz), 7.45-7.40 (5H, m), 5.30 (2H, s).

Example 4

N-[[4-(Benzyloxycarbonyloxy)phenyl]sulfonyl]glycine t-butyl ester




To a solution of glycine t-butyl ester hydrochloride (1.5 g) in pyridine (20 ml), a compound prepared in reference example 4 (3.0 g) was added. The mixture was stirred overnight at room temperature. The reaction mixture was concentrated and the residue was dissolved into ethyl acetate. The solution was washed with 1N hydrochloric acid, water and a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated to give the title compound (2.4 g) having the following physical data.

TLC: R_f 0.78 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃) : δ 7.90 (2H, d, J=8.0Hz), 7.50-7.30 (5H, m), 7.35 (2H, d, J=8.0Hz), 5.30 (2H, s), 5.05 (1H, t, J=6.0Hz), 3.70 (2H, d, J=6.0Hz), 1.40 (9H, s).

Reference example 5

N-[4-(Hydroxyphenyl)sulfonyl]glycine t-butyl ester




To a solution of a compound prepared in example 4 (2.3 g) in ethanol (50 ml), 10% palladium carbon (200 mg) was added. The mixture was stirred for 2 hours at room temperature under an atmosphere of hydrogen. The reaction mixture was filtered through celite (registered trade mark). The filtrate was concentrated. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 3 : 1 → 2 : 1) to give the title compound (1.5 g) having the following physical data.

TLC: R_f 0.19 (Hexane : Ethyl acetate = 2 : 1),

NMR (CDCl₃) : δ 7.70 (2H, d, J=8.0Hz), 6.90 (2H, d, J=8.0Hz), 3.75 (1H, br.s), 3.60 (2H, br.s), 1.40 (9H, s).

Example 5

N-[[4-(Benzoyloxy)phenyl]sulfonyl]glycine t-butyl ester



The compounds having the following physical data were obtained by the same procedure as a series of reactions of Example 1, using a compound prepared in reference Example 5 instead of a compound prepared in reference Example 2, and benzoyl chloride instead of p-toluoyl chloride.

TLC: Rf 0.62 (Hexane : Ethyl acetate = 1 : 1),


NMR (CDCl₃): δ 8.20 (2H, d, J=7.2Hz), 7.95 (2H, d, J=9.0Hz), 7.68 (1H, t, J=7.2Hz), 7.54 (2H, t, J=7.2Hz), 7.39 (2H, d, J=9.0Hz), 5.07 (1H, t, J=5.2Hz), 3.71 (2H, d, J=5.2Hz), 1.39 (9H, s).

Example 5(1)-5(6)

The compounds having the following physical data were obtained by the same procedure as a series of reactions of Example 4, using a corresponding amino acid ester derivative instead of glycine t-butyl ester hydrochloride, and then by the same procedure as a series of reactions of Reference Example 5, and then by the same procedure as a series of reactions of Example 5, using a corresponding acyl chloride derivative or a corresponding carboxylic acid derivative and a condensing agent (e.g. 1,3-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-[3-(dimethylamino)propyl] carbodiimide (EDC)) instead of benzoyl chloride, or converting to a corresponding salt by conventional method.

Example 5(1)


N-[[4-(4-Amidinobenzoyloxy)phenyl]sulfonyl]glycine t-butyl ester



TLC: Rf 0.41 (Chloroform : Methanol : Acetic acid = 10 : 2 : 1).

Example 5(2)


N-[[4-(4-Guanidinobenzoyloxy)phenyl]sulfonyl]glycine t-butyl ester



TLC: Rf 0.35 (Chloroform : Methanol : acetic acid = 10 : 2 : 1).

Example 5(3)


N-[[4-(4-Amidinobenzoyloxy)phenyl]sulfonyl]-L-phenylalanine t-butyl ester



TLC Rf 0.43 (Chloroform : Methanol : Acetic acid = 10 : 2 : 1).

Example 5(4)

N-[[4-(Benzoyloxy)phenyl]sulfonyl]glycine ethyl ester




TLC Rf 0.44 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.20 (2H, d, J=7.0Hz), 7.95 (2H, d, J=8.7Hz), 7.68 (1H, m), 7.53 (2H, m), 7.40 (2H, d, J=8.7Hz), 5.11 (1H, t, J=5.4Hz), 4.13 (2H, q, J=7.1Hz), 3.82 (2H, d, J=5.4Hz), 1.23 (3H, t, J=7.1 Hz).

Example 5(5)

N-[[4-(Benzoyloxy)phenyl]sulfonyl]-β-alanine t-butyl ester




TLC Rf 0.77 (Ethyl acetate),

NMR (CDCl₃): δ 8.21 (2H, d, J=8.0Hz), 7.95 (2H, d, J=9.0Hz), 7.68 (1H, t, J=8.0Hz), 7.54 (2H, t, J=8.0Hz), 7.40 (2H, d, J=9.0Hz), 5.31 (1H, t, J=6.0Hz), 3.19 (2H, q, J=6.0Hz), 2.49 (2H, t, J=6.0Hz), 1.44 (9H, s).

Example 5(6)


N-[[4-(4-Amidinobenzoyloxy)phenyl]sulfonyl]-β-alanine t-butyl ester acetate



TLC : Rf 0.36 (Chloroform : Methanol Acetic acid = 10 : 2 : 1).

Example 6

N-[[4-(Benzoyloxy)phenyl]sulfonyl]glycine



The title compound having the following physical data were obtained by the same procedure as a series of reactions of Example 2, using a compound prepared in Example 5 instead of a compound prepared in Example 1.

TLC : Rf 0.12 (Chloroform : Methanol : Water = 90 : 10 : 1),


NMR (CDCl₃+CD₃OD): δ 8.16 (2H, d, J=7.6Hz), 7.93 (2H, d, J=9.0Hz), 7.66 (1H, t, J=7.6Hz), 7.55 (2H, t, J=7.6Hz), 7.34 (2H, d, J=9.0Hz), 3.77 (2H, S).

Example 6(1)-6(5)

The compounds having the following physical data were obtained by the same procedure as a series of reactions of Example 6, if necessary, by converting to corresponding salts by conventional method, using a compound prepared in Example 5(1)-5(3), 5(5) and 5(6) instead of a compound prepared in example 5.

Example 6(1)

N-[[4-(4-Amidinobenzoyloxy)phenyl]sulfonyl]glycine methansulfonate




TLC: Rf 0.27 (Chloroform : Methanol : Acetic acid = 3 : 1 : 1),

NMR (DMSO-d₆): δ 9.55 (2H, br.), 9.35 (2H, br.), 8.35 (2H, d, J=8.0Hz), 8.00 (2H, d, J=8.0Hz), 7.95 (d, J=9.0Hz), 7.60 (2H, d, J=9.0Hz), 3.60 (2H, br.), 3.40 (1H, br.), 2.40 (6H, s).

Example 6(2)


N-[[4-[[[4-(Guanidinobenzoyloxy)phenyl]sulfonyl]glycine methansulfonate



10 TLC: R_f 0.45 (Chloroform : Methanol : Acetic acid = 3 : 1 : 1),
NMR (CD₃OD): δ 8.25 (2H, d, J=8.0Hz), 7.95 (2H, d, J=8.0Hz), 7.45 (2H, d, J=8.0Hz), 7.43 (2H, d, J=8.0Hz), 3.73 (2H, s), 2.69 (3H, s).

15 Example 6(3)


N-[[4-[[4-Amidinobenzoyloxy]phenyl]sulfonyl]-L-phenylalanine acetate



30 TLC: R_f 0.24 (Chloroform : Methanol : Acetic acid = 10 : 2 : 1),
NMR (CD₃COOD): δ 8.40 (2H, d, J=7.5Hz), 8.05 (2H, d, J=7.5Hz), 7.80 (2H, d, J=8.0Hz), 7.35 (2H, d, J=8.0Hz), 7.30-7.15 (5H, m), 4.30 (1H, t, J=6.0Hz), 3.20 (1H, dd, J=15, 6.0Hz), 2.95 (1H, dd, J=15, 6.0Hz).

35 Example 6(4)


N-[[4-(Benzoyloxy)phenyl]sulfonyl]-β-alanine



45 TLC: R_f 0.36 (Chloroform : Methanol : Acetic acid : Water = 100 : 10 : 1 : 1),
NMR (CDCl₃ + CD₃OD): δ 8.20 (2H, d, J=7.0Hz), 7.95 (2H, d, J=9.0Hz), 7.69 (1H, t, J=7.0Hz), 7.55 (2H, t, J=7.0Hz), 7.40 (2H, d, J=9.0Hz), 3.22 (2H, t, J=6.0Hz), 2.55 (2H, t, J=6.0Hz).

50 Example 6(5)


N-[[4-(4-Amidinobenzoyloxy)phenyl]sulfonyl]-β-alanine



TLC : Rf 0.176 (Chloroform : Methanol : Acetic acid = 10 : 2 : 1),
 NMR (CD₃COOD) : δ 8.40 (2H, d, J=7.5Hz), 8.05 (2H, d, J=7.5Hz), 8.00 (2H, d, J=8.0Hz), 7.50 (2H, d, J=8.0Hz), 3.25 (2H, t, J=6.0Hz), 2.60 (2H, t, J=6.0Hz).

Reference example 6


4-(Methoxycarbonyl)benzenesulfonyl chloride



A suspension of 4-Carboxybenzenesulfonyl chloride (2.2 g) in thionyl chloride (10 ml) was refluxed for 1 hour. The reaction mixture was cooled to room temperature and concentrated. The residue was dissolved in methanol (10 ml), and stirred for 1 hours at room temperature. The reaction mixture was concentrated to give the title compound (2.3 g).

Reference example 7


3-(Methoxycarbonyl)benzenesulfonyl chloride



The title compound was obtained by the same procedure as a series of reactions of reference example 6, using 3-carboxybenzenesulfonyl chloride instead of 4-carboxybenzenesulfonyl chloride.

Example 7

N-[[4-(Methoxycarbonyl)phenyl]sulfonyl]glycine t-butyl ester



The title compound having the following physical data was obtained by the same procedure as a series of reactions of Example 4, using a compound prepared in reference Example 6 instead of a compound prepared in reference Example 4.

TLC: Rf 0.56 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.16 (2H, d, J=8.8Hz), 7.93 (2H, d, J=8.8Hz), 5.09 (1H, t, J=5.4Hz), 3.95 (3H, s), 3.70 (2H, d, J=5.4Hz), 1.34 (9H, s).

5 Example 7(1)-7(8)


The compounds having the following physical data were obtained by the same procedure as a series of reactions of Example 7, using a compound prepared in reference Example 6 or 7, and a corresponding amino acid.

10 Example 7(1)

N-[[4-(Methoxycarbonyl)phenyl]sulfonyl]-L-phenylalanine t-butyl ester

15

20



25

TLC: Rf 0.59 (Hexane : Ethyl acetate = 2 : 1),

NMR (CDCl₃): δ 8.10 (2H, d, J=8.0Hz), 7.80 (2H, d, J=8.0Hz), 7.30-7.20 (3H, m), 7.20-7.10 (2H, m), 5.15 (1H, d, J=9.0Hz), 4.10 (1H, m), 3.95 (3H, s), 3.00 (2H, d, J=6.0Hz), 1.20 (9H, s).


30 Example 7(2)

30

N-[[4-(Methoxycarbonyl)phenyl]sulfonyl]-L-aspartic acid di-t-butyl ester

35

40



45

TLC: Rf 0.64 (Hexane : Ethyl acetate = 2 : 1),


NMR (CDCl₃): δ 8.10 (2H, d, J=8.0Hz), 7.90 (2H, d, J=8.0Hz), 5.65 (1H, d, J=9.0Hz), 3.95 (1H, m), 3.90 (3H, s), 2.75 (1H, dd, J=15, 5.0Hz), 2.65 (1H, dd, J=15, 5.0Hz), 1.35 (9H, s), 1.25 (9H, s).

50 Example 7(3)

50

N-[[3-(Methoxycarbonyl)phenyl]sulfonyl]glycine t-butyl ester


55



TLC: Rf 0.45 (Hexane : Ethyl acetate = 2 : 1).

Example 7(4)

N-[(4-Methoxycarbonylphenyl)sulfonyl]-L-glutamic acid di-t-butyl ester




TLC: Rf 0.59 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.14 (2H, d, J=9.0Hz), 7.90 (2H, d, J=9.0Hz), 5.31 (1H, d, J=9.0Hz), 3.96 (3H, s), 3.92-3.80 (1H, m), 2.43-2.35 (2H, m), 2.16-1.98 (1H, m), 1.88-1.66 (1H, m), 1.46 (9H, s), 1.24 (9H, s).

Example 7(5)

N-[(4-Methoxycarbonylphenyl)sulfonyl]-L-aspartic acid di-t-butyl ester




TLC: Rf 0.83 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.15 (2H, d, J=9.0Hz), 7.94 (2H, d, J=9.0Hz), 5.72 (1H, d, J=9.0Hz), 4.08-4.00 (1H, m), 3.96 (3H, s), 2.91-2.65 (2H, m), 1.43 (9H, s), 1.30 (9H, s).

Example 7(6)

N-[(3-Methoxycarbonylphenyl)sulfonyl]-L-aspartic acid di-t-butyl ester




TLC: Rf 0.33 (Hexane : Ethyl acetate = 8 : 2),

NMR (CDCl₃): δ 8.51 (1H, t, J=2.0Hz), 8.24 (1H, dt, J=8.0Hz, 2Hz), 8.06 (1H, dt, J=8.0Hz, 2Hz), 7.60 (1H, t, J=8.0Hz), 5.73 (1H, d, J=9.0Hz), 4.10-4.01 (1H, m), 3.96 (3H, s), 2.91-2.66 (2H, m), 1.41 (9H, s), 1.27 (9H, s).

Example 7(7)

N-[(3-Methoxycarbonylphenyl)sulfonyl]-L-glutamic acid di-t-butyl ester




TLC: Rf 0.33 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.48 (1H, t, J=2.0Hz), 8.23 (1H, dt, J=8.0Hz, 2Hz), 8.02 (1H, dt, J=8.0Hz, 2Hz), 7.59 (1H, t, J=8.0Hz), 5.32 (1H, d, J=9.0Hz), 3.96 (3H, s), 3.92-3.81 (1H, m), 2.40 (2H, t, J=8.0Hz), 2.13-1.96 (1H, m), 1.87-1.66 (1H, m), 1.46 (9H, s), 1.23 (9H, s).

Example 7(8)

N-[4-(Methoxycarbonyl)phenyl]sulfonyl-β-alanine t-butyl ester




TLC: Rf 0.43 (Hexane : Ethyl acetate = 2 : 1),

NMR (CDCl₃): δ 8.20 (2H, d, J=8.0Hz), 7.95 (2H, d, J=8.0Hz), 5.40 (1H, t, J=6.0Hz), 4.00 (3H, s), 3.20 (2H, dt, J=6.0Hz, 6.0Hz), 2.50 (3H, t, J=6.0Hz), 1.45 (9H, s).

Example 8

N-[(4-Carboxyphenyl)sulfonyl]glycine t-butyl ester



To a solution of a compound prepared in Example 7 (658 mg) in methanol (2 ml) and dioxane (2 ml), 5N aqueous solution of sodium hydroxide (0.8 ml) was added. The mixture was stirred for one day at room temperature. The reaction mixture was neutralized by adding 2N hydrochloric acid and extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (methylene chloride : methanol : acetic acid : water = 100 : 10 : 1 : 1) to give the title compound (333 mg) having the following physical data.

TLC: Rf 0.49 (Chloroform : Methanol : Acetic acid : Water = 90 : 10 : 1 : 1),


NMR (CD₃OD): δ 8.16 (2H, d, J=8.8Hz), 7.94 (2H, d, J=8.8Hz), 3.69 (2H, s), 1.31 (9H, s).

Example 8(1)-8(8)

The compounds having the following physical data were obtained by the same procedure as a series of reactions of Example 8, using a compound prepared in Example 7(1)-7(8) instead of a compound prepared in Example 7.

Example 8(1)

N-[(4-Carboxyphenyl)sulfonyl]-L-phenylalanine t-butyl ester




TLC: Rf 0.25 (Chloroform : Methanol = 9 : 1),

NMR (CDCl₃): δ 8.15 (2H, d, J=8.0Hz), 7.85 (2H, d, J=8.0Hz), 7.30-7.20 (3H, m), 7.20-7.10 (2H, m), 5.30 (1H, d, J=9.0Hz), 4.15 (1H, m), 3.00 (2H, d, J=6.0Hz), 1.25 (9H, s).

Example 8(2)

N-[(4-Carboxyphenyl)sulfonyl]-L-aspartic acid di-t-butyl ester




TLC: Rf 0.28 (Chloroform : Methanol = 9 : 1),

NMR (CDCl₃): δ 8.20 (2H, d, J=8.0Hz), 8.00 (2H, d, J=8.0Hz), 5.80 (1H, d, J=9.0Hz), 4.05 (1H, m), 2.80 (2H, m), 1.40 (9H, s), 1.30 (9H, s).

Example 8(3)


N-[(3-Carboxyphenyl)sulfonyl]glycine t-butyl ester



TLC: Rf 0.22 (Chloroform : Methanol = 9 : 1).

Example 8(4)

N-[4-(Carboxyphenyl)sulfonyl]-L-glutamic acid di-t-butyl ester




TLC: Rf 0.25 (Chloroform : Methanol = 9 : 1),

NMR (CDCl₃): δ 8.30-8.10 (2H, br.d, J=8.0Hz), 8.10-7.80 (2H, br.d, J=8.0Hz), 5.50-5.30 (1H, br.d, J=9.0Hz), 4.00-3.78 (1H, m), 2.50-1.60 (8H, m), 1.43 (9H, s), 1.23 (9H, s).

Example 8(5)

N-[(4-Carboxyphenyl)sulfonyl]-L-aspartic acid di-t-butyl ester




TLC: Rf 0.30 (Chloroform : Methanol = 9 : 1),

NMR (CDCl₃): δ 8.22-8.04 (2H, br.d, J=8.0Hz), 7.96-7.76 (2H, br.d, J=8.0Hz), 6.00-5.82 (1H, br.d, J=9.0Hz), 4.16-4.00 (1H, m), 2.92-2.63 (2H, m), 1.40 (9H, s), 1.25 (9H, s).

Example 8(6)

N-[(3-Carboxyphenyl)sulfonyl]-L-aspartic acid di-t-butyl ester




TLC: Rf 0.46 (Chloroform : Methanol : Water = 8 : 2 : 0.1),

NMR (CDCl₃): δ 8.63 (1H, t, J=2.0Hz), 8.29 (1H, dt, J=8.0Hz, 2.0Hz), 8.12 (1H, dt, J=8.0Hz, 2.0Hz), 7.64 (1H, t, J=8.0Hz), 6.00 (1H, d, J=9.0Hz), 4.16-4.07 (1H, m), 2.94-2.69 (2H, m), 1.43 (9H, s), 1.28 (9H, s).

Example 8(7)

N-[(3-Carboxyphenyl)sulfonyl]-L-glutamic acid di-t-butyl ester




TLC Rf 0.54 (Chloroform : Methanol : Water = 8 : 2 : 0.1),

NMR (CDCl₃): δ 8.57 (1H, t, J=2.0Hz), 8.29 (1H, dt, J=8.0Hz, 2.0Hz), 8.08 (1H, dt, J=8.0Hz, 2.0Hz), 7.63 (1H, t, J=8.0Hz), 5.61 (1H, d, J=9.0Hz), 3.97-3.86 (1H, m), 2.42 (2H, t, J=7.0Hz), 2.15-1.98 (1H, m), 1.90-1.72 (1H, m), 1.47 (9H, s), 1.25 (9H, s).

Example 8(8)

N-[(Carboxyphenyl)sulfonyl]-β-alanine t-butyl ester




TLC Rf 0.31 (Chloroform : Methanol = 4 : 1),

NMR (CDCl₃): δ 8.20 (2H, d, J=8.0Hz), 7.95 (2H, d, J=8.0Hz), 3.20 (2H, t, J=6.0Hz), 2.45 (2H, t, J=6.0Hz), 1.45 (9H, s).

Example 9

N-[[4-(Phenoxycarbonyl)phenyl]sulfonyl]glycine t-butyl ester



To a solution of a compound prepared in example 8 (221 mg) in pyridine (3.5 ml), phenol (79 mg), N, N-dimethyl-aminopyridine (9 mg) and dicyclohexylcarbodiimide (159 mg) were added successively. The mixture was stirred overnight and concentrated. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 5 : 1), to give the title compound having the following physical data.

TLC Rf 0.77 (Ethyl acetate),


NMR (CDCl₃): δ 8.35 (2H, d, J=8.8Hz), 8.02 (2H, d, J=8.8Hz), 7.47 (2H, t, J=6.0Hz), 7.31 (1H, t, J=6.0Hz), 7.22 (2H, d, J=5.0Hz), 5.16 (1H, t, J=5.4Hz), 3.74 (2H, d, J=5.4Hz), 1.37 (9H, s).

Example 9(1)-9(10)

The compounds having the following physical data were obtained by the same procedure as a series of reactions of Example 9, if necessary, by converting to corresponding salts by conventional method using a compound prepared in Example 8 and 8(1)-8(8) and a corresponding alcohol and amine.

Example 9(1)

N-[[4-(4-Amidinophenoxy)carbonyl]phenyl]sulfonyl]-L-phenylalanine t-butyl ester




TLC : Rf 0.45 (Chloroform : Methanol : Acetic acid = 10 : 2 : 1),

NMR (CD₃OD): δ 8.25 (2H, d, J=8.0Hz), 7.95 (2H, d, J=8.0Hz), 7.85 (2H, d, J=8.0Hz), 7.55 (2H, d, J=8.0Hz), 7.25-7.10 (5H, m), 4.00 (1H, t, J=7.5Hz), 3.00 (1H, dd, J=15.0, 7.5Hz), 2.85 (1H, dd, J=15.0, 7.5Hz), 1.25 (9H, s).

Example 9(2)

N-[[4-(4-Amidinophenoxy)carbonyl]phenyl]sulfonyl]-L-aspartic acid di-t-butyl ester




TLC : Rf 0.51 (Chloroform : Methanol : Acetic acid = 10 : 2 : 1),

NMR (CD₃OD): δ 8.35 (2H, d, J=8.0Hz), 8.05 (2H, d, J=8.0Hz), 7.95 (2H, d, J=9.0Hz), 7.55 (2H, d, J=9.0Hz), 4.20 (1H, m), 2.60 (2H, m), 1.45 (9H, s), 1.30 (9H, s).

Example 9(3)

N-[[3-(4-Amidinophenoxy)carbonyl]phenyl]sulfonyl]glycine t-butyl ester




TLC : Rf 0.33 (Chloroform : Methanol : Acetic acid = 10 : 2 : 1),

NMR (CD₃OD): δ 8.60 (1H, s), 8.40 (1H, d, J=8.0Hz), 8.20 (1H, d, J=8.0Hz), 7.95 (2H, d, J=9.0Hz), 7.80 (1H, t, J=8.0Hz), 7.55 (2H, d, J=9.0Hz), 3.75 (2H, s), 1.35 (9H, s).

Example 9(4)


N-[[4-(4-Amidinophenoxy)phenyl]sulfonyl]glycine t-butyl ester



TLC : Rf 0.45 (Chloroform : Methanol : Acetic acid = 10 : 2 : 1),
 NMR (CD₃OD): δ 8.35 (2H, d, J=8.0Hz), 8.05 (2H, d, J=8.0Hz), 7.95 (2H, d, J=8.0Hz), 7.55 (2H, d, J=8.0Hz), 3.75 (2H, s), 1.40 (9H, s).

Example 9(5)


N-[[4-(N-Phenylcarbamoyl)phenyl]sulfonyl]glycine t-butyl ester



TLC : Rf 0.40 (Hexane : Ethyl acetate = 1 : 1),
 NMR (CDCl₃+CD₃OD): δ 8.04 (2H, d, J=8.8Hz), 7.95 (2H, d, J=8.8Hz), 7.69 (2H, d, J=8.0Hz), 7.39 (2H, t, J=8.0Hz), 7.18 (1H, t, J=8.0Hz), 3.70 (2H, s), 1.36 (9H, s).

Example 9(6)


N-[[4-[N-(4-Amidinophenyl)carbamoyl]phenyl]sulfonyl]-L-glutamic acid di-t-butyl ester



TLC : Rf 0.59 (Chloroform : Methanol : Acetic acid = 10 : 2 : 1),
 NMR (CD₃OD): δ 8.07 (2H, d, J=9.0Hz), 7.99 (2H, d, J=8.0Hz), 7.93 (2H, d, J=9.0Hz), 7.80 (2H, d, J=8.0Hz), 3.84 (1H, m), 2.35-2.23 (2H, m), 2.03-1.85 (1H, m), 1.76-1.55 (1H, m), 1.39 (9H, s), 1.21 (9H, s).

Example 9(7)

N-[[4-[N-(4-Amidinophenyl)carbamoyl]phenyl]sulfonyl]-L-aspartic acid di-t-butyl ester




TLC Rf 0.59 (Chloroform : Methanol : Acetic acid = 10 : 2 : 1),

NMR (CD₃OD): δ 8.12 (2H, d, J=9.0Hz), 8.04 (2H, d, J=8.0Hz), 8.01 (2H, d, J=9.0Hz), 7.85 (2H, d, J=8.0Hz), 4.18 (1H, dd, J 7.0Hz, 6.0Hz), 2.70 (1H, dd, J=16Hz, 6.0Hz), 2.57 (1H, dd, J=16Hz, 7Hz), 1.44 (9H, s), 1.29 (9H, s).

Example 9(8)

N-[[3-[N-(4-Amidinophenyl)carbamoyl]phenyl]sulfonyl]-L-aspartic acid di-t-butyl ester




TLC Rf 0.59 (Chloroform : Methanol : Acetic acid = 10 : 2 : 1),

NMR (CD₃OD): δ 8.45 (1H, s), 8.20 (1H, d, J=8.0Hz), 8.09 (1H, d, J=8.0Hz), 8.05 (2H, d, J=9.0Hz), 7.86 (2H, d, J=9.0Hz), 7.73 (1H, t, J=8.0Hz), 4.21 (1H, dd, J=7.0Hz, 6.0Hz), 2.70 (1H, dd, J=16Hz, 6.0Hz), 2.57 (1H, dd, J=16Hz, 7Hz), 1.43 (9H, s), 1.27 (9H, s).

Example 9(9)

N-[[3-[N-(4-Amidinophenyl)carbamoyl]phenyl]sulfonyl]-L-glutamic acid di-t-butyl ester




TLC Rf 0.59 (Chloroform : Methanol : Acetic acid = 10 : 2 : 1),

NMR (CD₃OD): δ 8.44 (1H, t, J=2.0Hz), 8.22 (1H, dt, J=8.0Hz, 2.0Hz), 8.08 (1H, dt, J=8.0Hz, 2.0Hz), 8.06 (2H, d, J=9.0Hz), 7.87 (2H, d, J=9.0Hz), 7.74 (1H, t, J=8.0Hz), 3.92 (1H, dd, J=9.0Hz, 5.0Hz), 2.37 (2H, m), 1.98 (1H, m), 1.76 (1H, m), 1.45 (9H, s), 1.25 (9H, s).


Example 9(10)

N-[[4-(4-Amidinophenoxy)carbonyl]phenyl]sulfonyl]-β-alanine t-butyl ester acetate

TLC : R_f 0.35 (Chloroform : Methanol : Acetic acid = 10 : 2 : 1),NMR (CD₃OD): δ 8.40 (2H, d, J=8.0Hz), 8.05 (2H, d, J=8.0Hz), 7.95 (2H, d, J=8.0Hz), 7.60 (2H, d, J=8.0Hz), 3.15 (2H, t, J=6.0Hz), 2.45 (2H, t, J=6.0Hz), 2.00 (3H, s), 1.45 (9H, s).

Example 10

N-[[4-(Phenoxycarbonyl)phenyl]sulfonyl]glycine




The title compound having the following physical data was obtained by the same procedure as a series of reactions of Example 2, using a compound prepared in Example 9 instead of a compound prepared in Example 1.

TLC: R_f 0.22 (Chloroform : Ethyl acetate : Acetic acid : Water = 90 : 10 : 1 : 1),NMR (CDCl₃+CD₃OD): δ 8.33 (2H, d, J=8.8Hz), 8.02 (2H, d, J=8.8Hz), 7.46 (2H, t, J=7.4Hz), 7.33 (1H, t, J=7.4Hz), 7.21 (2H, d, J=7.4Hz), 3.81 (2H, s).


Example 10(1)-10(12)

The compounds having the following physical data were obtained by the same procedure as a series of reactions of Example 10, if necessary, by converting to corresponding salts by conventional method, using a compound prepared in Example 7, 8 and 9(1)-9(10). N-[[4-(4-Amidinophenoxy)carbonyl]phenyl]sulfonyl]-L-phenylalanine methansulfonate




NMR (CD₃OD): δ 8.20 (2H, d, J=8.0Hz), 7.95 (2H, d, J=8.0Hz), 7.80 (2H, d, J=8.0Hz), 7.60 (2H, d, J=8.0Hz), 7.25-7.10 (5H, m), 4.10 (1H, dd, J=9.0, 5.0Hz), 3.10 (1H, dd, J=14, 5.0Hz), 2.85 (1H, dd, J=14, 9.0Hz), 2.70 (3H, s).

N-[[4-(4-Amidinophenoxy)carbonyl]phenyl]sulfonyl]-L-aspartic acid methansulfonate




NMR (CD₃OD): δ 8.35 (2H, d, J=8.0Hz), 8.10 (2H, d, J=8.0Hz), 7.95 (2H, d, J=8.0Hz), 7.55 (2H, d, J=8.0Hz), 4.30 (1H, t, J=6.5Hz), 2.80 (2H, d, J=6.5Hz), 2.70 (3H, s).

Example 10(3)



NMR (CD₃OD): δ 8.85 (1H, br.s), 8.40 (1H, d, J=8.0Hz), 8.20 (1H, d, J=8.0Hz), 7.95 (2H, d, J=9.0Hz), 7.80 (1H, t, J=8.0Hz), 7.60 (2H, d, J=9.0Hz), 3.80 (2H, s), 2.70 (3H, s).


Example 10(4)



NMR (CD₃OD): δ 8.35 (2H, d, J=8.0Hz), 8.05 (2H, d, J=8.0Hz), 7.95 (2H, d, J=9.0Hz), 7.60 (2H, d, J=9.0Hz), 3.80 (2H, s), 2.70 (3H, s).

Example 10(5)

N-[[4-(N-Phenylcarbamoyl)phenyl]sulfonyl]glycine




TLC : Rf 0.04 (Chloroform : Methanol : Acetic acid : Water = 100 : 10 : 1 : 1),

NMR (CDCl₃+CD₃OD+DMSO-d₆): δ 8.10 (2H, d, J=8.3Hz), 7.95 (2H, d, J=8.3Hz), 7.75 (2H, d, J=8.0Hz), 7.35 (2H, t, J=8.0Hz), 7.13 (1H, t, J=8.0Hz), 3.67 (2H, s).

Example 10(6)

N-[(4-Methoxycarbonylphenyl)sulfonyl]glycine




TLC : Rf 0.16 (Chloroform : Methanol : Acetic acid : Water = 90 : 10 : 1 : 1),

NMR (CDCl₃+CD₃OD): δ 8.13 (2H, d, J=8.8Hz), 7.90 (2H, d, J=8.8Hz), 3.92 (3H, s), 3.74 (2H, s).

Example 10(7)

N-[(4-Carboxyphenyl)sulfonyl]glycine




TLC : Rf 0.02 (Chloroform : Methanol : Acetic acid : Water = 90 : 10 : 1 : 1),

NMR (DMSO-d₆): δ 8.25 (1H, t, J=6.2Hz), 8.08 (2H, d, J=8.8Hz), 7.89 (2H, d, J=8.8Hz), 3.63 (2H, d, J=6.2Hz).

Example 10(8)

N-[[4-[N-(4-Amidinophenyl)carbamoyl]phenyl]sulfonyl]-L-glutamic acid




TLC : Rf 0.51 (Ethyl acetate : Acetic acid : Water = 3 : 1 : 1),

NMR (DMSO-d₆+ MeSO₃H(1drop)): δ 10.85 (1H, s), 9.24 (2H, s), 8.98 (2H, s), 8.39 (1H, d, J=9.0Hz), 8.15 (2H, d, J=9.0Hz), 8.03 (2H, d, J=9.0Hz), 7.93 (2H, d, J=9.0Hz), 7.87 (2H, d, J=9.0Hz), 3.85 (1H, dt, J=9.0Hz, 7Hz), 2.23 (2H, t, J=7.0Hz), 2.00-1.60 (2H, m).

Example 10(9)

N-[[4-[N-(4-Amidinophenyl)carbamoyl]phenyl]sulfonyl]-L-aspartic acid




TLC : Rf 0.51 (Ethyl acetate : Acetic acid : Water = 3 : 1 : 1),

NMR (DMSO-d₆+ MeSO₃H(1drop)): δ 10.85 (1H, s), 9.24 (2H, s), 8.97 (2H, s), 8.43 (1H, d, J=9.0Hz), 8.14 (2H, d, J=9.0Hz), 8.03 (2H, d, J=9.0Hz), 7.95 (2H, d, J=9.0Hz), 7.87 (2H, d, J=9.0Hz), 4.13 (1H, dt, J=9.0Hz, 6.0Hz), 2.64 (1H, dd, J=16.0Hz, 6.0Hz), 2.46 (1H, dd, J=16.0Hz, 6.0Hz).

Example 10(10)

N-[[3-[N-(4-Amidinophenyl)carbamoyl]phenyl]sulfonyl]-L-aspartic acid




TLC : Rf 0.67 (Ethyl acetate : Acetic acid : Water = 3 : 1 : 1),

NMR (DMSO-d₆+ MeSO₃H(1drop)): δ 10.88 (1H, s), 9.24 (2H, s), 8.95 (2H, s), 8.40 (1H, s), 8.23 (1H, d, J=8.0Hz), 8.03 (2H, d, J=9.0Hz), 8.02 (1H, d, J=8.0Hz), 7.87 (2H, d, J=9.0Hz), 7.76 (1H, t, J=8.0Hz), 4.14 (1H, m), 2.64 (1H, dd, J=16Hz, 6.0Hz), 2.46 (1H, dd, J=16Hz, 6.0Hz).

Example 10(11)


N-[[3-[N-(4-Amidinophenyl)carbamoyl]phenyl]sulfonyl]-L-glutamic acid



TLC : Rf 0.65 (Ethyl acetate : Acetic acid : Water = 3 : 1 : 1),
 NMR (DMSO-d₆+ MeSO₃H(1drop)): δ 10.88 (1H, s), 9.24 (2H, s), 9.01 (2H, s), 8.37 (1H, s), 8.35 (1H, d, J=8.0Hz), 8.24 (1H, d, J=8.0Hz), 8.03 (2H, d, J=9.0Hz), 8.01 (1H, d, J=8.0Hz), 7.87 (2H, d, J=9.0Hz), 7.76 (1H, t, J=8.0Hz), 3.85 (1H, m), 2.22 (2H, t, J=7.0Hz), 1.90 (1H, m), 1.69 (1H, m).

Example 10(12)


N-[[4-(4-Amidinophenoxy)phenyl]sulfonyl]-β-alanine methanesulfonate



TLC : Rf 0.34 (Chloroform : Methanol : Acetic acid = 10 : 2 : 1),
 NMR (CD₃OD): δ 8.40 (2H, d, J=8.0Hz), 8.05 (2H, d, J=8.0Hz), 7.95 (2H, d, J=8.0Hz), 7.60 (2H, d, J=8.0Hz), 3.20 (2H, t, J=6.5Hz), 2.75 (3H, s), 2.55 (2H, t, J=6.5Hz).

Example 11

N-[[4-(N-Phenylureido)phenyl]sulfonyl]glycine t-butyl ester




To a solution of a compound prepared in reference example 2 (1.20 g) in acetone (20 ml), phenyl isocyanate (500 μl) was added. After the mixture was stirred for 24 hours at room temperature, phenyl isocyanate (200 μl) was added to the mixture. The mixture was stirred for 24 hours. Additional phenyl isocyanate (500 μl) was added and the mixture was stirred for 12 hours. The reaction mixture was concentrated. The residue was washed with ether and dried to give the title compound (1.40 g) having the following physical data.

TLC: Rf 0.25 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 7.72-7.60 (1H), 7.66 (2H, d, J=8.8Hz), 7.46-7.20 (5H, m), 7.28 (2H, d, J=8.8Hz), 7.12-7.00 (1H, m), 5.39 (1H, t, J=5.6Hz), 3.63 (2H, d, J=5.6Hz), 1.36 (9H, s).

Example 12

N-[[4-(N-Phenylureido)phenyl]sulfonyl]glycine




The title compound having the following physical data was obtained by the same procedure as a series of reactions of Example 2, using a compound prepared in Example 11.

TLC : Rf 0.34 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d6): δ 13.50-11.50 (1H, br.s), 9.08 (1H, s), 8.77 (1H, s), 7.82 (1H, t, J=6.2Hz), 7.69 (2H, d, J=9.0Hz), 7.60 (2H, d, J=9.0Hz), 7.52-7.40 (2H, m), 7.28 (2H, t, J=7.4Hz), 6.98 (1H, t, J=7.4Hz), 3.53 (2H, d, J=6.2Hz)

Reference example 8


2-(4-Chlorosulfonyl)phenylacetophenone



Deoxybenzoine (5.0 g) was added by portions to sulfonyl chloride (8.45 ml) at 0°C. The solution was stirred for 30 minutes at 10-15°C and then stirred for 15 minutes at 50°C. The reaction mixture was poured into ice-water and extracted with ethyl acetate. The extract was washed with water, a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was washed with ether and dried to give the title compound (2.25 g). Besides, the ether layer was purified by column chromatography on silica gel (hexane : ethyl acetate = 17 : 3) to give additional title compound (1.09g; total 3.34 g) having the following physical data. TLC: Rf 0.27 (Hexane : Ethyl acetate = 9 : 1).

Example 13

N-[(4-Benzoylmethylphenyl)sulfonyl]glycine t-butyl ester




The title compound having the following physical data was obtained by the same procedure as a series of reactions of Example 4, using a compound prepared in reference Example 8.

TLC : Rf 0.21 (Hexane : Ethyl acetate = 7 : 3),

NMR (CDCl₃): δ 8.05-7.97 (2H, m), 7.83 (2H, d, J=8.6Hz), 7.65-7.45 (3H, m), 7.41 (2H, d, J=8.6Hz), 5.05 (1H, t, J=5.4Hz), 4.35 (2H, s), 3.67 (2H, d, J=5.4Hz), 1.34 (9H, s).

Example 14

N-[(4-Benzoylmethylphenyl)sulfonyl]glycine




The title compound having the following physical data was obtained by the same procedure as a series of reactions of Example 3, using a compound prepared in Example 13.

TLC : Rf 0.56 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d₆): δ 13.50-11.50 (1H, br.s), 8.10-8.00 (2H, m), 7.98 (1H, t, J=6.2Hz), 7.74 (2H, d, J=8.4Hz), 7.72-7.50 (3H, m), 7.45 (2H, d, J=8.4Hz), 4.53 (2H, s), 3.57 (2H, d, J=6.2Hz).

Example 14(1)

N-[4-[(4-Methoxybenzoyl)methyl]sulfonyl]glycine




The title compound having the following physical data was obtained by the same procedure as a series of reactions of Example 3, using N-[4-[(4-Methoxybenzoyl)methyl]sulfonyl]glycine t-butyl ester which was obtained by the same procedure as a series of reactions of reference Example 8 and Example 14 using corresponding compounds.

TLC : Rf 0.35 (Chloroform : Methanol : Acetic acid : Water = 50 : 10 : 1 : 1),

NMR (CDCl₃+CD₃OD): δ 8.00 (2H, d, J=8.8Hz), 7.82 (2H, d, J=8.3Hz), 7.41 (2H, d, J=8.3Hz), 6.98 (2H, d, J=8.8Hz), 4.36 (2H, s), 3.90 (3H, s), 3.71 (2H, s).

Reference example 9

N-[4-(Benzoylamino)phenyl]sulfonyl]-N-t-butoxycarbonylglycine t-butyl ester




To a solution of a compound prepared in example 1(10) (1.20 g) in acetonitrile (60 ml), 4-dimethylaminopyridine (37 mg) and di-t-butyl dicarbonate (811 μ l) were added. The mixture was stirred for 30 minutes at room temperature. The reaction mixture was concentrated and extracted with ethyl acetate. The extract was washed with water, a saturated aqueous solution of sodium bicarbonate, water and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated to give the title compound (1.61 g) having the following physical data.

TLC: Rf 0.61 (Hexane : Ethyl acetate = 1 : 1).

Reference example 10


N-[4-(N-Methyl-N-benzoylamino)phenyl]sulfonyl]-N-t-butoxycarbonylglycine t-butyl ester



To a solution of a compound prepared in reference example 9 (1.60 g) in dimethylformamide (20 ml), 60% sodium hydride (143 mg) was added at 0°C. The mixture was stirred for 1 hour. To the reaction mixture, iodomethane (558 µl) was added. The mixture was stirred for 30 minutes. Water was added to the reaction mixture, and then the mixture was extracted with ethyl acetate. The extract was washed a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 7 : 3) to give the title compound (1.05 g) having the following physical data. TLC: Rf 0.54 (Hexane : Ethyl acetate = 1 : 1).

Example 15

N-[[4-(N-Methyl-N-benzoylamino)phenyl]sulfonyl]glycine



The title compound (641 mg) having the following physical data was obtained by the same procedure as Example 2, using a compound prepared in reference example 10 (1.00 g).
TLC : Rf 0.47 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),
NMR (DMSO-d6): δ 13.20-12.00 (1H, br.s), 8.00 (1H, t, J=5.8Hz), 7.65 (2H, d, J=8.8Hz), 7.33 (2H, d, J=8.8Hz), 7.31-7.20 (5H, m), 3.51 (2H, d, J=5.8Hz), 3.40 (3H, s).

Formulation example 1

The following components were admixed in conventional method and punched out to obtain 100 tablets each containing 50 mg of active ingredient.

- N-[[4-(p-Toluoylamino)phenyl]sulfonyl]glycine 5g
- Carboxymethyl Cellulose calcium (disintegrating agent) 0.2g
- Magnesium stearate (lubricating agent) 0.1g
- Microcrystalline cellulose 4.7g


Formulation example 2

The following components were admixed in conventional method. The solution was sterilized in conventional manner, placed 2 ml portions into 5 ml ampoules and freeze-dried to obtain 100 ampoules each containing 20 mg of the active ingredient.

- N-[[4-(p-Toluoylamino)phenyl]sulfonyl]glycine 2.00g
- mannitol 20 g
- distilled water 500 ml

Claims

1. Use of a compound of formula (Ia) :



wherein

15 R^1 is hydrogen, or C1-4 alkyl;

R^2 is (1) hydrogen, (2) C1-8 alkyl, (3) phenyl, or (4) C1-4 alkyl substituted by phenyl, $-\text{OCOR}^{16}$, in which R^{16} is C1-4 alkyl; or $-\text{CONR}^{17}\text{R}^{18}$, in which R^{17} and R^{18} each, independently, is hydrogen or C1-4 alkyl;
E is

20 (1) $-\text{CONR}^3-$, in which R^3 is hydrogen, C1-4 alkyl, phenyl, or C1-4 alkyl substituted by phenyl;

(2) $-\text{NR}^3\text{CO}-$, in which R^3 is as hereinbefore defined;

(3) $-\text{CO}-\text{O}-$,

(4) $-\text{O}-\text{CO}-$,

(5) $-\text{NR}^3-\text{CO}-\text{NR}^3-$, in which R^3 is as hereinbefore defined;

25 (6) $-\text{CO}-\text{CH}_2-$,

(7) $-\text{CO}-$,

(8) $-\text{O}-\text{CO}-\text{NR}^3-$, in which R^3 is as hereinbefore defined;

(9) $-\text{NR}^3-\text{CO}-\text{O}-$, in which R^3 is as hereinbefore defined;

(10) $-\text{O}-\text{CO}-\text{O}-$,

30 (11) $-\text{CS}-\text{NR}^3-$, in which R^3 is as hereinbefore defined;

(12) $-\text{NR}^3-\text{CS}-$, in which R^3 is as hereinbefore defined;

(13) $-\text{NR}^3-\text{CS}-\text{NR}^3-$, in which R^3 is as hereinbefore defined;

(14) $-\text{O}-\text{CS}-\text{NR}^3-$, in which R^3 is as hereinbefore defined;

(15) $-\text{NR}^3-\text{CS}-\text{O}-$, in which R^3 is as hereinbefore defined;

35 (16) $-\text{CS}-\text{O}-$,

(17) $-\text{O}-\text{CS}-$, or

(18) $-\text{O}-\text{CS}-\text{O}-$,

40 A is (1) hydrogen, (2) C1-8 alkyl, (3) C3-7 cycloalkyl, or (4) Ar, in which Ar is carbocyclic aryl or heterocyclic aryl, and is unsubstituted or substituted by 1-3 of C1-15 alkyl, C1-15 alkoxy, halogen, nitro, cyano, guanidino, amidino, hydroxy, benzyloxy, $-\text{NR}^9\text{R}^{10}$, in which R^9 and R^{10} each, independently, is hydrogen or C1-4 alkyl; $-\text{COOR}^{11}$, in which R^{11} is hydrogen or C1-4 alkyl; trifluoromethyl, phenyl or heterocyclic ring;

J is (1) a bond, (2) C2-4 alkylene, (3) C2-4 alkenylene, or (4)



50 in which R^4 and R^5 each, independently, is (i) hydrogen, (ii) C1-4 alkyl, or (iii) C1-4 alkoxy, or R^4 and R^5 , taken together with the carbon to which they are attached, form a C3-7 cycloalkyl group,

G is (1) $-(\text{CH}_2)_m-$, in which m is 2, 3 or 4, or (2)



in which R^6 and R^7 each, independently, is (i) hydrogen, (ii) C1-8 alkyl, (iii) $-\text{COOR}^8$, in which R^8 is hydrogen,

C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl; (iv) Ar, in which Ar is as hereinbefore defined; (v) heterocyclic ring, (vi) C1-8 alkyl substituted by: -COOR⁸, in which R⁸ is as hereinbefore defined; C1-4 alkoxy; hydroxy; benzyloxy; -NR¹²R¹³, in which R¹² and R¹³ each, independently, is hydrogen or C1-4 alkyl; -NR¹⁴COOR¹⁵, in which R¹⁴ is hydrogen or C1-4 alkyl, and R¹⁵ is hydrogen, C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl; Ar; or heterocyclic ring; with the proviso that one of the carbon atoms in C1-8 alkyl may be replaced by a sulfur atom; or R⁶ and R⁷, taken together with the carbon to which they are attached, form a C3-7 cycloalkyl group; with the proviso that, when E is -O-CO-NR³-, -O-CO-O-, -O-CS-NR³- or -O-CS-O-, and J is a bond, A is not hydrogen; or a non-toxic salt thereof, in the manufacture of a medicament for the prevention and/or treatment of a disease induced by overexpression or excess activity of a metalloproteinase.


2. Use according to claim 1, in which the disease induced by overexpression or excess activity of a matrix metalloproteinase is a rheumatoid disease, arthroseitis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis, invasion or growth of tumor cells, an autoimmune disease, a disease caused by vascular emigration or infiltration of leukocytes, or arterialization.

3. Use according to claim 1 or 2, wherein the compound of formula (Ia) is selected from

N-[[4-(Benzoylamino)phenyl]sulfonyl]glycine,
 N-[[3-(Benzoylamino)phenyl]sulfonyl]glycine,
 N-[[2-(Benzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(Acetylamino)phenyl]sulfonyl]glycine,
 N-[[4-(Phenylacetylamino)phenyl]sulfonyl]glycine,
 N-[[4-[(Phenylethylcarbonyl)amino]phenyl]sulfonyl]glycine,
 N-[[4-(Cinnamoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(N-Phenylureido)phenyl]sulfonyl]glycine,
 N-[[4-(N-Phenylthioureido)phenyl]sulfonyl]glycine,
 N-[[4-[(Benzyloxycarbonyl)amino]phenyl]sulfonyl]glycine,
 N-[[4-[(Phenylloxymethylcarbonyl)amino]phenyl]sulfonyl]glycine,
 N-[[4-[(Benzyloxymethylcarbonyl)amino]phenyl]sulfonyl]glycine,
 N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Fluorobenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(3-Nitrobenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(2-Nitrobenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Formylbenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
 N-[[4-(4-Methylbenzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
 N-[[4-(4-Methylbenzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
 N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
 N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
 N-[[4-(4-Fluorobenzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
 N-[[4-(4-Fluorobenzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
 N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
 N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
 N-[[4-(4-Pivaloyloxyphenyl)phenyl]sulfonyl]-D, L- α -phenylglycine,
 N-[[4-(4-Pivaloyloxyphenyl)phenyl]sulfonyl]-D, L-phenylalanine,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-alanine,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]- β -alanine,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-valine,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-valine,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-leucine,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-leucine,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-serine,

N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-phenylalanine,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-tyrosine,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D,L-alanine methyl ester,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-valine methyl ester,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-valine methyl ester,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-leucine methyl ester,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D, L-serine methyl ester,
 N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-tyrosine methyl ester,
 N-[[4-(3-Nitrobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
 N-[[3-(3-Nitrobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
 N-[[4-(3-Aminobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
 N-[[3-(3-Aminobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-glutamic acid,
 N-[[4-(4-chlorobenzoylamino)phenyl]sulfonyl]-L-glutamic acid,
 N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]-L-glutamic acid,
 N-[[4-[2-(4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-3-morpholinoalanine ethyl ester,
 N-[[4-[2-(4-(1-Nitrophenyl)butyryloxy]phenyl]sulfonyl]-D,L-3-morpholinoalanine ethyl ester,
 N-[[4-(2-Methoxy-2-phenylacetyloxy)phenyl]sulfonyl]-D,L-3-morpholinoalanine ethyl ester,
 N-[[4-[1-(4-Nitrophenyl)cyclobutyl]carbonyloxy]phenyl]sulfonyl]-D,L-3-morpholinoalanine ethyl ester,
 N-[[3-Methyl-4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-t-butoxycarbonyl-L-lysine,
 N-[[4-(2-Phenylbutyryloxy)phenyl]sulfonyl]glycine,
 N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-phenylalanine,
 N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-aspartic acid,
 N-[[4-[[1-(4-Nitrophenyl)cyclobutyl]carbonyloxy]phenyl]sulfonyl]-D,L-aspartic acid,
 1-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonylamide]-1-cyclopropanecarboxylic acid,
 N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-2-(2-furanyl)glycine,
 N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-2-(2-thienyl)glycine,
 N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-L-valine,
 N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-S-carboxymethyl-L-cysteine,
 N-[[4-[2-Ethyl-2-(4-methoxyphenyl)butyryloxy]phenyl]sulfonyl]-glycine,
 N-[[3-Methyl-4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-L-lysine,
 5-[N-[[3-Methyl-4-[2-[4-(1-pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]amino]pentanoic acid, and
 N-[[3-Methyl-4-pivaloyloxy]phenyl]sulfonyl]-β-alanine.

4. A compound of the formula (Ib):



wherein

R¹ is hydrogen, or C1-4 alkyl;


R² is (1) hydrogen, (2) C1-8 alkyl, (3) phenyl, or (4) C1-4 alkyl substituted by phenyl, -OCOR¹⁶, in which R¹⁶ is C1-4 alkyl; or -CONR¹⁷R¹⁸, in which R¹⁷ and R¹⁸ each, independently, is hydrogen or C1-4 alkyl;

E is

- (1) -CONR³-, in which R³ is hydrogen, C1-4 alkyl, phenyl, or C1-4 alkyl substituted by phenyl;
- (2) -NR³CO-, in which R³ is as hereinbefore defined;
- (3) -CO-O-,
- (4) -O-CO-,
- (5) -NR³-CO-NR³-, in which R³ is as hereinbefore defined;
- (6) -CO-CH₂-,
- (7) -CO-,
- (8) -O-CO-NR³-, in which R³ is as hereinbefore defined;

- (9) $\text{-NR}^3\text{-CO-O-}$, in which R^3 is as hereinbefore defined;
 (10) -O-CO-O- ,
 (11) $\text{-CS-NR}^3\text{-}$, in which R^3 is as hereinbefore defined;
 (12) $\text{-NR}^3\text{-CS-}$, in which R^3 is as hereinbefore defined;
 (13) $\text{-NR}^3\text{-CS-NR}^3\text{-}$, in which R^3 is as hereinbefore defined;
 (14) $\text{-O-CS-NR}^3\text{-}$, in which R^3 is as hereinbefore defined;
 (15) $\text{-NR}^3\text{-CS-O-}$, in which R^3 is as hereinbefore defined;
 (16) -CS-O- ,
 (17) -O-CS- ,
 (18) -O-CS-O- , or

A is is (1) hydrogen, (2) C1-8 alkyl, (3) C3-7 cycloalkyl, or (4) Ar, in which Ar is carbocyclic aryl or heterocyclic aryl, and is unsubstituted or substituted by 1-3 of C1-15 alkyl, C1-15 alkoxy, halogen, nitro, cyano, guanidino, amidino, hydroxy, benzyloxy, $\text{-NR}^9\text{R}^{10}$, in which R^9 and R^{10} each, independently, is hydrogen or C1-4 alkyl; -COOR^{11} , in which R^{11} is hydrogen or C1-4 alkyl; trifluoromethyl, phenyl or heterocyclic ring;
 J is (1) a bond, (2) C2-4 alkylene, (3) C2-4 alkenylene, or (4)



in which R^4 and R^5 each, independently, is (i) hydrogen, (ii) C1-4 alkyl, or (iii) C1-4 alkoxy, or R^4 and R^5 , taken together with the carbon to which they are attached, form a C3-7 cycloalkyl group,
 G is (1) $\text{-(CH}_2\text{)}_m\text{-}$, in which m is 2, 3 or 4, or (2)



in which R^6 and R^7 each, independently, is (i) hydrogen, (ii) C1-8 alkyl, (iii) -COOR^8 , in which R^8 is hydrogen, C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl; (iv) Ar, in which Ar is as hereinbefore defined; (v) heterocyclic ring, (vi) C1-8 alkyl substituted by: -COOR^8 , in which R^8 is as hereinbefore defined; C1-4 alkoxy; hydroxy; benzyloxy; $\text{-NR}^{12}\text{R}^{13}$, in which R^{12} and R^{13} each, independently, is hydrogen or C1-4 alkyl; $\text{-NR}^{14}\text{COOR}^{15}$, in which R^{14} is hydrogen or C1-4 alkyl, and R^{15} is hydrogen, C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl; Ar; or heterocyclic ring; with the proviso that one of the carbon atoms in C1-8 alkyl may be replaced by a sulfur atom; or R^6 and R^7 , taken together with the carbon to which they are attached, form a C3-7 cycloalkyl group;
 with the proviso that, when E is $\text{-O-CO-NR}^3\text{-}$, -O-CO-O- , $\text{-O-CS-NR}^3\text{-}$ or -O-CS-O- , and J is a bond, A is not hydrogen;
 or a non-toxic salt thereof;
 with the exclusion of the following compounds:

- (1) N-[[4-(Benzoylamino)phenyl]sulfonyl]glycine,
- (2) N-[[3-(Benzoylamino)phenyl]sulfonyl]glycine,
- (3) N-[[2-(Benzoylamino)phenyl]sulfonyl]glycine,
- (4) N-[[4-(Acetylamino)phenyl]sulfonyl]glycine,
- (5) N-[[4-(Phenylacetylamino)phenyl]sulfonyl]glycine,
- (6) N-[[4-[(Phenylethylcarbonyl)amino]phenyl]sulfonyl]glycine,
- (7) N-[[4-(Cinnamoylamino)phenyl]sulfonyl]glycine,
- (8) N-[[4-(N-Phenylureido)phenyl]sulfonyl]glycine,
- (9) N-[[4-(N-Phenylthioureido)amino]phenyl]sulfonyl]glycine,
- (10) N-[[4-[(Benzyloxycarbonyl)amino]phenyl]sulfonyl]glycine,
- (11) N-[[4-[(Phenylloxymethylcarbonyl)amino]phenyl]sulfonyl]glycine,
- (12) N-[[4-[(Benzyloxymethylcarbonyl)amino]phenyl]sulfonyl]glycine,
- (13) N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]glycine,
- (14) N-[[4-(4-Fluorobenzoylamino)phenyl]sulfonyl]glycine,

- (15) N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]glycine,
- (16) N-[[4-(3-Nitrobenzoylamino)phenyl]sulfonyl]glycine,
- (17) N-[[4-(2-Nitrobenzoylamino)phenyl]sulfonyl]glycine,
- (18) N-[[4-(4-Formylbenzoylamino)phenyl]sulfonyl]glycine,
- 5 (19) N-[[4-(Benzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
- (20) N-[[4-(Benzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
- (21) N-[[4-(4-Methylbenzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
- (22) N-[[4-(4-Methylbenzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
- (23) N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
- 10 (24) N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
- (25) N-[[4-(4-Fluorobenzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
- (26) N-[[4-(4-Fluorobenzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
- (27) N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]-D- α -phenylglycine,
- (28) N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]-L- α -phenylglycine,
- 15 (29) N-[[4-(4-Pivaloyloxyphenyl)sulfonyl]-D,L- α -phenylglycine,
- (30) N-[[4-(4-Pivaloyloxyphenyl)sulfonyl]-D,L-phenylalanine,
- (31) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]glycine,
- (32) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D,L-alanine,
- (33) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]- β -alanine,
- 20 (34) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-valine,
- (35) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D,L-valine,
- (36) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-leucine,
- (37) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D,L-leucine,
- (38) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D,L-serine,
- 25 (39) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-phenylalanine,
- (40) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-tyrosine,
- (41) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D,L-alanine methyl ester,
- (42) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-valine methyl ester,
- (43) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D,L-valine methyl ester,
- 30 (44) N-[[4-[[2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-leucine methyl ester,
- (45) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-D,L-serine methyl ester,
- (46) N-[[4-(2,4-Dichlorobenzoylamino)phenyl]sulfonyl]-L-tyrosine methyl ester,
- (47) N-[[4-(3-Nitrobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
- (48) N-[[3-(3-Nitrobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
- 35 (49) N-[[4-(3-Aminobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
- (50) N-[[3-(3-Aminobenzoylamino)phenyl]sulfonyl]-L-aspartic acid,
- (51) N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-glutamic acid,
- (52) N-[[4-(4-chlorobenzoylamino)phenyl]sulfonyl]-L-glutamic acid,
- (53) N-[[4-(4-Nitrobenzoylamino)phenyl]sulfonyl]-L-glutamic acid,
- 40 (54) N-[[4-[2-(4-(1-Pyrrolidinyl)phenyl]butyryloxy)phenyl]sulfonyl]-D,L-3-morpholinoalanine ethyl ester,
- (55) N-[[4-[2-(4-(1-Nitrophenyl)butyryloxy)phenyl]sulfonyl]-D,L-3-morpholinoalanine ethyl ester,
- (56) N-[[4-(2-Methoxy-2-phenylacetyloxy)phenyl]sulfonyl]-D,L-3-morpholinoalanine ethyl ester,
- (57) N-[[4-[[1-(4-Nitrophenyl)cyclobutyl]carbonyloxy]phenyl]sulfonyl]-D,L-3-morpholinoalanine ethyl ester,
- 45 (58) N-[[3-Methyl-4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-t-butoxycarbonyl-L-lysine,
- (59) N-[[4-(2-Phenylbutyryloxy)phenyl]sulfonyl]glycine,
- (60) N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-phenylalanine,
- (61) N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-aspartic acid,
- (62) N-[[4-[[1-(4-Nitrophenyl)cyclobutyl]carbonyloxy]phenyl]sulfonyl]-D,L-aspartic acid,
- 50 (63) 1-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonylamide]-1-cyclopropanecarboxylic acid,
- (64) N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-2-(2-furanyl)glycine,
- (65) N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-D,L-2-(2-thienyl)glycine,
- (66) N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-L-valine,
- (67) N-[[4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-S-carboxymethyl-L-cysteine,
- 55 (68) N-[[4-[2-Ethyl-2-(4-methoxyphenyl)butyryloxy]phenyl]sulfonyl]-glycine,
- (69) N-[[3-Methyl-4-[2-[4-(1-Pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]-L-lysine,
- (70) 5-[N-[[3-Methyl-4-[2-[4-(1-pyrrolidinyl)phenyl]butyryloxy]phenyl]sulfonyl]amino]pentanoic acid, and
- (71) N-[[3-Methyl-4-pivaloyloxy]phenyl]sulfonyl]- β -alanine.

5. A compound according to claim 4, wherein E is -CONR³-, -NR³CO-, -NR³-CO-NR³-, -O-CO-NR³-, -NR-CO-O-, -CS-NR³-, -NR³-CS-, -NR³-CS-NR³-, -O-CS-NR³- or -NR³-CS-O-.

6. A compound according to claim 4, wherein E is -CO-O-, -O-CO-, -CO-CH₂-, -CO-, -O-CO-O-, -CS-O-, -O-CS- or -O-CS-O-.

7. A compound according to claim 4, which is selected from

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(Isobutyrylamino)phenyl]sulfonyl]glycine,
 N-[[4-(Acetylamino)phenyl]sulfonyl]glycine,
 N-[[4-(o-Toluoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(m-Toluoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(2-Chlorobenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(3-Chlorobenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Chlorobenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(2-Methoxybenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(3-Methoxybenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Ethylbenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Propylbenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(2-Fluorobenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(3-Fluorobenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(Cyclohexylcarbonylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Trifluoromethylbenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(2-Thienylcarbonylamino)phenyl]sulfonyl]glycine,
 N-[[4-(2-Furylcarbonylamino)phenyl]sulfonyl]glycine,
 N-[[4-(2-Pyridylcarbonylamino)phenyl]sulfonyl]glycine,
 N-[[4-(3-Pyridylcarbonylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Pyridylcarbonylamino)phenyl]sulfonyl]glycine,
 N-[[4-(3-Thienylcarbonylamino)phenyl]sulfonyl]glycine,
 N-[[4-(3-Furylcarbonylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Methoxycarbonylbenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Cyanobenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Benzyloxybenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Carboxybenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Butylbenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Pentylbenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Phenylbenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-valine,
 N-[[4-(1-Naphthoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(2-Naphthoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(3-Benzyloxybenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(2-Benzyloxybenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-aspartic acid,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-leucine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-leucine,
 N-[[4-(Phenoxycarbonylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Dimethylaminobenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-valine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-Phenylalanine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-Phenylalanine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-alanine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-alanine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-lysine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-lysine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-glutamic acid,
 N-[[4-(4-Dodecylbenzoylamino)phenyl]sulfonyl]glycine,
 4-[N-[[4-(Benzoylamino)phenyl]sulfonyl]amino]butyric acid,

N-[[4-(Benzoylamino)phenyl]sulfonyl]amino]-L-serine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]amino]-D-serine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-aspartic acid,
 N-[[4-(p-Toluoilamino)phenyl]sulfonyl]-D-phenylalanine,
 5 N-[[4-(4-Pentylbenzoylamino)phenyl]sulfonyl]-D-phenylalanine,
 N-[[4-(p-Toluoilamino)phenyl]sulfonyl]-L-valine,
 N-[[4-(4-Hexylbenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Heptylbenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Isopropylbenzoylamino)phenyl]sulfonyl]glycine,
 10 N-[[4-(4-Isobutylbenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-2,2-dimethylglycine,
 N-[[4-(p-Toluoilamino)phenyl]sulfonyl]amino]-D-serine,
 N-[[4-(p-Toluoilamino)phenyl]sulfonyl]-L-leucine,
 N-[[4-(p-Toluoilamino)phenyl]sulfonyl]-D-alanine,
 15 N-[[4-(p-Toluoilamino)phenyl]sulfonyl]-D-valine,
 N-[[4-(p-Toluoilamino)phenyl]sulfonyl]-D-leucine,
 N-[[2-Methyl-4-(p-Toluoilamino)phenyl]sulfonyl]glycine,
 N-[[3-Methyl-4-(p-Toluoilamino)phenyl]sulfonyl]glycine,
 N-[[4-(2-Hydroxy-4-methylbenzoylamino)phenyl]sulfonyl]-D-alanine,
 20 N-[[4-(2-Thienylcarbonylamino)phenyl]sulfonyl]-D-alanine,
 N-[[3-(Benzoylamino)phenyl]sulfonyl]glycine,
 N-[[2-(Benzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(2-Aminobenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(3-Aminobenzoylamino)phenyl]sulfonyl]glycine,
 25 N-[[4-(4-Aminobenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(4-Hydroxybenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-[(2-Phenylethyl)carbonylamino]phenyl]sulfonyl]glycine,
 N-[[4-(3-Hydroxybenzoylamino)phenyl]sulfonyl]glycine,
 N-[[4-(2-Hydroxybenzoylamino)phenyl]sulfonyl]glycine,
 30 N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-tryptophan,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-L-tyrosine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-tryptophan,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-tyrosine,
 N-[[4-(Benzoylamino)phenyl]sulfonyl]-D-histidine,
 35 2-[N-[[4-(Benzoylamino)phenyl]sulfonylamino]-(3-pyridyl)]-D-alanine,
 N-[[4-(p-Toluoilamino)phenyl]sulfonyl]-D-tryptophan,
 N-[[4-(N-Phenylcarbonyl)phenyl]sulfonyl]glycine,
 N-[[4-[N-(4-Amidinophenyl)carbonyl]phenyl]sulfonyl]-L-glutamic acid,
 N-[[4-[N-(4-Amidinophenyl)carbonyl]phenyl]sulfonyl]-L-aspartic acid,
 40 N-[[3-[N-(4-Amidinophenyl)carbonyl]phenyl]sulfonyl]-L-aspartic acid,
 N-[[3-[N-(4-Amidinophenyl)carbonyl]phenyl]sulfonyl]-L-glutamic acid, and
 N-[[4-(N-Methyl-N-benzoylamino)phenyl]sulfonyl]glycine,

and esters and non-toxic salts thereof.

8. A compound according to claim 4, which is selected from


N-[[4-(Benzyloxy)phenyl]sulfonyl]glycine,
 N-[[4-(Benzoyloxy)phenyl]sulfonyl]glycine,
 50 N-[[4-(4-Amidinobenzoyloxy)phenyl]sulfonyl]glycine,
 N-[[4-[(4-Guanidinobenzoyloxy)phenyl]sulfonyl]glycine,
 N-[[4-[(4-Amidinobenzoyloxy)phenyl]sulfonyl]-L-phenyl-alanine,
 N-[[4-(Benzoyloxy)phenyl]sulfonyl]-β-alanine,
 N-[[4-(4-Amidinobenzoyloxy)phenyl]sulfonyl]-β-alanine,
 55 N-[[4-(Phenoxycarbonyl)phenyl]sulfonyl]glycine,
 N-[[4-(4-Amidinophenoxycarbonyl)phenyl]sulfonyl]-L-phenylalanine,
 N-[[4-(4-Amidinophenoxycarbonyl)phenyl]sulfonyl]-L-aspartic acid,
 N-[[3-(4-Amidinophenoxycarbonyl)phenyl]sulfonyl]glycine,

N-[[4-(4-Amidinophenoxy)carbonyl]phenyl]sulfonyl]glycine,
 N-[(4-Methoxycarbonylphenyl)sulfonyl]glycine,
 N-[(4-Carboxyphenyl)sulfonyl]glycine,
 N-[[4-(4-Amidinophenoxy)carbonyl]phenyl]sulfonyl]- β -alanine,
 N-[(4-Benzoylmethylphenyl)sulfonyl]glycine, and
 N-[4-[(4-Methoxybenzoyl)methyl]sulfonyl]glycine,

and esters and non-toxic salts thereof.

9. A compound of formula (Ib) according to any one of claims 4 to 8 or a non-toxic salt thereof for use in the prevention and/or treatment of a disease induced by overexpression or excess activity of a matrix metalloproteinase.
10. A compound of formula (Ib) according to any one of claims 4 to 8 or a non-toxic salt thereof for use in the prevention and/or treatment of a disease induced by overexpression or excess activity of a matrix metalloproteinase, which disease is a rheumatoid disease, arthrositis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis, invasion or growth of tumor cells, an autoimmune disease, a disease caused by vascular emigration or infiltration of leukocytes, or arterialization.
11. A process for the preparation of a compound of formula (Ib) according to any one of claims 4 to 8 or a non-toxic salt thereof, which process comprises:

(1) (a) reacting a compound of formula (IIb-a):




wherein R^{2-1} is C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl, $-OCOR^{16}$, in which R^{16} is as defined in claim 4, or $-CONR^{17}R^{18}$, in which R^{17} and R^{18} are as defined in claim 4, G^1 is as defined in claim 4 for G, with the proviso that R^6 and R^7 in G are not $-COOH$, amino, hydroxy or a group containing $-COOH$, amino or hydroxy, and the other symbols are as defined in claim 4;
 with a compound of formula (IIIb-a):



wherein J^1 and A^1 are as defined in claim 4 for J and A, with the proviso that substituents of Ar in A^1 are not $-COOH$, amino, hydroxy, or a group containing $-COOH$, amino or hydroxy; if necessary, followed by deprotection; or

(b) reacting a compound of formula (IIb-a) with a compound of formula (IIIb-b):




wherein X is halogen and the other symbols are as hereinbefore defined; if necessary, followed by deprotection; or

(c) reacting a compound of formula (IIb-a) with a compound of formula (IIIb-c):




wherein all the symbols are as hereinbefore defined;
and with a compound of formula (IVb-c):




wherein T is oxygen or sulfur; if necessary, followed by deprotection;
or reacting a compound of formula (IIb-a) with a compound of formula (IIIb-c1):




wherein all the symbols are as hereinbefore defined; or with a compound of formula (IIIb-c2):



wherein all the symbols are as hereinbefore defined; if necessary, followed by deprotection; or
d) by reacting a compound of the formula (IIb-d):



wherein all the symbols are as hereinbefore defined;
with a compound of formula (IIIb-a); if necessary, followed by deprotection; or
(e) reacting a compound of formula (IIb-d) with a compound of formula (IIb-b); if necessary, followed by deprotection; or
(f) reacting a compound of formula (IIb-f):




wherein all the symbols are as hereinbefore defined;
with a compound of formula (IIIb-c); if necessary, followed by deprotection; or
(g) reacting a compound of formula (IIb-f) with a compound of formula (IIIb-g):




wherein all the symbols are as hereinbefore defined;


if necessary, followed by deprotection; or
 (h) reacting a compound of formula (IIb-h):




wherein all the symbols are as hereinbefore defined;
 with a compound of formula (IIIb-c); if necessary, followed by deprotection; or
 (j) reacting a compound of formula (IIb-j-1):




wherein all the symbols are as hereinbefore defined;
 or a compound of formula (IIb-j-2):



wherein all the symbols are as hereinbefore defined;
 with a compound of formula (IIIb-j):



wherein all the symbols are as hereinbefore defined;
 if necessary, followed by deprotection; or
 (j-1) reacting a compound of formula (XII):




wherein $\text{E}^{1\text{A}}$ is $-\text{CO}-\text{NR}^3$ -, $-\text{O}-\text{CO}-\text{NR}^3$ -, $-\text{NR}^3-\text{CO}-\text{O}$ -, $-\text{CO}-\text{O}$ -, $-\text{CO}-\text{CH}_2$ - or $-\text{O}-\text{CO}-\text{O}$ -, and the other symbols are as hereinbefore defined;
 with a compound of formula (XIII):



wherein all the symbols are as hereinbefore defined;

if necessary, followed by deprotection; or


(j-2) conversion of -NH- into -N(R³⁻¹)-, wherein R³⁻¹ is C1-4 alkyl, phenyl or C1-4 alkyl substituted by phenyl; in a compound of formula (Ib-1-AB1):



wherein E^{1BB} is -CO-NH-, -NH-CO-, -NH-CO-NH-, -O-CO-NH- or -NH-CO-O-, R^B is an amino protecting group and the other symbols are as hereinbefore defined;


followed by deprotection of the amino group protected by R^B; or

(k) reacting a compound of formula (Ib-m):




wherein E^m is -CO-NR³⁻-, -NR³⁻-CO-, -NR³⁻-CO-NR³⁻-, -O-CO-NR³⁻-, -NR³⁻-CO-O-, -CO-O-, -O-CO- or -O-CO-O- and the other symbols are as hereinbefore defined;

with Lawesson's reagent of formula (IIIb-k):




if necessary, followed by deprotection; or

(2) subjecting a compound of formula (Ib-1):



wherein R²⁻¹ is C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl, -OCOR¹⁶, in which R¹⁶ is as hereinbefore defined, or -CONR¹⁷R¹⁸, in which R¹⁷ and R¹⁸ are as hereinbefore defined; G¹, E¹, J¹, and A¹ are as defined in claim 4 for G, E, J and A, with the proviso that when E¹ is -OCO- or -OCS- and J¹ is a bond, A¹ is not hydrogen; and with the proviso that substituents of Ar in A¹, and R⁶ and R⁷ in G¹ are not -COOH, amino, hydroxy, or a group containing -COOH, amino or hydroxy; and R¹ is as defined in claim 4; to deprotection; or subjecting a compound of formula (Ib-4):



wherein A^4 is as defined in claim 4 for Ar, with the proviso that A^4 is substituted by at least one nitro group, and the other symbols are as hereinbefore defined; to hydrogenolysis; optionally followed by the conversion of the compound of formula (Ib) thus obtained into a non-toxic salt thereof.

12. A pharmaceutical composition which comprises a compound of formula (Ib) according to any one of claims 4 to 8 or a non-toxic salt thereof and a pharmaceutically acceptable carrier.

(19)



Europäischer Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 757 037 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
22.12.1999 Bulletin 1999/51

(51) Int Cl.⁶: **C07C 311/42**, A61K 31/63,
C07D 209/20, C07D 213/59,
C07D 233/64, C07D 333/24,
C07D 213/82, C07D 307/68

(43) Date of publication A2:
05.02.1997 Bulletin 1997/06

(21) Application number: **96305554.6**

(22) Date of filing: **29.07.1996**

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE**

(30) Priority: **28.07.1995 JP 21255695**
19.03.1996 JP 9049196

(71) Applicant: **ONO PHARMACEUTICAL CO., LTD.**
Chuo-ku Osaka 541 (JP)

(72) Inventors:
• **Sakaki, Katsuhito, Ono Pharmaceutical Co., Ltd.**
Shimamoto-cho, Mishima-gun, Osaka, 618 (JP)
• **Kanazawa, Hidekazu,**
Ono Pharmaceutical Co., Ltd.
Shimamoto-cho, Mishima-gun, Osaka, 618 (JP)


• **Sugiura, Tsuneyuki,**
Ono Pharmaceutical Co., Ltd.
Shimamoto-cho, Mishima-gun, Osaka, 618 (JP)
• **Miyazaki, Tohru, Ono Pharmaceutical Co., Ltd.**
Shimamoto-cho, Mishima-gun, Osaka, 618 (JP)
• **Ohno, Hyroyuki, Ono Pharmaceutical Co., Ltd.**
Shimamoto-cho, Mishima-gun, Osaka, 618 (JP)

(74) Representative: **Bentham, Stephen**
J.A. KEMP & CO.
14 South Square
Gray's Inn
London WC1R 5LX (GB)

(54) **Sulfonylamino acid derivatives as metalloproteinase inhibitors**

(57) The present invention relates to:

(i) matrix metalloproteinase (MMP) inhibitors containing sulfonylamino acid derivatives of the formula (Ia):




wherein R¹ is hydrogen, C1-4 alkyl; R² is hydrogen, C1-8 alkyl etc.; E is -CONR³-, in which R³ is hydrogen, C1-4 alkyl etc., -NR³CO-, -CO-O-, -O-CO- etc.; A is hydrogen, C1-8 alkyl, C3-7 cycloalkyl, or Ar; J is bond, C2-4 alkylene etc.; G is -(CH₂)_m-, in which m is 2, 3 or 4, or



in which R⁶ and R⁷ is hydrogen, C1-8 alkyl etc.; and non-toxic salts thereof,

(ii) novel sulfonylamino acid derivatives of the formula (Ib):

EP 0 757 037 A3



wherein all the symbols are as defined for formula (Ia), with the exclusion of certain compounds; and non-toxic salts thereof, and

(iii) processes for the preparation of the compounds of formula (Ib).

The compounds of formulae (Ia) and (Ib) are useful for prevention and/or treatment of diseases induced by over-expression or excess activity of MMP, such as rheumatoid diseases, arthroseitis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis, invasion or growth of tumor cells, autoimmune diseases (Crohn's disease, Sjogren's syndrome etc.), diseases caused by vascular emigration or infiltration of leukocytes, or arterialization.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 96 30 5554

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
P,Y	WO 96 11209 A (CHIROSCIENCE LTD.) 18 April 1996 (1996-04-18) * claims 1-20 *	1-12	C07C311/42 A61K31/63 C07D209/20 C07D213/59 C07D233/64 C07D333/24 C07D213/82 C07D307/68
P,Y	WO 96 00214 A (CIBA-GEIGY AG) 4 January 1996 (1996-01-04) * claims 1-24 *	1-12	
P,Y	WO 95 35276 A (BRITISH BIOTECH PHARMACEUTICALS LTD.) 28 December 1995 (1995-12-28) * claims 1-14 *	1-12	
D,Y	EP 0 606 046 A (CIBA-GEIGY AG.) 13 July 1994 (1994-07-13) * claims 1-25 *	1-12	
Y	J. BOUVIER ET AL.: "A fluorescent peptide substrate for the surface metalloprotease of Leishmania" EXP. PARASITOL., vol. 76, no. 2, 1993, pages 146-155, XP002118379 * figures 2,5 *	1-12	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C07C A61K C07D
INCOMPLETE SEARCH <p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search: see sheet C</p>			
Place of search MUNICH		Date of completion of the search 11 October 1999	Examiner Herz, C
CATEGORY OF CITED DOCUMENTS <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 96 30 5554

Claim(s) searched completely:
3,7,8

Claim(s) searched incompletely:
1-2,4-6,9-12

Reason for the limitation of the search:

Present claims 1-2, 4-6 and 9-12 relate to an extremely large number of possible compounds. Support within the meaning of Article 84 EPC and disclosure within the meaning of Article 83 EPC is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds claimed and those prepared in the examples.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 96 30 5554

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
P,Y	C. B. XUE ET AL.: "Potent matrix metalloproteinase inhibitors: amino-carboxylate compounds containin modifications of the P1 residue" BIOORG. MED. CHEM. LETT., vol. 6, no. 4, 1996, pages 379-384, XP002118380 * tables 1,2 * -----	1-12	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)

EPO FORM 1503 03.82 (P04C10)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 96 30 5554

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

11-10-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9611209 A	18-04-1996	AT 179431 T	15-05-1999
		AU 695796 B	20-08-1998
		AU 3612795 A	02-05-1996
		BR 9509237 A	21-10-1997
		CN 1193978 A	23-09-1998
		CZ 9700996 A	17-09-1997
		DE 69509401 D	02-06-1999
		DE 69509401 T	19-08-1999
		EP 0784629 A	23-07-1997
		ES 2133807 T	16-09-1999
		FI 971412 A	04-04-1997
		HU 77282 A	30-03-1998
		JP 10507170 T	14-07-1998
		NO 971537 A	04-06-1997
		PL 319503 A	18-08-1997
		ZA 9508396 A	07-10-1996
WO 9600214 A	04-01-1996	US 5506242 A	09-04-1996
		AU 692553 B	11-06-1998
		AU 2536995 A	19-01-1996
		CA 2192092 A	04-01-1996
		EP 0766672 A	09-04-1997
		FI 965156 A	20-12-1996
		HU 76548 A	29-09-1997
		JP 11505502 T	21-05-1999
		NO 965568 A	17-02-1997
		US 5552419 A	03-09-1996
		US 5646167 A	08-07-1997
		US 5672615 A	30-09-1997
		US 5817822 A	06-10-1998
		ZA 9505206 A	27-12-1995
WO 9535276 A	28-12-1995	AT 182581 T	15-08-1999
		AU 695507 B	13-08-1998
		AU 2746595 A	15-01-1996
		AU 690703 B	30-04-1998
		AU 2746695 A	15-01-1996
		CA 2193691 A	28-12-1995
		CA 2193692 A	28-12-1995
		CN 1151157 A	04-06-1997
		DE 69511089 D	02-09-1999
		EP 0766664 A	09-04-1997
		EP 0766665 A	09-04-1997
		ES 2133785 T	16-09-1999
		FI 965153 A	20-12-1996
		WO 9535275 A	28-12-1995

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 96 30 5554

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

11-10-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9535276 A		GB 2303850 A, B	05-03-1997
		GB 2303629 A, B	26-02-1997
		JP 10501806 T	17-02-1998
		JP 10507158 T	14-07-1998
		NO 965515 A	20-02-1997
		NZ 288298 A	23-12-1998
		NZ 288299 A	26-06-1998
EP 606046 A	13-07-1994	US 5455258 A	03-10-1995
		AT 159012 T	15-10-1997
		AU 684255 B	11-12-1997
		AU 5265593 A	04-05-1995
		CA 2112779 A	07-07-1994
		DE 69314456 D	13-11-1997
		DE 69314456 T	26-02-1998
		DK 606046 T	04-05-1998
		ES 2107648 T	01-12-1997
		FI 940012 A	07-07-1994
		GR 3025611 T	31-03-1998
		HK 1002633 A	04-09-1998
		HU 70536 A	30-10-1995
		IL 108229 A	30-10-1998
		JP 6256293 A	13-09-1994
		MX 9400276 A	29-07-1994
		NO 940038 A, B,	07-07-1994
		NZ 250517 A	26-10-1995
		SG 42933 A	17-10-1997
		US 5506242 A	09-04-1996
		US 5552419 A	03-09-1996
		US 5646167 A	08-07-1997
		US 5672615 A	30-09-1997
		ZA 9400048 A	11-08-1994

EPO FORM PUA9

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82